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Abstract
Tumor necrosis factor (TNF)-α is the most potent pro-inflammatory cytokine
in mammals. The degradation of TNFα mRNA is critical for restricting TNFα
synthesis and involves an AU-rich element (ARE) and a constitutive decay
element (CDE) in the 3’ untranslated region (UTR) of the mRNA. In the first
part of my thesis, I optimized an RNA-based method to identify RNA-binding
proteins (BPs) associated with TNFα mRNA. For this, I developed a modified
streptavidin-binding RNA aptamer termed S1m. It has improved affinity for
streptavidin and I found a four-fold repeat (4xS1m) to be most efficient. I then
used TNFα ARE-4xS1m RNA to purify ARE-BPs from cellular extracts. By
this, I found the majority of established ARE-BPs and confirmed Rbms1 and
Roxan as novel ARE-BPs. The optimized 4xS1m aptamer therefore provides
a powerful tool for the discovery of ribonucleoprotein (RNP) components.
In the second part of my thesis, I investigated the TNFα CDE in detail and
found that the CDE is a 17 nucleotide long structured motif. Structural prob-
ing and mutagenesis provide evidence that it folds into a short RNA stem-loop
in its active conformation. Using my 4xS1m protocol, I then identified CDE-
associated proteins by mass spectrometry. Thereby, I found that the CCCH-
type zinc and RING finger proteins Roquin (Rc3h1) and its paralog Roquin2
(Rc3h2) are stem-loop specific CDE-BPs. Next, I confirmed that the ROQ do-
main of Roquin specifically and directly binds to the CDE stem-loop. I could
further show that Roquin is required for CDE-mediated mRNA decay and
suppression of TNFα production in macrophages. TNFα expression was also
increased by introduction of a morpholino that interferes with CDE-Roquin
binding. My data provide evidence that Roquin proteins promote mRNA
degradation by recruiting the Ccr4-Caf1-Not deadenylase complex. CDE mo-
tifs are highly conserved and are found in over 50 vertebrate mRNAs, many of
which encode regulators of development and inflammation. In macrophages, I
confirmed that CDE-containing mRNAs are the primary targets of Roquin on
a transcriptome-wide scale. Thus, Roquin proteins act broadly as mediators
of mRNA deadenylation by recognizing a conserved class of stem-loop RNA
degradation motifs. In all, I unraveled a mechanism that adds an important
component to the complex network that governs posttranscriptional control of
gene expression.
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Zusammenfassung
Tumor Nekrose Faktor (TNF)-α ist das wirksamste pro-inflammatorische Zy-
tokin in Säugetieren. Der Abbau der TNFα mRNA ist entscheidend für die
begrenzte Herstellung von TNFα und schließt ein AU-reiches Element (ARE)
und ein konstitutives Abbauelement (CDE) in der 3’ untranslatierten Region
(UTR) der mRNA ein. Im ersten Teil meiner Doktorarbeit optimierte ich
eine RNA-basierte Methode um RNA-Bindeproteine (BP), die mit der TNFα
mRNA assoziiert sind, zu identifizieren. Dazu entwickelte ich ein modifiziertes
Streptavidin-bindendes RNA Aptamer, genannt S1m. Es hat eine verbesserte
Affinität zu Streptavidin, und ich fand heraus, dass eine vierfache Verkettung
(4xS1m) am effizientesten ist. Dann verwendete ich TNFα ARE-4xS1m RNA,
um ARE-BPe aus zellulären Extrakten zu reinigen. Dadurch fand ich die meis-
ten etablierten ARE-BPe und bestätigte Rbms1 und Roxan als neue ARE-BPe.
Das optimierte 4xS1m Aptamer stellt damit ein leistungsstarkes Hilfsmittel
dar, um Ribonukleinsäure-Protein (RNP) Komponenten zu entdecken.
Im zweiten Teil meiner Doktorarbeit untersuchte ich das TNFα CDE im Detail
und fand heraus, dass das CDE ein 17 Nukleotid-langes strukturiertes Motif
ist. Strukturanalyse und Mutagenese zeigten, dass es sich in seiner aktiven
Konformation in einen kurzen RNA Stem-Loop faltet. Indem ich das 4xS1m
Protokoll anwendete, identifizierte ich dann CDE-assoziierte Proteine durch
Massenspektrometrie. Dadurch fand ich, dass die CCCH-Typ Zink und RING
Finger Proteine Roquin (Rc3h1) und dessen Paralog Roquin2 (Rc3h2) Stem-
Loop-spezifische CDE-BPe sind. Anschließend bestätigte ich, dass die ROQ
Domäne von Roquin spezifisch und direkt an den CDE Stem-Loop bindet. Ich
zeigte weiterhin, dass Roquin notwendig ist für CDE-vermittelten mRNA Ab-
bau und für die Suppression der TNFα Produktion in Makrophagen. TNFα
Expression stieg durch das Einbringen eines Morpholinos an, das mit der
CDE-Roquin Bindung interferiert. Meine Daten zeigen, dass Roquin Proteine
mRNA Abbau fördern, indem sie den Ccr4-Caf1-Not Deadenylase Komplex
rekrutieren. CDE Motive sind hochkonserviert in Vertebraten und finden sich
in über 50 mRNAs, von denen viele für Entwicklungs- und Entzündungsreg-
ulatoren kodieren. Ich bestätigte CDE-enthaltende mRNAs als primäre Ziel-
gruppe von Roquin auf Traskriptom-weiter Ebene in Makrophagen. Folglich
agieren Roquin Proteine weitgehend als Vermittler von mRNA Deadenylierung
indem sie eine konservierte Klasse von Stem-Loop RNA Abbaumotiven erken-
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nen. Insgesamt entschlüsselte ich einen Mechanismus, der dem komplexen Sys-
tem, das die posttranskriptionelle Kontrolle von Genexpression steuert, eine
wichtige Komponente hinzufügt.
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1 Introduction
The ability of cells to rapidly alter their gene expression program depends on
multiple mechanisms. The lifespan of messenger RNAs (mRNAs) is increas-
ingly recognized as an important determinant in this respect. Despite the fact
that cellular mRNAs share a common set of important structural features like
the 5’ cap and poly(A) tail, mRNA half-life can vary largely, spanning from less
than one hour to >24 hours in mouse cells [1]. Short half-lives are particularly
important for dynamically regulated transcripts whose expression needs to be
rapidly turned on and off despite ongoing transcription. This includes mRNAs
encoding transcription factors (TF), signaling components, cell cycle proteins
and regulators of immune responses [2, 3, 4]. Particularly in the context of the
immune system, a major focus of this study, posttranscriptional dampening
of protein expression can actively promote the resolution of inflammation and
is required to prevent autoimmune diseases and chronic inflammation [5]. In
fact, the largest group of labile mRNAs in mammals encode pro-inflammatory
cytokines. Most factors that mediate mRNA decay and translation repression
bind to multiple cis-elements in the 5’ or 3’ untranslated region (UTR) of
mRNAs. Together with translation and protein stability control, the cell is
equipped to fine-tune gene expression according to environmental changes.
A classic example for highly integrated posttranscriptional expression control
is the most potent pro-inflammatory cytokine in mammals, Tumor Necrosis
Factor-α (TNFα), the main focus of this study. I will first introduce regula-
tory 3’UTR elements and decay machineries as mediators of mRNA decay in
the context of TNFα regulation. Moreover, I will present the Roquin fam-
ily of proteins. Finally, I will describe messenger ribonucleoprotein (mRNP)
purification approaches that aim at identifying novel RNA-binding proteins
(RNA-BPs) as regulators of TNFα.
1.1 The Cytokine Tumor Necrosis Factor-α
TNFα undergoes extensive transcriptional and posttranscriptional control
[6, 7]. While the local production of TNFα at sites of injury or infection
is important to trigger an immune response, its systemic or chronic release has
detrimental consequences by causing septic shock and chronic inflammatory
9
Chapter 1 Introduction
diseases [8, 9]. Hence, immune cells need to maintain strict control over the
expression of TNFα.
1.1.1 TNFα in Inflammation and Cancer
In response to bacterial components, especially lipopolysaccharide (LPS),
TNFα is secreted by macrophages, a major source of this cytokine. Together
with other cytokines, TNFα induces the acute-phase response of the immune
system in the liver and changes cell metabolism to provide energy for fever and
inflammation. In inflammation, TNFα plays a crucial role in the vasculature
to locally contain infections. Initially, TNFα increases vascular permeabil-
ity and blood flow, which enhances invasion of the infected site by immune
cells. Later, small blood vessel clotting blocks systemic infection via the blood
stream and thereby prevents septic shock. The pivotal role of TNFα in septic
shock highlights its potent physiological and pathological capacity. On the one
hand, during septic shock, excess TNFα is secreted by macrophages leading
to increased systemic vascular permeability, plasma loss and reduced perfu-
sion, which results in multiple organ failure. On the other hand, chronically
decreased or increased TNFα also leads to numerous deleterious inflamma-
tory and autoimmune diseases [10, 11]. Transgenic mice overproducing TNFα
suffer from multi-organ or tissue-specific inflammation, leading to a sponta-
neous pathology resembling rheumatoid arthritis [12, 13]. Dysregulation of
TNFα expression has been linked to chronic inflammatory arthritis, rheuma-
toid arthritis, inflammatory bowel disease, multiple sclerosis, asthma, cardio-
vascular diseases, type II diabetes, psoriasis, systemic lupus erythematosus,
inflammatory Crohn’s disease [8, 9, 14], as well as differential susceptibility to
infectious diseases including tuberculosis and cerebral malaria [15, 16]. Impor-
tantly, restricted expression of TNFα by either macrophages or T lymphocytes
is sufficient to induce intestinal inflammation [17].
The role of TNFα in cancer is less clear. Originally, TNFα was discovered as an
activity that causes tumor remission upon bacterial infection, hence its name
[18]. Later, the connection between LPS, macrophages and TNFα itself was
discovered, which is responsible for this anti-cancer effect. This effect is pri-
marily caused by the ability of TNFα to enhance tumor vasculature destruction
and necrosis of malignant cells. However, due to its severe systemic toxicity
and the risk of septic shock, therapeutic application of TNFα is restricted
to individual extremities [18]. In contrast, tumors themselves secrete TNFα
which promotes tumor growth, metastasis, DNA damage and neo-angiogenesis
[18]. TNFα is also produced by adipocytes and is involved in adipose tissue
regulation, energy mobilization and insulin resistance linking diseases like obe-
sity and type II diabetes [19]. Numerous processes, pathways and deleterious
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functions have been assigned to TNFα action which calls for a tight regulatory
network balancing TNFα expression.
1.1.2 Macrophages are a Major Source of TNFα
The innate immune system is the first line of defense against pathogens which
mediates a rapid, unspecific response to invaders. TNFα is mainly produced
by macrophages primarily in response to bacterial and inflammatory stimuli
like LPS [6]. It is expressed by many cells of the immune system, such as
T and B lymphocytes and mast cells, but also by endothelial cells and neu-
ronal tissues [20]. Macrophages have remarkable plasticity that allows them
to alter their phenotype and physiology in response to immune signals [21].
Initially, detection of gram-negative bacteria by macrophages involves binding
of the outer-wall component LPS to its cognate receptor complex, comprising
the pattern recognition receptor (PRR) Toll-like receptor 4 (TLR4), as well
as CD14 and MD2 [22] (Figure 1.1A). LPS-induced formation of this com-
plex elicits different intracellular pathways directly activated by TLR4. As
a consequence, indirect autocrine and paracrine signaling events are induced
to initiate an innate immune response [23]. There are two main groups of
macrophages, M1 and M2. The classically activated macrophages of the M1
“killer” type, stimulated via TLRs and interferon-γ (IFNγ), exhibit enhanced
killing of microorganisms, increased expression of co-stimulators and elevated
secretion of chemokines, cytokines like TNFα, and other communication signals
to coordinate inflammation.
The well-characterized TLR protein family consists of membrane bound PRRs
expressed by various cell types either located at the cellular surface (TLR1,
2, 4, 5, 6, 10) or in endosomes (TLR3, 7, 8, 9). There are in total 10 and 12
functional TLRs identified in human and mouse, respectively [22]. They detect
a variety of extra- and intracellular pathogens or damage-associated molecular
patterns [24, 25, 26]. Recognition of LPS by the TLR4/MD2 receptor complex
leads to dimerization of TLR4 and downstream signaling via recruitment of the
adaptors MyD88, TRIF, and TRAM. MyD88 orchestrates this early response
which leads to activation of the IκK/Nuclear Factor (NF)κB (NFκB) pathway
as well as mitogen-activated protein kinase (MAPK) members p38, ERK1/2,
and JNK. In activated macrophages and T-cells, NFκB shuttles from the cyto-
plasm to the nucleus and binds to promoters of inflammatory effector proteins
[27]. Sigaling pathways elicited by LPS are summarized in Figure 1.1A.
LPS-signaling then leads to rapid transcriptional and translational induction
of AU-rich element (ARE)-mRNAs encoding pro-inflammatory proteins (such
as TNFα, interleukin-1β (IL-1β), IL-6, cyclooxygenase 2 (COX-2), and IFNγ)
[5].
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For their primary function of rapid cytokine and chemokine secretion, acti-
vated macrophages dramatically increase their exocytotic trafficking activity.
This promotes efficient vesicle transport to and fusion with the cell membrane
[28]. Within 2 hours of LPS-stimulation, the newly synthesized transmem-
brane TNFα precursor accumulates in the perinuclear Golgi complex [29, 30],
is packaged and is released in small vesicles from the trans-Golgi network.
From there, it is delivered to sites of phagocytic cup formation [28].
Macrophages release pro- as well as anti-inflammatory mediators. Once ac-
tivated, they are subject to tight control to prevent an overshoot. The re-
lease of the anti-inflammatory cytokine IL-10, the most potent inhibitor of
macrophage activation, is one of the most critical anti-inflammatory feedback
loops. Macrophage-derived IL-10 suppresses the expression of many cytokines
(e.g. TNFα, IL-1, IL-6, IL-12, GM-CSF, IFNγ), several chemokines, and COX-
2, during resolution of inflammation [31]. IL-10 further inhibits the differenti-
ation of neighboring cells into activated macrophages. Most of this inhibitory
effect of IL-10 appears to occur at the transcriptional level involving STAT3-
signaling. The suppressive effect of IL-10 on TNFα expression depends on the
TNFα 3’UTR [32]. IL-10 also reduces TNFα translation through inhibition of
the p38-MAPK-MK2 pathway [33].
1.1.3 Function of TNFα Protein
TNFα is a type II transmembrane protein, whose ectodomain can be cleaved
by the metalloprotease TNFα converting enzyme (TACE or ADAM17) [34],
which is activated upon immune challenge. This releases a homotrimeric solu-
ble form, sTNFα, into the blood stream [35]. The ubiquitously expressed TNFα
receptor TFNR1 is fully activated by soluble and membrane-integrated TNFα.
In contrast, a second receptor, TNFR2, is mainly expressed on hematopoietic
cells and is primarily activated by membrane-bound TNFα. Both TNFα recep-
tors trimerize upon ligand binding and trigger signaling pathways that involve
the adaptor protein TRADD as a major mediator. Depending on the cellu-
lar context, TNFα can stimulate three different cascades [18, 35, 36] given in
Figure 1.1B. One leads to the activation of the TF AP1 via induction of the
MAPK pathway involving JNK-, p38-MAPK-, and ERK-signaling. Thereby,
TNFα stimulates differentiation, proliferation and apoptosis. A second path-
way results in activation of the TF NFκB that shuttles to the nucleus and
induces transcription of anti-apoptotic factors and mediators of cell survival,
proliferation and inflammation. A third pathway induces caspase-mediated
apoptosis, though it is antagonized by the anti-apoptotic function of TNFα-
induced NFκB. Signaling though TNFR1 mainly activates pro-inflammatory,
cytotoxic and apoptotic responses. However, TNFR2, which lacks an intracel-
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lular death domain, promotes cellular activation, proliferation and migration
[37]. Additionally, cleaved TNFRs can competitively bind to TNFα [18] dis-
playing reverse signaling and TNFα neutralization. This represents a complex
signaling network that involves extensive crosstalk.
1.1.4 Regulation of TNFα Expression
Potentially harmful factors like TNFα are expressed in a regulated pulse. Reg-
ulation on multiple levels includes mRNA transcription, splicing, export, sta-
bility, and translation. Posttranslational control includes control of protein
stability and activity by cleavage. These regulatory mechanisms are activated
by LPS or TNFα itself. Upon LPS-stimulation, coordinate transcriptional con-
trol is accomplished by TFs selectively recognizing TNFα promoter elements
[38]. Thereby, TNFα mRNA is transcribed within minutes independently of de
novo protein synthesis [39]. This involves enhanceosomes [40]. The conserved
proximal core promoter ~200 nt upstream the transcription start site is suffi-
cient for transcription in response to LPS [41, 42, 43, 44]. This core promoter
includes a TATA box and multiple cis-acting TF elements such as six NFAT
binding sites, an Egr binding site, and a cyclic AMP response element (CRE).
Numerous TFs induce TNFα mRNA synthesis, such as LITAF (LPS-induced
TNF-alpha factor) and particularly NFκB [45].
In the following, I give an overview of the main posttranscriptional mecha-
nisms that regulate TNFα, as not all of them will be presented in further detail
later. In lymphocytes, splicing of stored TNFα pre-mRNA occurs through a
PKR-dependent 3’UTR element upon activation [46]. Export of mature TNFα
mRNA from the nucleus in macrophages requires activation of the Tpl2 and
ERK kinases [47], whereas spliced TNFα mRNA is retained nuclear in non-
stimulated macrophages [47]. It was suggested that tethering of exon junction
complex proteins to spliced TNFαmRNA facilitates ERK/ARE-dependent nu-
clear export [48]. In the cytoplasm, both translation and degradation of TNFα
mRNA are extensively regulated [49, 50]. In particular, TNFα expression is
fine-tuned by control of translation initiation and polyadenylation [49, 51].
Translation regulation includes the JNK pathway and particularly the p38-
MAPK-MK2 pathway in the context of ARE-mediated mRNA stability con-
trol [52, 53, 54], as described later. Inhibition of JNKs blocks TNFα mRNA
translation in LPS-stimulated macrophages [55]. PKR and its substrate fascin
are also involved in 3’UTR-dependent regulation of TNFα and IL-6 transla-
tion upon LPS-stimulus [56]. Further, ARE-binding proteins (ARE-BPs) such
as TTP, TIA-1, TIAR and FXR-1, also serve as repressors of TNFα mRNA
translation via the ARE in macrophages. Tight posttranscriptional control of
TNFα also involves several regulatory elements in the 3’UTR.
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Figure 1.1: TLR4-signaling and the TNFα Response upon LPS-activation of
Macrophages. (A) TLR4-signaling. LPS-stimulation of TLR4 triggers the association
of MyD88 which recruits IRAK4 and IRAK1. Downstream signaling involves phosphory-
lation of IRAK1, TAB2, and TAK1. TAK1 phosphorylates the NFκB-inhibitor complex
IKK (IKK1, IKK2, NEMO). IKK then phosphorylates IκB, which is ubiquitylated and
degraded. NFκB translocates to the nucleus and induces target transcription. In parallel,
TRAF3 activates nuclear translocation of IRF TFs. This induces TNFα mRNA tran-
scription, splicing, export, and partial mRNA stabilization via p38-MAPK. This leads
to enhanced translation and secretion of TNFα. (B) TNFα-signaling. TNFR activation
leads to the recruitment of adaptor proteins to activate multiple pathways. TNFR1 ac-
tivation can have two different cellular context-dependent results. The default pathway
is induction of genes involved in inflammation and cell survival. TNFR1-TNFα binding
induces a range of inflammatory mediators and growth factors through activation of the
AP1 TF or IκB kinases (IKKs) that activate NFκB. Alternatively, if NFκB activation is
inadequate, apoptosis is mediated through caspase 8 and others. This is a late response
to TNFα. Figure adapted from: Schott and Stoecklin 2010, Balkwill 2009 [57, 18].
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1.2 Posttranscriptional Control of TNFα mRNA
Expression
Posttranscriptional control includes regulation of an mRNA’s life from nuclear
transcription to its degradation in cytosolic processing bodies (P-bodies). Sev-
eral quality control mechanisms have evolved in parallel, and many were linked
to TNFα mRNA. The ones not associated with TNFα mRNA regulation so far
include nonsense-mediated decay (NMD), no-go (NGD), and non-stop (NSD)
decay. These are means to detect and degrade aberrant transcripts harbor-
ing a premature stop codon, no start codon, or no stop codon, respectively.
Thereby, these translation-dependent mechanisms mediate mRNA surveillance
and ensure translational fidelity to protect the cell from potentially toxic pro-
teins. An attempt to present all aspects of this field can only be incomplete
without compromising to abstraction. This is why I will focus on important
posttranscriptional mechanisms in the context of TNFα mRNA regulation [58].
1.2.1 3’UTR Elements that Mediate TNFα mRNA Decay
The regulation of some mRNAs requires the activity of several regulatory el-
ements in the same UTR. Importantly, tight stability control of mRNAs en-
coding cytokines and chemokines is mediated by many 3’UTR destabilizing
elements [57, 59, 5] (Figure 1.2). These are recognized by trans-acting fac-
tors and thus serve as platforms for the recruitment of the decay machinery. A
prominent example is the ARE, a divergent and potent class of 3’UTR desta-
bilizing sequences that controls the degradation and translational repression
of many cytokine and TF mRNAs [60]. microRNA (miRNA) binding sites
also contribute to mRNA decay. They are recognized by miRNAs whereby
imperfect base-pairing leads to recruitment of argonaute (Ago) and TNRC6
proteins. This in turn causes translation repression and/or mRNA degradation
[61]. A third instability element that so far is exclusive for the TNFα 3’UTR
is the constitutive decay element (CDE) [62], the major focus of this study.
1.2.1.1 miRNA Binding Sites Induce miRNA-mediated Decay
miRNAs contribute to the posttranscriptional regulation of immune function
[57]. Overall, small non-coding RNAs regulate the majority of eukaryotic
genes by inducing translational repression and/or decay [63, 64]. miRNAs are
~22 nucleotide (nt) long single-stranded RNAs that are processed from longer
precursors. This involves cleavage and export from the nucleus (reviewed by
[64]). In short, a precursor pri-mRNA is transcribed from miRNA genes or
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generated from introns (miRtrons) and is processed by the RNase III type en-
donuclease Drosha-DGCR8 complex to ~70 nt pre-miRNA hairpins. In mam-
mals, the pre-miRNA is exported via exportin 5/Ran-GTP, associates with
the endoribonuclease Dicer in complex with TRBP and Argonaute 2 (Ago2),
and is cleaved by Dicer to obtain a mature miRNA. While one strand (pas-
senger strand) of the miRNA duplex is degraded, the other (guide strand)
functions as miRNA. It is bound by Ago proteins and confers target mRNA
specificity to the RNA-induced silencing complex (RISC). As part of the RISC,
the miRNA binds to partially complementary sequences mostly in the 3’UTR
of target mRNAs. While the small interfering RNA (siRNA) pathway leads
to direct endonucleolytic cleavage of base-paired miRNA-target site duplexes
(RNA interference) [65], miRNAs mostly target an mRNA with imperfect base-
pairing for which the context of the miRNA target sequence is crucial [66].
This includes a nucleating 5’ seed region, a bulged mismatched central region
and perfect complementarity to the miRNA 3’ half to stabilize the interaction
[67, 68]. mRNA-binding by RISC first leads to translational silencing followed
by mRNA degradation via deadenylation [69, 70]. Here, the RISC component
GW182 has a key role in recruiting both deadenylase complexes, PAN2-PAN3
and Ccr4-Not, to the target mRNA [71]. At the same time, GW182 promotes
dissociation of poly(A) binding protein (PABP) from the poly(A) tail which
inhibits translation [72, 73]. For silencing, miRNA-bound transcripts are de-
livered to P-bodies [74].
miRNA Binding Sites in the TNFα 3’UTR
The miRNA miR-125b participates in dampening TNFα expression [75, 76].
In resting macrophages, miR-125b binds to the TNFα 3’UTR and reduces its
expression. In activated macrophages, miR-125b is downregulated, and TNFα
mRNA becomes derepressed [75]. It is not yet clear whether miR-125b affects
mRNA stability or translation. With no direct binding site predicted, miR-
155, which is induced in LPS-stimulated macrophages [77, 76], enhances TNFα
production by indirectly regulating mRNA stability or translation. Thus, the
LPS-induced upregulation of miR-155 together with suppression of miR-125b
allows for efficient induction of TNFα. Moreover, miR-369-3 is required for
starvation-induced translational activation of TNFα by binding to the TNFα
ARE [78].
1.2.1.2 AU-Rich Elements Induce ARE-mediated Decay
In the 1980s, AREs were discovered in the 3’UTR of many labile mRNAs cod-
ing for cytokines, proto-oncogenes and TFs in mammals [79, 80, 81, 82, 83, 84]
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(reviewed by [85, 86]). AREs serve as binding sites for trans-acting ARE-BPs
and miRNAs that cause mRNA decay and translation repression [87, 5, 82,
83, 84]. In case of TNFα mRNA, a strong ARE suppresses translation and
causes rapid mRNA decay in the cytoplasm and thus prevents chronic inflam-
mation [13]. Thereby, the ARE ensures low expression levels of potentially
harmful proteins [88, 89, 90, 91]. This is reflected by the association of patho-
logical states such as cancer, chronic inflammation and autoimmune diseases
to deregulation of ARE-mediated decay (AMD) (reviewed by [92, 93]).
AREs are typically ~50 nt long sequences of high uracil and adenine content
[2, 94]. They mostly contain multiple repeats of a canonical AUUUA pen-
tamer, which is why cooperative binding of several factors in close proximity
has been proposed [87]. Due to variation in copy-number, sequence and po-
sition of pentanucleotides among ARE-mRNAs, AREs were sorted into three
different classes: Class I with one to three scattered AUUUAs and class II
with at least two overlapping copies of the UUAUUUA(U/A)(U/A) nonamers.
Class II AREs enhance deadenylation [95, 96, 97] and can contain a cluster of
four to seven partially overlapping AUUUAs within a U-rich context. Class
III AREs contain no AUUUAs, but a U-rich region [85]. Importantly, there
is no strict consensus sequence for any ARE class. The Stoecklin lab has de-
veloped the AREScore algorithm to identify AREs genome-wide [98]. Most
class II AREs are present in cytokine mRNAs, including TNFα, whereas TFs
and cell cycle regulators mostly contain class I and III AREs. AREs are very
common regulating 5-8% of all human mRNAs [99, 100, 81]. They are con-
served in 75% of mammalian ARE-containing mRNAs comparing human, rat
and mouse transcripts [101]. Among these, genes that regulate normal devel-
opment or processes like adhesion, growth, differentiation, and apoptosis, are
overrepresented.
ARE-mRNA stability is mainly regulated by altering mRNP composition that
either promotes or represses decay and/or translation. Numerous studies fo-
cused on ARE-BPs that bind to AREs [84, 100]. Only in rare cases, the
ARE itself can directly recruit the exosome [102]. The large number of ARE-
BPs identified includes tristetraprolin (TTP), butyrate response factor 1 and
2 (BRF1, BRF2), AU-rich binding factor-1 (AUF1 or hnRNP D), KH splic-
ing regulatory protein (KSRP), RHAU, Human antigen R (HuR) and other
members of the embryonic lethal abnormal vision (ELAV) protein family, T
cell intracellular antigen-1 (TIA-1), TIA-1-related protein (TIAR), and Frag-
ile X mental retardation syndrome related 1 (FXR1) (for summary see [60]).
ARE-BPs are evolutionarily conserved from yeast to mammals, exemplified
by Cth2, the yeast ortholog of TTP, that globally regulates the expression
of ARE-mRNAs in response to nutritional stress [103]. Several protein do-
mains are able to specifically bind AREs, including the RNA recognition motif
(RRM, found in TIA-1, TIAR, CUGBP2, HuR, AUF1 and AUF2), the zinc
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finger (ZF) domain (TTP, BRF1 and BRF2) and the K-homology (KH) do-
main (FXR1 and KSRP). Each of these proteins can individually affect the
translation and/or decay of ARE-mRNAs: Generally, TIA-1 [104], TIAR [104],
FXR1 [105] and CUGBP2 [106] inhibit translation; TTP [107], BRF1 [108],
BRF2 [108] and KSRP [109, 110] promote decay; AUF1 either promotes or in-
hibits decay [111, 112, 113, 114]; and HuR inhibits decay [115, 116] and either
promotes [117] or inhibits [118] translation.
The ARE in the TNFα 3’UTR
The class II TNFα ARE of nine successive AUUUA motifs triggers a rapid,
asynchronous and processive shortening of the poly(A) tail. Its crucial func-
tion for limiting TNFα overexpression in vivo was impressively illustrated in
knock-in mice by deletion of the ARE in one of the TNFα allels (TNFαΔARE)
[13]. Even heterozygous animals developed chronic inflammatory arthritis and
Crohn’s-like inflammatory bowel disease. This was due to TNFα overproduc-
tion as shown in macrophages and synovial fibroblasts of these mice, which
recapitulates the pathology in patients with rheumatoid arthritis [13]. In ad-
dition, analysis of autoimmunity-prone mice showed that they contained a
spontaneous dinucleotide insertion in the TNFα ARE, which paradoxically
correlated with reduced levels of TNFα and contributed to their development
of lupus autoimmunity [119]. In line with this, TNFα transgenic mice suffer
from inflammatory arthritis [12]. These results imply that posttranscriptional
control is essential for to prevent spontaneous inflammatory diseases.
The destabilizing effect of the TNFα ARE is mainly mediated by the ARE-
BPs TTP, BRF1 and BRF2, as well as KSRP and AUF1 [120, 113], whereas
HuR and Hel-N1 are stabilizing ARE-BPs that competitively antagonize TTP
[87, 116]. This illustrates the complexity of AMD. Moreover, the ARE also
represses translation [49] via TTP, as well as TIA-1 and TIAR, which medi-
ate translational silencing specifically in macrophages [121, 104, 122, 123, 124].
Upon stress, TIA proteins associate with translation initiation components and
are directed to stress granules (SGs) [125]. HuR overexpression in macrophages
correlates with reduced TNFα levels due to a strong translational block, along
increased mRNA stability, which requires TIA-1 [118]. FXR1 represses trans-
lation of TNFα via the ARE in LPS-activated macrophages [105]. It also
increases translation of an ARE-containing reporter mRNA upon serum star-
vation and cell cycle arrest [126]. Thus, environmental cues might convert the
ARE from a repressor to an activator of translation, which correlates with the
recruitment of FXR1 and Ago2 by the ARE, involving miR369-3 [126, 78].
Indeed, macrophages lacking FXR1 produce more TNFα than wild type (WT)
controls, a consequence of enhanced translation [105].
18
1.2 Posttranscriptional Control of TNFα mRNA Expression
Figure 1.2: Regulation of TNFα mRNA Expression upon LPS-stimulation.
The model for posttranscriptional regulation of TNFα mRNA summarizes previous data
and data obtained in this study. The multifunctional ARE is involved in mRNA export,
mRNA degradation via binding of TTP and others, which targets the mRNA for decay.
Translational inhibition occurs by binding of TIA-1 and others. The CDE contributes to
rapid mRNA degradation. LPS-stimulation interferes with ARE function: mRNA tran-
scription is induced NFκB-dependently, splicing is rendered 2-APRE/PKR-inducible, and
export is increased via the Tlp2/ERK pathway. MK2-signaling allows for efficient trans-
lation while p38/MAPK-signaling inhibits AMD. This switch results in efficient TNFα
mRNA translation. The net amount of mRNA available for translation remains limited
due to the CDE that attracts Roquin which constantly targets the mRNA for decay.
This restricts TNFα production and pathology even upon immune challenge. miR-155 is
induced upon macrophage stimulation, whereas miR-125b is repressed. SEE: ARE-like
stability and efficiency element [127]; 2-APRE: 2-aminopurine response element [46].
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The ARE-BP TTP is a Major Regulator of TNFα Expression
TTP, BRF1 and BRF2 comprise a family of related proteins with ZF domains
for RNA recognition [128]. As a major regulator of TNFα mRNA, TTP is
one of the best studied ARE-BPs [129]. TTP also destabilizes mRNAs encod-
ing other inflammatory modulators, including granulocyte-macrophage colony-
stimulating factor (GM-CSF), IL-2, IL-6, c-Fos, inducible nitric oxide (iNOS),
COX-2, chemokine (C-C motif) ligand 2 (CCL2), CCL3, CXC-chemokine lig-
and 1 (CXCL1), IFNγ and IL-10 (reviewed by [130]). With regard to TNFα,
TTP promotes rapid mRNA decay by binding to its ARE [107] and recruit-
ment of the Ccr4-Caf1-Not deadenylase complex [131], the decapping enzyme
Dcp2 [132] and the exosome [120, 133].
Similar to mice lacking the TNFα ARE, the phenotype of TTP-knockout
mice indicates that its main function is to dampen inflammation. These
mice develop cachexia, spontaneous arthritis, dermatitis, and neutrophilia
[134, 107, 135]. They show chronic overproduction of TNFα as a result of
increased stability and derepression of translation of TNFα mRNA, and ex-
hibit severe signs of systemic inflammation [135, 134]. Treatment of these mice
with TNFα-specific antibodies reverses almost all of the pathology, implicat-
ing TNFα to be the principal cause of this phenotype. This was confirmed by
breeding TTP-deficient mice with mice lacking TNFR1 or TNFR2. Whereas
TTP-/-TNFR1-/- mice did not develop cachexia or arthritis, TTP-/-TNFR2-/-
developed more severe arthritis than mice lacking TTP alone [135]. This
showed that TNFα binding to TNFR1 causes the described pathology.
In activated macrophages, the p38/MAP-kinase pathway is induced which
leads to inactivation of TTP through direct phosphorylation by MAPK p38-
MAPK-activated kinase 2 (MK2) on multiple serines and threonines [53, 54].
This triggers binding of 14-3-3 protein which blocks interactions with the de-
cay machinery [136]. This inactivation of TTP contributes to the stabiliza-
tion of TNFα mRNA [136] and translation derepression of TNFα and other
targets. Paradoxically, macrophage stimulation also induces TTP expression
[107]. Upon stimulation, ARE-mediated translational silencing of TNFα is
overcome via an MK2-dependent pathway [52]. As a component of an alterna-
tive p38-activated translational regulatory pathway, MAPK signal-integrating
kinase (Mnk) Mnk1 selectively promotes the translation of TNFα transcripts
by phosphorylation of the translational silencer hnRNP A1 and its release from
the TNFα ARE [137]. Recently, it was shown that TNFα mRNA translation
at the ER requires HuR with either p38 MAPK/MK2 pathway activity or in
absence of TTP [138]. MK2-phosphorylated TTP has decreased affinity to
the ARE, is unable to replace HuR from the ARE, and thus allows for HuR-
mediated TNFα translation initiation. This is also part of a feedback loop
increasing TTP’s own phosphorylation-regulated translation. In later stages
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of inflammation, TTP is dephosphorylated by the phosphatase PP2A, which
restores TTP activity [139]. This allows for immediate cytokine synthesis
upon infection, yet ensures limited expression. In addition, stimuli like LPS
and TNFα itself induce TTP transcription [140] as part of a feedback loop that
dampens cytokine expression to promote resolution of inflammation [107].
It has also been controversially discussed whether miRNA and ARE function is
integrated to control the expression of immune mediators [141, 142] (reviewed
by [143]). It was proposed that in Drosophila, Dicer1, Ago1 and Ago2, in hu-
man cells only Dicer, are required for decay of TNFα ARE-containing mRNA
reporters involving miR-16 [141]. The miR-16 seed sequence is only partially
complementary to its proposed target site in the TNFα ARE, which makes it
unlikely to efficiently target the ARE. It was claimed that an indirect interac-
tion of miR-16 with TTP in complex with Ago proteins is required to assist in
ARE-targeting. Presumably, TTP compensates for the weak complementarity
of miR-16 to the ARE. Another report demonstrated that recognition of an
ARE by miRNA-loaded RISC, in association with FXR-1, activates mRNA
translation in quiescent cells [126, 78]. Contradictory, there is evidence that
tethering of TTP to non-ARE transcripts alone can induce degradation. This
demonstrates the ability of TTP to directly recruit the decay machinery with-
out the need for miRNAs [133]. A more recent study used Dicer-knockout
MEFs and knockdown of Dicer and Ago proteins in Drosophila cells to show
that there is no general requirement of miRNAs for ARE function [142]. Hence,
while involvement of miRNAs in regulating the expression of immune media-
tors is well established [57], their role in AMD is controversial.
Interestingly, while TTP targets like GM-CSF mRNA become fully stabilized
in LPS-stimulated macrophages, TNFα mRNA stays labile [62]. This effect
on TNFα mRNA can be assigned to the presence of a second element, the
constitutive decay element (CDE) [62].
1.2.1.3 The Constitutive Decay Element
The CDE was previously described as a second destabilizing element in the
TNFα 3’UTR [62]. Whereas AMD is transiently blocked during macrophage
activation, the CDE was found to cause constitutive mRNA decay. Thereby,
the CDE limits TNFα expression by promoting mRNA decay also under pro-
inflammatory conditions.
It was initially found that in AMD-deficient human fibrosarcoma HT1080 cells,
an mRNA reporter containing the fulllength TNFα 3’UTR was still labile
[144]. This suggested a second, ARE-independent pathway targeting the TNFα
3’UTR for decay. In a subsequent study, deletion mapping and actinomycin D
(actD)-chase experiments in mouse macrophages and fibroblasts showed that
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a 80 nt long region downstream of the ARE mediates this decay activity [62].
This region was later narrowed down to an active element of 40 nt ([145];
Bernd Rattenbacher and Christoph Moroni, personal communication). The
CDE is highly conserved in ten mammalian species. Thus, all mutants tested
containing largly altered sequence stretches or mutated nucleotides, abolished
CDE decay activity [62]. Signaling pathways that abrogate AMD did not af-
fect CDE-mediated mRNA decay. Precisely, CDE-harboring mRNA reporters
were insensitive to all established AMD inhibitors tested, which included LPS,
ionomycin or TPA, or transfection with constitutively active forms of PI3K,
MEK6 or v-H-ras [62]. This led to the name Constitutive Decay Element or
CDE. The CDE has dramatic consequences for TNFα abundance upon immune
challenge. TNFα mRNA remains short-lived irrespective of AMD inhibition
as the CDE constantly targets it for decay, while TTP inactivation can only
partially stabilize the mRNA. This provides a safeguard mechanism to prevent
fatal TNFα overexpression.
Later, a biased crosslinking approach identified nucleolin as a CDE-binding
protein (CDE-BP) [145]. Nucleolin is a large and abundant nucleolar RNA-
BP that functions in ribosome biogenesis. It has been linked to AMD as
binding of nucleolin to the ARE stabilized bcl-2 mRNA [146]. However, besides
binding the Nucleolin Recognition Element (NRE), nucleolin interacts with
numerous highly diverse RNA sequence motifs and is more considered a general
RNA-BP [147]. Together with the fact that I did not confirm the nucleolin-
CDE interaction (data not shown), the specificity and relevance of this is
questionable and was not further investigated.
1.2.1.4 Other Regulatory Elements in Cytokine UTRs
Several short hairpins involved in mRNA stability control in cytokine and
early response genes [5, 84] are distinct from, though often adjacent to, the
ARE. Examples of such structured motifs are the CDE (TNFα, this thesis),
SLDE (G-CSF), 2-APRE (TNFα), and a pseudoknot (IFNγ). Regulatory RNA
structures in bacteria, e.g. riboswitches or thermosensors, are well-known as
remnants of an ancient RNA world [148, 149], but are also present in mod-
ern genomes of higher eukaryotes [150, 151]. This is demonstrated by the
increasing list of diverse roles of RNA structures in eukaryotic gene expres-
sion, including short and long non-coding RNAs, riboswitches, and structured
motifs in mRNAs [152]. Most families of human regulatory RNA elements
identified so far consist of short hairpins [153] which are the most wide-spread
among known regulatory RNA structures [154].
RNA structures in TNFα and IFNγ mRNAs strongly activate the RNA-
dependent protein kinase PKR [46], a stress kinase that is activated by
22
1.3 mRNA Decay Machineries
double-stranded RNA (dsRNA). The cis-acting RNA element 2-APRE (2-
aminopurine response element) in the human TNFα 3’UTR, upstream of the
ARE, acts at the level of pre-mRNA splicing [46]. The 104 nt 2-APRE con-
tains a stable 17 bp stem-loop which mimics viral RNA. It locally activates
PKR more potently than dsRNA. Activated PKR inhibits translation by eIF2α
phosphorylation [155] which blocks translation. 2-APRE renders TNFα pre-
mRNA splicing dependent on PKR activation and increases splicing efficiency
by locally activating PKR, while it does not reduce TNFα translation [46]. It
was named 2-APRE because mRNA splicing becomes sensitive to inhibition
by the PKR inhibitor 2-aminopurine. In case of IFNγ, PKR activation is me-
diated by a type H RNA pseudoknot in the 5’UTR. This in turn induces eIF2α
phosphorylation and inhibits its own translation locally [156]. Downstream
of the ARE, the TNFα 3’UTR contains a second conserved AU-rich region
containing a single AUAUUUAU motif, the “ARE-like stability and efficiency
element” (SEE) [127]. It was suggested to function in translation efficiency
and is bound by at least seven macrophage proteins, some of which compete
for ARE-binding. Stability of G-CSF mRNA involves a 3’UTR hairpin termed
“stem-loop destabilizing element” (SLDE), which is functionally distinct from
its ARE [157, 158]. The SLDE hairpin, which contains a trinucleotide loop and
a less than 11 base-pairs long stem flanked by unpaired sequence, promotes
mRNA deadenylation under conditions where the nearby ARE is inhibited
[157, 158]. IL-6 mRNA also contains a predicted stem-loop upstream of a non-
canonical ARE; both elements cooperatively regulate mRNA stability [159].
1.3 mRNA Decay Machineries
Most eukaryotic mRNAs have a 5’ cap and a 3’ poly(A) tail that promote
mRNA translation and circularization. They also protect the ends from ex-
onucleases. mRNA decay machineries enzymatically execute transcript degra-
dation. In eukaryotes, deadenylation is the rate limiting step [60, 160]. Degra-
dation of the mRNA body can then follow two distinct pathways, each of
which is initiated by a gradual poly(A) tail shortening (Figure 1.3). Then,
the mRNA is either decapped and degraded via the nuclease Xrn1 in 5’-3’ di-
rection or further deadenylated and degraded by the exosome in 3’-5’ direction.
1.3.1 The Major Eukaryotic Deadenylase Complexes
The main eukaryotic deadenylases are PAN2 (poly(A) nuclease 2) in complex
with its binding partner PAN3, the Ccr4-Not complex containing the dead-
enylase Caf1 (Pop2 in yeast), and the Pop2-related PARN (poly(A)-specific
ribonuclease) (reviewed in [60, 161, 160, 162, 163]) (Figure 1.3). The poly(A)
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tail is shortened in two consecutive steps: Initially, PAN2-PAN3 initiates
poly(A) trimming to a length of ~50 As, which is stimulated by binding to
PABP [164, 161]. In PAN2-PAN3, PAN2 is the catalytic deadenylase while
the pseudokinase PAN3 is the regulatory subunit. The PAN2-PAN3 structure
was solved recently [165]. In a second step, the conserved Ccr4-Not com-
plex completes the trimming of the bulk poly(A) tail to a length of 10-15 As
[166, 164, 60]. Ccr4-Not, the major cytoplasmic eukaryotic deadenylase [167],
which also has a role in transcription, is a large conserved complex of nine pro-
teins, five of which are the canonical subunits (Ccr4, Pop2/Caf1, Not1, Not2
and Not3/5). In Ccr4-Not, only Ccr4 and Caf1 have 3’-5’ exonuclease activity
[163]. They are docked onto the scaffold protein Not1 [168, 140]. Ccr4, whose
activity is blocked by PABP, is tethered to the Ccr4-Not complex through
Caf1. The structure of Caf1 is known [169, 170], as well as the one of Caf1 in
complex with Not1 [171]. Similar to Ccr4, the activity of Caf1 is dependent on
the poly(A) tail length [172]. Overall, the conserved core of Ccr4-Not consists
of at least two modules: the NOT module and a catalytic module comprising
both Ccr4 and Caf1. The recent structure of the Not1-Caf1-Ccr4 interaction
shows that the N-terminal arm of Not1 forms a docking site [173]. The ternary
Not-module, minimally consisting of the C-terminus of Not1, Not2 and Not5
in yeast [174] and of the Not1, Not2, and Not3 C-terminal regions in human
[175], have recently been crystallized. In yeast, Ccr4 is the main deadenylase
while in mammals, Caf1 seems to be dominant [176]. The nuclease PARN is
unique in that its processivity is enhanced by the presence of and it directly
binds to the 5’ cap [177, 178], but is inhibited by cap-binding proteins. Unlike
PAN2-PAN3 and Ccr4-Not, PARN is a single protein that has no counterparts
in yeast or Drosophila [60]. Thus, it is not essential in all eukaryotes. It is
a nucleo-cytoplasmic shuttling protein but is mainly nuclear [164], where it
destabilizes ARE-mRNAs in resting cells [179].
1.3.2 Exosome-mediated 3’-5’ mRNA Degradation
Upon deadenylation, the exosome complex is the major 3’-5’ RNA degradation
complex that catalyzes 3’-5’ degradation of mRNAs [180, 181]. The yeast core
exosome (Exo-10) is an RNase complex consisting of nine catalytically inert
subunits (Exo-9) and a single active RNase, Rrp44, with endonuclease and
3’-5’ exonuclease activity [182, 183]. It forms a huge barrel-shaped complex
with nuclear and cytoplasmic forms. The crystal structure of the yeast exosome
and the associated Ski complex required for cytoplasmic function were recently
solved [184, 185, 186]. These show how single-stranded RNA is funnelled into
the Exo-9 channel by an unwinding pore whereupon Rrp44 captures the RNA
3’ end that exits from the side of Exo-9. While the cytoplasmic form appears
to target only mRNAs, the nuclear exosome is involved in 3’ end processing
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of small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs) and 5.8S
rRNA [187, 188, 189]. In addition, it degrades aberrant mRNAs that are
products of miss-splicing or -processing in the nucleus. After 3’-5’ exosomal
degradation, the 5’ cap is removed by the scavenger decapping enzyme DcpS
that is specific for oligonucleotides [190, 191].
1.3.3 Decapping and 5’-3’ mRNA Degradation
Usually, mRNA deadenylation precedes decapping which is the irreversible re-
moval of the 5’ 7-methyl-guanosine (7meG) cap [192, 193]. This is followed
by exonucleolytic degradation of the residual mRNA body. Shortening of the
poly(A) tail to fewer than ~12 nts prevents PABP binding which normally in-
hibits the activity of the heterodimer Dcp1-Dcp2 decapping complex. The dis-
placement of PABP allows the recruitment of Pat1, an enhancer of decapping
and a repressor of translation [60] in S. cerevisiae [194], Drosophila [195] and
mammals [196, 197], as well as of the Lsm1-7 heptamer, seven SM-like proteins
[198], to the mRNA 3’ end. This blocks further trimming. The Pat1-Lsm1-7
complex [199, 200] preferentially binds short terminal oligo(A) and oligo(U)
tracts [201] and stimulates decapping by recruiting Dcp1-Dcp2 [202]. This
complex consists of the decapping activator Dcp1 and the decapping enzyme
Dcp2 [203]. In S. cerevisiae, the dimer Dcp1p-Dcp2p is responsible for cap
removal upon deadenylation [204, 60]. In higher eukaryotes, the additional
component Hedls (Ge-1) has decapping stimulatory activity in the complex
[60]. The accessory proteins enhancer of decapping 3 (Edc3) and DExD/H-box
RNA helicase Dhh1 (RCK/p54) join for efficient decapping. Edc3 is proposed
to serve as a scaffold which forms a complex with Dcp1, Dcp2 and Dhh1. Fol-
lowing cap removal, the accessible 5’ end of the mRNA body can be degraded
by the cytoplasmic 5’-3’ exoribonuclease 1 (Xrn1) [205, 206] (Figure 1.3).
Recently, it was shown that Dcp1 and Xrn1 directly interact which couples
decapping to 5’ exonucleolytic decay [207]. Alternatively, or in addition, dead-
enylation can continue degradation from the 3’ end via the exosome. While
several components of the Ccr4-Not complex, as well as Xrn1, Dcp1-Dcp2 and
Pat1-Lsm1-7, all localize to P-bodies [208], at least some decapping and 5’-3’
decay occurs in S. cerevisiae while mRNAs remain with translating ribosomes.
This suggests that ribosome dissociation and mRNA localization to P-bodies
are not prerequisites for deadenylation [209].
With regard to ARE-mRNAs in mammals, deadenylation initiates decay
by either mediating processive (classes I and III) or distributive (class II)
poly(A) shortening [85]. Once deadenylated, the ARE-mRNA undergoes rapid
degradation through the exosome [120, 210]. Alternatively, ARE mRNAs
can also be degraded through the 5’-3’ decapping-Xrn1 pathway in P-bodies
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[132, 211, 212, 213]. It it still not clear whether the 5’-3’ or the 3’-5’ direction
is the preferential pathway for degradation of ARE-mRNAs. Moreover, it has
recently been shown that a set of transcripts, including ARE-mRNAs encod-
ing IL-6 and IL-12b, are specifically destabilized via endonucleolytic cleavage
of a stem-loop in their 3’UTRs by the ZF ribonuclease Regnase-1 upon TLR-
stimulation of macrophages [214, 215, 216, 217].
1.3.4 P-bodies as Sites of mRNA Decay and Storage
P-bodies and SGs are discrete cytoplasmic foci that are enriched in mRNA
catabolizing enzymes and translational repressors [218, 219, 208]. Thus, they
participate in the regulation of mRNA translation or decay [102]. SGs form
when polysomes disassemble in cells exposed to stress; eIF2α kinases are ac-
tivated and translation is globally inhibited [102] (reviewed by [123]). Thus,
SGs serve as specialized storage sites where untranslated mRNAs are kept
under stress. P-bodies are related RNA granules found in both stressed and
unstressed cells [219]. Their formation is stimulated by the release of mRNAs
from polysomes [220, 221]. At least the final steps of mRNA degradation are
thought to occur in P-bodies [102, 208]. Components of the main 5’-3’ mRNA
decay pathway are concentrated there together with factors involved in trans-
lation initiation, deadenylation including Ccr4-Not and PAN2-PAN3 [222], de-
capping, 5’-3’ exonucleolytic decay, NMD and miRNA-mediated mRNA decay.
Translation factors found in P-bodies excludes eIF4E indicating the presence
of non-translating mRNPs only. Thus, mRNAs are either degraded or stored
there in a translationally silent state [218, 219]. In stressed cells, SG and P-
bodies interact, which is regulated by proteins like shuttling ARE-BPs [102].
Thereby, mRNAs destined for decay are sorted at the SG and delivered to the
P-body for degradation. Notably, ARE-mRNA delivery to P-bodies and SGs is
a reversible process. Several destabilizing proteins such as ARE-BPs directly
bind to components of the degradation machinery, e.g. Ccr4-Not, to direct
their associated mRNAs to P-bodies [131]. Consequently, bound regulatory
factors can enhance mRNA decay in P-bodies.
Upon binding to the ARE, TTP directly recruits mRNA deadenylases and
exosome components [131], and nucleates the formation of P-bodies [223]. TTP
can be recruited to both P-bodies and SGs and delivers ARE-mRNAs to them
[213, 223]. It also facilitates the transfer of selected mRNAs between these
distinct classes of RNA granules [213] and promotes interactions between them.
In its active form, TTP is recruited to SGs, but it is excluded from them in
its inactive phosphorylated form [136], accumulating in the cytoplasm. While
TTP preferentially mediates degradation of ARE-mRNAs by the exosome [120,
109], the exosome is found in neither P-bodies nor SGs.
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Figure 1.3: Cytoplasmic Eukaryotic mRNA Degradation, Decay and Qual-
ity Control. Most eukaryotic mRNAs undergo deadenylation-dependent decay. Initial
poly(A) tail trimming by the PAN2–PAN3 deadenylase is stimulated by PABP. Default
mRNA decay proceeds via further deadenylation by the Ccr4-Not complex, which is inhib-
ited by PABP. It may be stimulated by RNA-BPs in an mRNA-specific manner. Trimming
of the residual poly(A) tail yields a deadenylated intermediate that is no longer bound
by PABP susceptible to both of two mechanisms: decay by further 3’-5’ exonucleolysis by
the exosome or, more frequently, by recruitment of the Pat1-Lsm1-Lsm7 complex, which
stimulates decapping by Dcp1-Dcp2 and subsequent 5’-3’ exonucleolysis by the exoribonu-
clease Xrn1. Several quality control mechanisms detect possible erroneous features of an
mRNA leading to different outcomes. Upon exosome-mediated 3’-5’ decay, the remaining
cap is hydrolysed by DcpS. Figure modified from: Norbury 2013 [160].
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1.4 The Roquin Protein Family
Roquin (Rc3h1) is a member of the Roquin protein family consisting of Roquin
and its paralog Roquin2 (Rc3h2). Their names are due to their unique ROQ
domain [224]. Roquin was previously found to suppress the expression of
inducible T cell co-stimulator (ICOS), a co-stimulatory receptor on follicular
T helper (TFH) cells, by accelerating ICOS mRNA degradation in T cells by
targeting the ICOS 3’UTR [225, 226].
1.4.1 Immunological Relevance of Roquin and ICOS
In the sanroque mutant mouse (Roquinsan/san), that was identified in a random
mutagenesis-based screen for autoimmunity phenotypes, the Roquin gene is ex-
clusively affected harboring a point mutation. Homozygous sanroque mice con-
tain a single amino acid substitution (M199R) in the ROQ domain of Roquin
[227]. They display a severe, lupus-like autoimmune syndrome resembling sys-
temic lupus erythematosus (SLE), autoantibody formation due to aberrant,
excessive germinal center (GC) reactions [227], as well as intestinal inflamma-
tion in the small intestine but not the colon [228]. This phenotype results
from an expansion of TFH cells with elevated ICOS levels due to its dysregu-
lated expression based on Roquin’s function as a repressor of ICOS [227, 225].
The M199R substitution in Roquin does not affect protein stability and is a
rather hypomorphic mutation that only leads to intermediate upregulation of
ICOS on the cell surface [227]. ICOS mRNA stabilization in cells expressing
sanroque Roquin leads to enhanced T cell activation due to elevated ICOS
co-stimulation, a common trigger of autoimmunity. Indeed, ICOS is associ-
ated with the pathogenesis of SLE: ICOS levels are elevated in SLE patients
[229], and blockage of ICOS can prevent autoimmunity in mouse models of
lupus [230]. Physiologically, ICOS is induced on activated T cells and is de-
pendent on CD28 co-stimulation, while ectopic expression of ICOS on naïve
T cells induces spontaneous differentiation and expansion of TFH cells [231].
ICOS binds to its ligand ICOSL, which is expressed on activated dendritic
cells (DCs), monocytes, macrophages and B cells. It can also be induced
on non-lymphoid tissues by inflammatory stimuli [232] (Figure 1.4). This
plays a crucial role in TFH cell development, which is severely impaired in the
absence of ICOS co-stimulation [233, 234]. Overexpression and deficiency of
ICOS are both linked to autoimmune diseases. When naïve CD4+ T cells are
stimulated with an antigen, they can further differentiate into several subsets
depending on the context of activation. The formation of the TFH subset,
which provides help to B cells in the GC reaction, is controlled by Roquin
and supposedly miR-101 [227, 225]. Consistently, the ICOS repressor miR-
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101 is highly expressed in naïve T cells, but downregulated in TFH cells. A
second target of miR-101 and Roquin is neuropilin-1 [225], a surface protein
that participates in the activation of T cells by mediating interactions between
T cells and DCs [235]. Recently, in addition to ICOS mRNA, Ox40 mRNA
was found to be specifically bound and regulated by Roquin and Roquin2 in
a 3’UTR-dependent manner [226, 236]. INFγ mRNA was also reported to be
destabilized by Roquin [237, 238]. Recently, Pratama et al. (2013) found that
TNFα expression was increased in sanroque macrophages that show elevated
inflammation in an arthritis model [239]. Icos originates from gene duplication
of the more ancient but similar Cd28 gene that act via distinct pathways. It
was suggested that Roquin ensures discrimination between ICOS and CD28
functions [240].
1.4.2 Roquin and Roquin2 Knockout Mouse Models
The complete knockout of Roquin causes perinatal lethality and malforma-
tions of the tail and spinal column, as well as insufficiently ventilated lungs
[241]. However, the knockout of Roquin in the hematopoietic system did not
cause autoimmunity, but a a rather different, more inflammatory phenotype.
A similar phenotype was observed for Roquin2 gene ablation in mice [236]. In
comparison, heterozygous sanroque mice do not show autoimmunity but de-
velop tumors resembling angioimmunoblastic T cell lymphoma (AITL) [242].
The effect of Roquin ablation in T cells was dominated by the expansion of
eosinophilic granulocytes, macrophages and CD8+ effector-like T cells [241].
Mice with Roquin-deficient T cells showed increased ICOS levels on T cells
and failed to elicit elevated numbers of TFH cells or anti-nuclear antibody
responses [241]. In contrast, conditional deletion of Roquin2 did not lead to
increased CD8+ effector-like T cells or ICOS or Ox40 induction [236]. In B
cells, Roquin knockout led to impaired immune homeostasis; particularly ex-
pansion of total B, regulatory T, activated CD4+ and CD8+ T, and germinal
center B cells [241]. Therefore, in the hematopoietic system, Roquin is re-
quired to maintain immune homeostasis, while loss of Roquin is not sufficient
to cause autoimmunity. Thus, the conditional gene ablation of either Roquin
[241] or Roquin2 [236] in mice did not recapitulate the phenotype of the san-
roque mouse model. However, mice harboring the combined deletion of both
paralogs in CD4+ T cells develop lymphadenopathy and splenomegaly with in-
creased spleen weight, as well as cellularity with increased TFH cell and GC B
cell numbers, which phenocopies sanroque mice [236]. Thus, on the one hand,
this suggests a functional redundancy between Roquin and Roquin2 in the
control of T cell activation and TFH cell differentiation [236]. It was proposed
that the lack of compensation of Roquin-defects by Roquin2 in sanroque mice
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may be due to the mutated protein retaining its scaffold position within RNA
granules, preventing Roquin2 to access target mRNAs for regulation [239]. On
the other hand, it is likely that the complex phenotypes of the hematopoietic
Roquin knockout and sanroque mice may in fact arise from the simultaneous
deregulation of multiple mRNAs encoding regulators of the immune system or
of early development.
1.4.3 Function of Roquin Proteins
The Roquin protein family contains the two paralogs Roquin (Rc3h1) [227]
and Roquin2 (Rc3h2, also membrane-associated nucleic acid binding protein,
Mnab) [243]. They harbor a single C3H-type ZF, as found in the ZFP36 family
including TTP, a RING (really interesting new gene) domain and an exclusive
ROQ domain [224] (Figure 1.4). Roquin protein is highly conserved from hu-
mans to sponges (see alignment in the Supplemental Data) and is ubiquitously
expressed in almost all tissues. Roquin2 is however generally lower expressed
compared to Roquin, five-fold in T cells [236]. The two paralogs are very
similar in primary sequence and domain organization, predominantly in the
C-terminal portion, while Roquin2 has an extended C-terminus harboring a
predicted hydrophobic patch. This was speculated to allow Roquin2 to insert
into the plasma membrane [243]. Roquin2 was otherwise only known to be a
nucleic acid binding protein [243]. Roquin instead has a C-terminal coiled-coil
domain that might mediate oligmerization. Due to its N-terminal RING do-
main, Roquin was suggested to have RING-type E3 ubiquitin ligase activity
[227]. While uninvestigated in mammals, the single Roquin protein homolog
RLE-1 in C. elegans was shown to induce the degradation of the transcription
activator DAF-16 by ubiquitination [244]. The RLE-1 C-terminus interacts
with DAF-16 while the RING domain mediates DAF-16 ubiquitination for
proteasomal degradation. The Foxo3a homolog DAF-16 is important for stress
resistance and longevity. Thus, its RLE-1-mediated degradation shortens the
worm’s lifespan. Previous studies indicate that the ZF domain in Roquin/2 is
not required for mRNA interaction but the ROQ domain is involved in RNA
binding [226, 245]. Of note, the sanroque mutation did not interfere with RNA
binding [245]. It was proposed that the putative Roquin/2 binding motif in the
ICOS mRNA is located 100-200 nts downstream of the stop codon [226, 236],
as was a short 47 nt long sequence adjacent to the miR-101 site at the 3’end
of the 3’UTR [225]. Thus, the ICOS 3’UTR might contain several cis-acting
elements.
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Figure 1.4: Roquin Regulation of ICOS Expression. (A) Roquin, possibly together
with miR-101, destabilizes the ICOS and neuropilin-1 mRNAs in naïve CD4+ T cells.
ICOS and neuropilin-1 are upregulated during differentiation into TFH cells and mediate
interactions with dendritic cells (DC). Downstream ICOS-signaling is mediated via PI3K
recruitment. (B) Domain architechture of Roquin family proteins Roquin and Roquin2.
M199 indicates the position of the Roquin sanroque mutation. Figure A modified from:
Schott and Stoecklin 2010 [57].
It was previously reported that Roquin suppresses ICOS mRNA expression
via miRNAs [225]. In contrast to Yu et al. (2007), who proposed that
Roquin destabilizes ICOS mRNA together with miR-101, a more recent study
found that Roquin acts on ICOS mRNA independently of miRNAs [226]. We
observed that CDE-mediated mRNA decay, which is caused by Roquin as
demonstrated in this study, is Dicer-independent (Johanna Schott, data not
shown, [246]). This also argues against the involvement of miRNAs in Roquin-
mediated suppression. Glasmacher et al. (2010) also show that Roquin directly
binds to ICOS mRNA via the 3’UTR without the need for miRNA interac-
tion [226]. The Roquin mRNA 3’UTR might itself be regulated by miR-223,
as shown in mouse colon intraepithelial lymphocytes [247]. Interestingly, the
sanroque mutation M199R in ROQ does not impair Roquin binding to ICOS
mRNA, but is rather likely to prevent the interaction with critical effector pro-
teins [245]. Roquin-mediated repression requires functional RNA-independent
cooperation with other decay-related proteins such as the decapping compo-
nents Rck and Edc4 [226]. This suggests that Roquin causes ICOS mRNA
degradation via the decapping pathway. Further studies are required to clarify
the precise mechanisms by which Roquin recognizes its target mRNAs includ-
ing characterization of a precise binding motif.
The etiology of the Roquin sanroque mutation-induced autoimmune syndrome
has been linked to SGs [227, 225]. Roquin, sanroque Roquin and Roquin2 are
cytoplasmic and localize to P-bodies or SGs while ICOS mRNA localizes to
both SGs and P-bodies [227, 226, 245]. Hereby, the ROQ domain alone was
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sufficient for SG localization [245], whereas a C-terminal deletion mutant was
impaired in P-body localization [226]. Recently, analysis of a RING- and a
ROQ-deletion mutant mice of Roquin and Roquin2 showed that both Roquin
mutants disrupted ICOS mRNA regulation. While the ROQ mutant of Roquin
still localized to SGs, RING-deficient Roquin failed to do so, which allowed
Roquin2 to compensate in ICOS repression [239]. As Roquin shuttles between
P-bodies and SGs in T cells upon stress [226], it was suggested that Roquin
might cause mRNA degradation by directing translationally silenced mRNAs
from SGs to P-bodies [225]. With the examples of the ZF proteins TTP,
Regnase-1, and Roquin, a set of CCCH-type ZF and/or P-body proteins are
recognized to have an important function as immune regulators that control
RNA metabolism.
1.5 mRNP Affinity Purification Techniques
mRNAs are controlled by trans-acting factors at virtually every step of their
complex lives [248, 249, 250]. The fate of any given mRNA is essentially
determined by its mRNP complex, i.e. the ensemble of proteins and regulatory
RNAs an mRNA interacts with. Although decades of research have uncovered
specific functions of numerous RNA-BPs, surprisingly little is known about
the composition, heterogeneity and dynamics of whole mRNPs.
1.5.1 Protein- and RNA-centric Purification Approaches
There are essentially two strategies to explore the content of mRNPs: protein-
based or RNA-based methods [251]. On the one hand, protein-based ap-
proaches rely on the immunoprecipitation of a particular RNA-BP with an
antibody together with all associated mRNAs, whose identity can be deter-
mined by cDNA cloning, microarray analysis (RIP-ChIP) or deep sequencing
(RIP-Seq) [252]. RNA-sequencing technologies in combination with crosslink-
ing protocols, e.g. (i)CLIP, PAR-CLIP and HITS-CLIP, recently emerged as
efficient tools to identify protein recognition sites at a transcriptome-wide level
[253, 254, 255, 256] (reviewed by [257]). These approaches are increasingly ap-
plied to investigate whole RNA interactomes for a specific protein. This is
in line with deep sequencing becoming broadly available with decreasing cost
and high throughput. Such protein-based approaches provide the spectrum
of target mRNAs a particular RNA-BP interacts with. However, they do not
reveal the complexity and dynamics of mRNPs. This means whether different
proteins associate with the same mRNA in a cooperative, independent or com-
petitive manner. These methods are technically challenging in addition. As
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native protein-based purifications have previously been widely used to identify
protein components of mRNPs (e.g. [258]), specific mRNAs cannot be assigned
to interacting proteins, as indirect RNA interactions might be detected.
These limitations call for alternative, RNA-centric strategies for mRNP iso-
lation. Here, a single mRNA species is purified together with its associated
proteins and RNAs. These can be identified by mass spectrometry (MS) and
RNA-Seq, respectively. The advantage of this alternative approach is that one
obtains a less biased picture of the mRNP, including proteins that were not
known to interact with a certain RNA. Ideally, RNA-based purification should
reveal changes that occur during the lifetime of an mRNP or in response to
signaling events. However, this approach faces major difficulties: finding a suit-
able way to purify a specific mRNA in the context of its chaperoning proteins
as part of an intact mRNP; the generally low abundance of mRNAs compared
to proteins in the cell; and the scale of purification needed for successful iden-
tification of proteins by MS. Moreover, some RNA-BPs bind to mRNAs only
transiently with high off-rates in a regulatory manner. This calls for the need
to crosslink prior to RNP-purification [259]. This freezes the mRNP in its
current composition in the cell, a step that comes along with its own set of
disadvantages. The two most prevalent principles for RNA-mediated mRNP
purification either make use of RNA-protein interactions found in nature or of
in vitro selected aptamers that exhibit high affinity for specific ligands.
1.5.2 Bacteriophage RNA-protein Systems
One way to purify endogenous RNA-protein complexes by using antisense
oligonucleotides, as exemplified by the isolation of the telomerase RNP [260] or
bulk poly(A)-mRNPs via oligo(dT) [261, 262]. A different approach exploits
naturally occurring, bacteriophage-derived RNA-protein interactions of high
specificity and affinity consisting of a bacteriophage RNA structure and an
RNA-binding portion. One such example is the boxB RNA motif, which binds
to the λN peptide of the Escherichia coli (E. coli) bacteriophage λ antiter-
minator protein N [263, 264]. Another example is the coat protein (cp) from
the single-stranded group I RNA bacteriophage MS2 of E. coli. As a dimer,
MS2cp binds tightly to an 19 nt RNA stem-loop, termed operator hairpin or
MS2 binding site (MS2bs), in the MS2 RNA. Precisely, the hairpin is at the 5’
end of the viral replicase sequence encompassing the replicase start codon and
thereby represses its translation [265, 266]. Upon cp aggregation for capsid
assembly, translation repression is released. The MS2 protein-RNA interac-
tion has been studied extensively and its crystal structure has been solved
[267, 268, 269]. The Pseudomonas aeroginosa (P. aeroginosa) bacteriophage
PP7cp binds with high specificity to a distinct stem-loop in the PP7 RNA
33
Chapter 1 Introduction
[270, 271]. Its recognition specificity differs substantially from the one of its
distant relative coliphage MS2, as the cps only share 13% sequence identity
[270, 271, 272]. The PP7cp dimer is also a translational repressor that binds a
single translational operator hairpin in the replicase initiation site [270]. The
PP7 binding site (PP7bs) has structural features that make it unrecognizable
by the cps of other phages, which is beneficial for applications that use both
systems simultaneously. The MS2 and PP7 RNA hairpins differ in the posi-
tion of a bulged A as well as in the size and nucleotide composition of the loop
[272].
These systems (λN peptide, MS2cp and PP7cp) have proven powerful for vi-
sualizing RNAs in living cells [273]; and for tethering approaches whereby
proteins of interest are fused to λN, MS2cp or PP7cp, and are artificially at-
tracted to reporter mRNAs bearing the respective recognition motifs inside
cells [274, 275, 276, 196]. MS2 has also been used in a yeast three-hybrid
system to identify RNA-BPs for regulatory RNAs [277]. With regard to RNP
purification, the λN peptide has been applied for coupling in vitro transcribed
RNAs to a matrix with the aim of capturing RNA-associated proteins from
cellular lysates [264]. MS2 was used for purification of highly stable RNPs such
as the U1 snRNP [267], less stable mRNPs [278] from both yeast and mam-
malian cells, as well as RNPs associated with non-coding regulatory RNAs
[279, 280, 281, 282]. Precisely, for the latter, MS2-tagged RNA was used
to elucidate RNA-RNA and RNA-protein interactions, namely miRNAs with
MS2bs-tagged long intergenic non-coding RNA-p21 [280], protein and RNA
interactors of lncRNA-MS2bs in STAU1-mediated mRNA decay [281], and in-
teracting proteins of bacterial small regulatory RNAs [282, 283, 284]. The
MS2 system was also combined with stable isotope labeling of amino acids
in cell culture (SILAC)-based quantitative MS to investigate viral non-coding
RNA interactors as well as UV-crosslinked MS2-tagged RNPs in HEK cells
[279, 285]. Similar to MS2, the PP7 system has been exploited for the iso-
lation of both stable 7SK RNPs [286] and mRNPs [287], in this case in vivo
assembled complexes of Upf1 on PP7bs-tagged mRNAs from HEK cells. For
the isolation of human 7SK RNP, Hogg et al. (2007) combined two RNA ap-
tamers, PP7bs and the tobramycin motif, to yield an RNA Affinity in Tandem
(RAT) tag that allows sequential purifications [286]. Recently, the Csy4 en-
doribonuclease of the P. aeroginosa CRISPR system has been engineered for
RNP affinity purification, making use of its catalytic activity for elution [288].
Here, an inactive biotinylated Csy4 nuclease associates with its target hairpin
fused to an RNA of interest and is immobilized on an avidin-matrix. Upon
RNP formation in vitro, addition of imidazole activates Csy4 to cleave the
RNA for release of the RNP. This shows that bacteriophage-derived systems
were successfully modified to be utilized for RNP purification in a variety of
experimental settings.
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1.5.3 RNA Aptamers for Purification
A further possibility is to use aptamers, structured RNA motifs selected in
vitro for the ability to bind proteins or small molecule ligands. In contrast to
bacteriophage systems, they do not require synthesis of recombinant proteins.
Examples include a streptomycin-binding aptamer (StreptoTag), which was
used for U1 snRNP isolation [289], and a tobramycin-binding aptamer that
was used for purification of pre-spliceosomal RNP complexes [290]. Moreover,
Srisawat and Engelke developed a streptavidin (SA)-binding aptamer termed
S1 by which yeast and human RNase P-associated RNPs could be purified
[291, 292]. S1 was selected in vitro by SELEX (Systematic Evolution of Ligands
by Exponential Enrichment) from a random RNA library with SA as bait [291].
The S1 aptamer is advantageous as native complexes can be eluted from the
SA-resin by biotin, which makes use of one of the strongest noncovalent and
irreversible interactions in nature of biotin to SA (Kd 10-14 M), while S1 binds
to SA with a Kd of 7x10-8 M [291]. Another advantage of this system is that
biotinylated molecules in cellular lysates can be efficiently blocked by avidin
[293] which has no affinity for the S1 aptamer [294].
Examples of successful mRNP recovery via S1 are limited. After UV-
crosslinking of bound proteins to an S1-tagged mRNA inside human cells,
the S1 aptamer was used for the isolation of an in vivo assembled ARE-mRNP
that mediates translation activation upon starvation [126]. Beside this sin-
gle example for S1-mediated mRNP purification from mammalian cells, the
S1-tag was applied to isolate intact RNPs of the yeast snR30 small nucleolar
RNA complex [295] and bacterial ribosomes via S1-tagged 23S rRNA [296].
Moreover, mRNA-interacting proteins of the Crb3 mRNA complex were affin-
ity purified from human cells and Drosophila embryo extracts using in vitro
transcribed RNAs attached to SA via the S1 tag [297, 298, 299]. Finally, when
a SILAC-based RNA pulldown of S1-tagged RNAs was combined with PAR-
CLIP, RNA-protein interactions were mapped in a quantitative MS approach
[300, 301]. In a different setting which used a Cy3-labelled anti-S1 probe,
S1-tagged yeast RNAs were localized in vivo by applying fluorescent in situ
hybridization [302].
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1.6 Aim of the Study
The principle aim of this study was to investigate CDE-mediated mRNA decay.
So far, it was only known that the CDE in the 3’UTR conveys constitutive
decay to the TNFα mRNA. This occurs in an apparently non-regulated fashion
with respect to immune challenge, a condition that inhibits the neighboring
ARE. This highlights the CDE’s ability to serve as a robust safeguard signal
against TNFα overshoot. The CDE employs an unknown mechanism, which
contributes to dampening TNFα mRNA and protein levels upon stimulation.
The aim of my PhD thesis was to investigate the CDE RNA structure, to
identify proteins that bind to the CDE and that are crucial for CDE activity,
as well as to classify the mechanism of CDE function. For this, I established
an optimized protocol to purify mRNP complexes from cells via RNA tags to
enrich for specific RNA-interacting proteins. I also used this method to isolate
well-known and novel ARE-BPs. Finally, this study also aimed at identifying
CDE-like motifs in other mRNAs on a genome-wide scale, which allows me to
characterize the CDE as a novel class of decay elements in mammals.
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2.1 An Optimized RNA Aptamer for mRNP
Purification
The first aim of my PhD thesis was to develop an improved protocol for mRNP
purification based on structured RNA aptamers that have affinity for specific
matrices, which allows for RNA-based purification of RNA-protein complexes.
For several reasons this has always been a challenging task. Its importance
becomes evident as it offers the ability to study and understand processes in
the cell that involve large RNA-protein complexes. Notably, the majority of
crucial cellular machineries consist of RNA and protein. My goal was to use
this technique to identify novel RNA-BPs as effectors of defined RNA elements.
In this study, I first focused on improving a previously established streptavidin
(SA)-binding RNA aptamer and applied my protocol to find unknown protein
regulators of the ARE [303].
2.1.1 Development of the RNA Aptamer S1m
The S1 aptamer was originally developed by Srisawat and Engelke (2001)
through in vitro selection of an SA-binding aptamer from a random RNA
library by SELEX [291]. The minimal S1 motif consists of a 44 nt long struc-
tured RNA containing two double-stranded (ds) RNA helices, a 13 nt internal
loop between the two helices, and a 9 nt terminal loop (Figure 2.1A) [294].
To test the efficiency of the S1 aptamer for mRNP purification, I introduced a
single copy of S1 into the 3’UTR of a β-globin reporter gene that contains the
53 nt long ARE of mouse TNFα [304] (Figure 2.1B). The globin-ARE-1xS1
reporter gene was then transiently transfected into COS7 cells, which were
harvested the following day by rapid freezing in liquid nitrogen. I prepared
cellular lysates by detergent-free cryomilling as previously suggested for RNP
purification [305]. Compared to detergent-based lysis, cryolysis was equally
efficient with regard to RNA recovery (data not shown). After pre-clearing
with avidin-beads that do not bind the aptamer [294] but remove biotin and
biotinylated proteins due to the high affinity of egg white avidin for biotin, I
incubated the lysates with SA Sepharose to capture the mRNP. Beads were
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Figure 2.1: Improved Streptavidin-binding Efficiency of the S1m Aptamer.
(A) Left: secondary structure of S1 [291]. Right: secondary structure of the modified
S1m. Nucleotides mutated (red) or added to prolong the stem (yellow) are highlighted.
(B) Schematic representation of globin reporter mRNAs encoding rabbit β-globin fused to
the T7 epitope. The TNFα ARE was inserted into the β-globin 3’UTR, upstream of S1 or
S1m. (C) COS7 cells were transiently transfected with globin-TNFα-ARE, globin-TNFα-
ARE-1xS1, -1xS1m, -4xS1 or -4xS1m. One day later, cells were lysed by cryomilling,
and cleared supernatants were incubated with SA Sepharose beads. RNA was isolated
from the cleared supernatants (input) and from the beads after five washing steps (SA
pulldown). The RNA was resolved on 1.1% agarose gels, and subjected to Northern blot
analysis using a β-globin probe against the globin reporter mRNA. Nucleolin (ncl) mRNA
serves as a loading control. (D) COS7 cells were transiently transfected with globin re-
porter genes containing the TNFα ARE, or the ARE together with 1–7 copies of S1m.
Retention of the mRNAs by SA pulldown was analyzed as in panel C. (E) Quantification
of SA pulldown efficiencies. Different reporter mRNAs were expressed in COS7 cells as in
panels C and D, and the amount of mRNA retained by SA Sepharose was expressed as
% of input. Shown are average values ± SD, n is indicated above the graph. Reproduced
with permission from Nucleic Acids Research, Oxford Journals.
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then washed and RNA was eluted by phenol/chloroform extraction to assess
the efficiency of mRNP recovery. Northern blot analysis of input and puri-
fied (SA pulldown) RNA showed only minimal binding of globin-ARE-1xS1
mRNA (Figure 2.1C, lane 7). Quantification indicated that only 0.3% of
globin-ARE-1xS1 mRNA was retained on SA Sepharose compared to 0.2%
background binding of globin-ARE mRNA lacking the S1 aptamer (Figure
2.1E).
With the aim to improve binding efficiency, I generated a modified aptamer
termed S1m (Figure 2.1A and Suppl. Figure 5.1) in which the terminal S1
RNA structure was stabilized by introducing perfect strand complementarity
in the basal stem (shown in red), as was done previously for a modified S1
aptamer in the design of an RNA-based antibody mimic [306]. Similar to Xu
and Shi (2009), I also extended the basal stem of S1, yet only by 8 base-
pairs (Figure 2.1A, in yellow) to a total length of 15 base-pairs. When the
modified S1m aptamer was inserted into the reporter mRNA (globin-TNFα-
ARE-1xS1m), I observed 3–4 fold higher binding efficiency (Figure 2.1C,
lane 8) with 1.1% of the mRNA retained on SA Sepharose (Figure 2.1E). I
then introduced multiple copies of the S1m aptamer into the reporter gene,
speculating that a synergistic effect might further increase binding efficiency. A
linear 21 nt spacer sequence lacking secondary structure (Suppl. Figure 5.2)
was inserted between the individual aptamers to increase flexibility between
consecutive motifs. Indeed, I observed steadily increasing binding efficiencies
with 2, 3 and 4 copies of S1m (Figure 2.1D, lanes 11–13). Additional copies
of S1m (up to 7) did not further improve mRNA recovery; in fact, these longer
repeats were less efficient than 4xS1m (lanes 14–16). Using 4 copies of the
original S1 aptamer also improved RNA binding compared to the single copy
1xS1 construct (2.3 versus 0.3%, Figures 2.1C and 2.1E). Quantification of
several repeat experiments showed that of all constructs tested, 4xS1m had
the highest binding efficiency: with 4.5% of mRNA retained on SA Sepharose,
it was 15 times more efficient than the original S1 aptamer.
To assess functionality of the aptamer tagged mRNPs, I tested whether in-
sertion of 4xS1m would interfere with ARE-mediated mRNA decay. NIH3T3
cells were stably transfected with globin-TNFα-ARE-4xS1m, globin-4xS1m or
globin alone, and reporter mRNA stability was measured by actinomycin D
(actD) chase experiments (Figure 2.2A). Northern blot analysis showed that
the globin and globin-4xS1m control mRNAs were stable over time with half-
lives >9 hours, whereas the globin-TNFα-ARE-4xS1m mRNA was rapidly de-
graded with a half-life of 1.9 ± 0.1 hours. As demonstrated in transiently
transfected NIH3T3 cells (Figure 2.2B), there was no difference between
the decay rate of globin-TNFα-ARE (1.8 ± 0.3 hours) and globin-TNFα-ARE-
4xS1m (1.8 ± 0.5 hours). Thus, ARE-mRNA decay was not affected by placing
4xS1m in the vicinity of the ARE, a prerequisite for purifying mRNPs.
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Figure 2.2: The S1m Aptamer Does Not Interfere with ARE-mRNA Decay.
(A) Globin reporter genes containing no insert in the 3’UTR (-), 4xS1m or ARE-4xS1m
were stably transfected into NIH3T3 cells. Reporter mRNA decay was measured by treat-
ment with actinomycin D (actD), extraction of total RNA at 2 hours intervals followed by
Northern blot analysis. Globin mRNA signals normalized to nucleolin (ncl) were used for
calculation of average mRNA half-lives (t1/2) ± SD, n = 3. (B) After transient transfec-
tion of NIH3T3 cells, the decay of globin-ARE and globin-ARE-4xS1m reporter mRNAs
was measured as in panel A; shown are average mRNA half-lives (t1/2) ± SD, n = 3.
Reproduced with permission from Nucleic Acids Research, Oxford Journals.
2.1.2 Comparison to the PP7 and MS2 Systems
My next goal was to compare the S1m aptamer with the PP7 and MS2 sys-
tems. To capture the globin reporter mRNAs that contained either the PP7bs
or the MS2bs, PP7cp and MS2cp were expressed in E. coli as glutathione S
transferase (GST)-fusion proteins (Figure 2.3). In addition, one or two cleav-
age sites for the Tobacco Etch Virus protease (TEV, T in Figures 2.3A and
2.4A) were engineered between GST and the coat proteins (Figures 2.3A
and 2.4A). To this end, globin reporter mRNAs were generated by Georg
Stoecklin containing the TNFα ARE and six copies of either the PP7bs or the
MS2bs (Figure 2.4A). From tethering assays it is know that inserting 6–8
copies of the MS2bs strongly increases binding efficiency to the MS2cp [274].
The globin-TNFα-ARE-6xPP7bs and globin-TNFα-ARE-6xMS2bs reporter
genes were transiently transfected into COS7 cells, and lysates were prepared
by cryomilling as described for the S1 aptamer above. After pre-clearing with
glutathione (GSH) Sepharose beads, I incubated the lysates with the recom-
binant GST-tagged coat proteins before capture on GSH Sepharose beads.
Northern blot analysis showed that only 0.7% of globin-ARE-6xPP7bs mRNA
was retained by GST-T-PP7cp on GSH Sepharose (Figure 2.4B, lane 6, quan-
tification in Figure 2.4C). I also tested an optimized (o)PP7cp, a previously
published PP7cp mutant containing two mutations to alanine (C68A, C73A;
Figure 2.3B) that confer higher affinity to its cognate RNA and reduced ten-
dency to multimerize [286]. With oPP7cp, 1.0% of the globin-ARE-6xPP7bs
mRNA was retained on GSH Sepharose, slightly more than with the WT
PP7cp protein.
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Figure 2.3: Recombinant Protein Purification and PP7cp Sequence Align-
ment. (A) The four recombinant proteins schematically depicted on the right side were
expressed as GST-fusion proteins in E. coli and purified via GSH chromatography. Pu-
rity of the recombinant proteins after dialysis was determined by SDS-PAGE followed
by Coomassie blue staining. Concentration of the purified proteins was determined with
help of a bovine serum albumin (BSA) dilution series. Black arrows indicate the full-
length proteins; MW, molecular weight marker. (B) ClustalW alignment of the original
P. aeroginosa phage PP7cp and the optimized (o)PP7cp, a mutant generated by Hogg
and Collins [286] with reduced tendency to multimerize.
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Figure 2.4: Binding Efficiencies of the MS2 and PP7 Systems. (A) Schematic
representation of globin reporter mRNAs containing in their 3’UTR the TNFα ARE
upstream of six copies of either the PP7bs or the MS2bs. GST-tagged coat proteins
used for mRNP purification are depicted on the right side: GST-T-PP7cp containing the
WT PP7cp cDNA, GST-T-oPP7cp containing an optimized (o)PP7cp with higher RNA
binding affinity [286], GST-MS2cp as well as GST-TT-MS2cp. T, TEV cleavage site.
(B) COS7 cells were transiently transfected with either globin-TNFα-ARE-6xPP7bs or
globin-TNFα-ARE-6xMS2bs. Cell lysates were pre-cleared and incubated with recombi-
nant GST-T-PP7cp, GST-T-oPP7cp, GST-MS2cp or GST-TT-MS2cp before addition of
GSH Sepharose beads. RNA was extracted from the lysates before (input) and after pre-
clearing (pre-clear), and from the beads after five washing steps (GSH pulldown). The
RNA was subjected to Northern blot analysis as in Figure 2.1C. Protein was extracted
from the beads and detected by Western blot analysis using an anti-GST antibody. (C)
Quantification of GSH pulldown efficiencies from panel B and repeat experiments. The
amount of mRNA retained by the different GST fusion proteins was expressed as % of
input mRNA. Shown are average values ± SD, n = 3. Reproduced with permission from
Nucleic Acids Research, Oxford Journals.
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MS2cp was either fused to GST directly, or via a linker containing two con-
secutive TEV protease cleavage sites (TT, Figures 2.3A and 2.4A). With
both GST-MS2cp and GST-TT-MS2cp, more globin-ARE-MS2bs mRNA was
recovered than with PP7cp or oPP7cp (Figure 2.4B, lanes 9 and 10, quan-
tification in Figure 2.4C). GST-MS2cp gave the best result with 3.2% of the
input mRNA retained on the beads. When compared to the 4xS1m aptamer,
however, the PP7 and MS2 systems performed less well, so I decided to pursue
mRNP purification using 4xS1m.
2.1.3 Higher Affinity of S1m for Streptavidin
To further explore to which extent the S1m aptamer performs better than S1, I
compared their binding affinities to SA in vitro. By electromobility shift assay
(EMSA), I showed that one copy of S1 RNA binds to recombinant SA protein
with an apparent dissociation constant (Kd) of 59 nM (Figure 2.5A), similar
to the Kd of 70 nM reported previously [291, 292]. S1m showed a 2-fold higher
affinity with an apparent Kd of 29 nM (Figure 2.5A). I noticed that a consid-
erable amount of the RNA remained unbound even at high SA concentrations.
This did not affect calculation of the Kd since I achieved saturated binding,
but this suggested that a proportion of the RNA was incorrectly folded. An
unrelated, unstructured 23 nt long ARE RNA did not form a complex with
SA by EMSA (Figure 2.5C), confirming that the complex I observed between
SA and S1/S1m was due to specific binding. Taken together, these data re-
vealed that S1m has higher affinity towards SA than S1. This, together with
the synergistic effect of connecting four copies of the aptamer, explained the
improved efficiency of the 4xS1m tag in capturing a cellular mRNA (Figure
2.1C–E).
2.1.4 Elution with Biotin and RNase
Next, I wanted to compare the ability of biotin to elute 4xS1- and 4xS1m-
tagged RNAs from SA Sepharose in the presence of a cellular lysate. ARE-
4xS1 and ARE-4xS1m RNAs as well as the control RNAs 4xS1 and 4xS1m,
as depicted in Figure 2.6A, were transcribed in vitro, subjected to a folding
step and coupled to SA beads (Figure 2.6B). As expected from the higher
affinity of S1m, binding of ARE-4xS1m (59%, input minus unbound) was more
efficient than binding of ARE-4xS1 (27%). The RNA affinity resin was then
incubated with a highly concentrated pre-cleared NIH3T3 cell extract (30-50
mg/ml), washed three times and eluted with 10 mM biotin. Residual RNA
on the beads was recovered by a second elution using Trizol. This analysis
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Figure 2.5: Binding Affinities of the S1 and S1m Aptamers. (A) In vitro
binding of recombinant SA protein to S1 and S1m RNA was measured by electromobility
shift assay (EMSA). Radiolabeled S1 and S1m RNAs were incubated with increasing
concentrations of SA. Free RNA (black arrow) was separated from RNA-protein complexes
(white arrow) by native 6% PAGE. (B) The apparent dissociation constant Kd ± SD was
calculated from quantification of three independent experiments. (C) In vitro binding
of SA protein to S1 and S1m RNA was compared to that of a 23 nt long control ARE
RNA by EMSA. Radiolabeled ARE, S1 and S1m RNAs were incubated with increasing
concentrations of SA along the range shown in A. Reproduced with permission from
Nucleic Acids Research, Oxford Journals.
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showed that 70% of the bound ARE-4xS1 RNA and 47% of the bound ARE-
4xS1m RNA was eluted with biotin (Figure 2.6B). 28% (ARE-4xS1) and
17% (ARE-4xS1m) of the RNA remained on the beads and was recovered only
after Trizol elution.
As an alternative for eluting proteins bound to the captured RNA, I observed
that RNase A degraded the SA-bound ARE-4xS1 and ARE-4xS1m RNAs com-
pletely (Figure 2.6C). I also saw that RNase A was efficient in eluting protein
from mRNPs recovered from intact cells (data not shown). Thus, cellular pro-
teins did not interfere with access of the RNase to RNA-protein complexes. I
then examined the release of proteins bound to the RNA by RNase A elution
(Figure 2.6D). HuR, a well-established ARE-BP, was captured specifically
by ARE-4xS1 and ARE-4xS1m, but not by the corresponding control RNAs
lacking the ARE. RNase A was able to release most of the bound HuR, whereas
only small amounts remained bound to the SA beads, visualized by SDS elu-
tion. Notably, ARE-4xS1m RNA was able to recover more HuR protein than
ARE-4xS1. G3BP, an RNA-BP not associated to AREs, did not interact with
any of the RNA-affinity resins, demonstrating specificity of my purification
method. In all, this was a first indication that an ARE-BP can be specifically
purified via 4xS1m-tagged ARE-RNA.
Taken together, elution with biotin appears somewhat less efficient, releasing
only about half of the bound ARE-4xS1m RNA, yet might be chosen as an
alternative if the goal is to recover native RNP complexes from the column
i.e. for a second purification step. However, my results suggested that elution
by RNase A is the method of choice if the goal is to recover proteins from the
RNA-affinity column.
2.1.5 Purification of ARE-associated Proteins via 4xS1m
In my initial experiments, I attempted to identify proteins associated with
the globin-ARE-4xS1m mRNA stably expressed in NIH3T3 cells. However,
I mostly detected cytoskeletal proteins in both the ARE and control purifi-
cations, and I was not able to capture specific RNA-BPs (data not shown).
Therefore I turned to the in vitro RNA affinity chromatography approach es-
tablished in Figure 2.6B–D (schematically depicted in Figure 2.7), and
optimized the protocol (details are given in the Methods section).
The ARE-4xS1m and negative control 4xS1m RNAs were transcribed in vitro,
refolded and coupled to SA beads. In this approach, RNA binding to the
column was found to be highly efficient (77–95%, Figure 2.8A). Then, highly
concentrated cell extracts (70 mg protein/ml) were obtained by cryomilling
of NIH3T3 cells, cleared from cellular debris by centrifugation at 17.000 x g,
pre-blocked with avidin and SA beads, and incubated with the RNA affinity
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Figure 2.6: Elution of the S1 and S1m Aptamers. (A) Schematic representation
of DNA templates used for in vitro transcription of 4xS1, 4xS1m, ARE-4xS1 and ARE-
4xS1m RNAs. (B) Left: elution by biotin was examined by in vitro SA pulldown. In
vitro transcribed RNAs were coupled to SA Sepharose beads, incubated with NIH3T3 cell
extracts, washed and eluted using 10 mM biotin (EB). Residual RNA bound to beads was
subsequently eluted with Trizol (ET). RNA was resolved by 6% denaturing urea-PAGE
and visualized by methylene blue staining. Each lane represents 20% of the starting
amount. Reference: Low Range ssRNA Ladder (NEB). Right: the percentage of RNA
recovered at each step was quantified based on three independent repeat experiments,
average values ± SD. (C) The same experiment as in B, except that the first elution
was carried out with 0.05 µg/µl RNase A. (D) Upon RNA affinity purification using an
NIH3T3 cell lysate as in B, proteins were eluted with RNase A followed by elution with
SDS to determine residual protein bound to the beads. Upper panels: 10% of each RNA
fraction was resolved by denaturing urea-PAGE and stained with methylene blue. Bottom
panels: 23% of the RNase A and SDS eluates was resolved by PAGE and proteins were
monitored by Western blot analysis. ARE-BP HuR, positive control; G3BP, negative
control. Reproduced with permission from Nucleic Acids Research, Oxford Journals.
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Figure 2.7: Schematic Representation of S1m-mediated in vitro RNP Purifi-
cation. In vitro transcribed ARE-4xS1m and control 4xS1m RNAs are coupled to SA
Sepharose beads and incubated with a highly concentrated cellular extract. RNP com-
plexes formed contain proteins specific to the ARE, as well as RNA-BPs that interact
with aptamers and linkers. Following high salt washes, elution by RNase A releases RNA-
associated proteins. Proteins enriched in the ARE-4xS1m eluate over the 4xS1m eluate are
identified by quantitative MS using dimethyl labeling after tryptic digestion. Reproduced
with permission from Nucleic Acids Research, Oxford Journals.
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columns. After washing with a buffer containing 300 mM NaCl, proteins bound
to the RNA were eluted with RNase A. One third of the eluate was resolved
by PAGE and visualized by colloidal Coomassie blue staining (Figure 2.8B,
left panel). Subsequent elution of the columns with SDS showed that vast
amounts of protein adhered unspecifically to the SA Sepharose resin (right
panel), whereas RNA-associated proteins represented a minority. Thus, elution
by RNase provides an important advantage in the purification scheme because
many of the unspecifically bound proteins remain on the column.
Two thirds of the RNase A eluates were vacuum-concentrated and resolved by
PAGE over a short distance (Figure 2.8C). The pattern of protein bands was
very similar in the 4xS1m and ARE-4xS1m samples, suggesting that most of
the purified proteins were associated with the 4xS1m aptamer or the spacer se-
quence. To detect ARE-specific proteins enriched in the ARE-4xS1m sample, I
therefore used quantitative MS with the help of the ZMBH Mass Spectrometry
(MS) Core Facility. The two lanes were cut into four slices each and proteins
were in-gel digested with trypsin, followed by peptide dimethyl labeling [307]
using either formaldehyde (4xS1m sample, light) or deuterated formaldehyde
(ARE-4xS1m sample, medium). The light and medium samples were then
combined for liquid chromatography-MS/MS analysis. This approach allowed
for calculation of the enrichment of low abundance proteins in one sample
despite the presence of highly abundant proteins in both samples.
The table in Figure 2.8D lists proteins that were enriched by >8-fold in the
ARE-4xS1m sample. Notably, my purification yielded most of the established
ARE-BPs (in green) including HuR (Elav1), BRF2 (Zfp36L2), TIAR (Tial1),
BRF1 (Zfp36L1) and AUF1 (Hnrnpd). I also found two proteins (in blue),
Fubp3 and Dazap1, which had previously been purified with the TNFα ARE
[308, 309], although their function in regulating ARE-mRNAs has not been es-
tablished. An additional five RNA-BPs (in yellow) were specifically enriched in
the ARE-4xS1m purification including two proteins of the U2 snRNP (A’ and
B’’), a general snRNP protein (Sm-D2), an RRM-containing protein (Rbms1)
and a ZF protein termed Roxan (Zc3h7b).
2.1.6 Confirmation of Rbms1 and Roxan as Novel ARE-BPs
To confirm binding of novel candidate ARE-BPs, I chose Rbms1 and Roxan
from the list of enriched proteins (Figure 2.8D), both of which had previ-
ously not been associated with the ARE. Rbms1 (RNA-binding motif, single-
stranded-interacting protein 1), also known as MSSP (c-myc single-strand
binding protein), contains two RNA recognition motif (RRM) domains. It
was initially identified as a DNA-binding protein that interacts with a region
upstream of the c-Myc gene [310] and was proposed to function in DNA repli-
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Figure 2.8: Identification of ARE-BPs by 4xS1m RNA Affinity Purification.
(A) In vitro transcribed RNAs were coupled to SA-beads. To monitor coupling effi-
ciency, 10% of the input and unbound RNA fraction were resolved on a 6% polyacry-
lamide/TBE/urea gel and stained with methylene blue. Reference: Low Range ssRNA
Ladder (NEB). (B) NIH3T3 cell extracts were incubated with the RNA-coupled SA-beads,
washed and eluted using RNase A. SDS was used for a second elution of the beads. 1/3 of
the eluates was resolved on a 5-20% polyacrylamide gradient gel and proteins were stained
with colloidal Coomassie blue. Black arrow: RNase A. (C) 2/3 of the RNase A elution
samples were resolved over a short distance on a 10% polyacrylamide gel and stained
with colloidal Coomassie blue. Lanes including the wells were cut into four gel slices
and in-gel trypsin-digested. Peptides from the 4xS1m (Light) and ARE-4xS1m (Medium)
eluate were differentially dimethyl-labeled and processed for MS; MW, molecular weight
marker. (D) List of proteins identified by MS in ARE-RNPs purified via 4xS1m. The
ratio of Medium/Light reflects the specific enrichment of proteins in ARE-4xS1m over
4xS1m. All proteins enriched >8-fold are depicted and categorized as established ARE-
BPs (green), putative ARE-BPs identified previously (blue) or other RNA-BPs (yellow).
Reproduced with permission from Nucleic Acids Research, Oxford Journals.
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cation [311]. Rbms1 was further shown to bind to the c-Myc protein and stim-
ulate its transforming activity [312], yet the RNA-binding properties of Rbms1
have not been investigated so far. The second candidate, Roxan (rotavirus X
protein associated with NPS3), also termed Zc3h7b (zinc finger CCCH-type
containing 7B), is a 110 kDa cellular protein of unknown function that was
shown to bind the rotavirus nonstructural protein NSP3. NSP3 interacts with
both the 3’ consensus sequence of non-polyadenylated viral mRNAs and eu-
karyotic translation initiation factor eIF4GI, suggesting that Roxan may func-
tion in the regulation of viral mRNA translation [313]. Moreover, Roxan was
shown to interact with poly(A)-binding protein (PABP-C1) and to promote
its nuclear localization during rotavirus infection [314].
Figure 2.9: Rbms1 and Roxan Specifically Bind to the TNFα ARE. (A) Binding
of Rbms1 to the ARE was analyzed by in vitro SA pulldown, as in in Figure 2.6D. Rbms1
was detected using an antibody against endogenous Rbms1. (B) Binding of endoge-
nous Rbms1 to the TNFα ARE was analyzed by RNA-IP. HEK293 cells were transiently
transfected with the globin reporter lacking an insert (-), globin-TNFα-CDE or globin-
TNFα-ARE. After IP of endogenous Rbms1 with an Rbms1-specific antibody, the protein
was monitored by Western blot analysis. White arrow: immunoglobulin heavy chain;
black arrow: Rbms1. Anti-myc antibody was used for the negative control IP. Globin
reporter mRNAs were visualized by Northern blot analysis, ncl mRNA serves as negative
control. (C) Binding of Roxan to the TNFα ARE was analyzed by RNA-IP. HEK293 cells
were transiently transfected with T7 or T7-Roxan together with the globin reporters as
in B. After IP with anti-T7 antibody, T7-Roxan was monitored by Western blot analysis.
Reproduced with permission from Nucleic Acids Research, Oxford Journals.
First, I confirmed the specific interaction of Rbms1 with the ARE in an in
vitro SA pulldown experiment (as in Figure 2.6D) using an antibody against
endogenous Rbms1 (Figure 2.9A). Indeed, Rbms1 was found to be specifi-
cally enriched by RNase A elution in the ARE-4xS1 and ARE-4xS1m samples.
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Notably, the second elution with SDS revealed additional, unspecific bind-
ing of Rbms1 to the beads, underlining the importance of elution by RNase.
By an inverse approach, i.e. RNA-immunoprecipitation (IP) of endogenous
Rbms1 from HEK293 cells, I confirmed that Rbms1 strongly associates with
globin-TNFα-ARE mRNA but not with globin mRNA alone (Figure 2.9B).
Likewise, Rbms1 did not bind globin-TNFα-CDE mRNA, which contains the
CDE, a stem-loop motif that confers ARE-independent TNFα mRNA decay
[246]. Since a negative control antibody against myc did not pull down any of
the reporter mRNAs, this experiment demonstrated that Rbms1 is a specific
ARE-BP.
To assess binding of Roxan to ARE-RNA, RNA-IP was then carried out with
T7-tagged Roxan transiently expressed in HEK293 cells. Similar to Rbms1,
I observed that T7-Roxan specifically interacts with globin-TNFα-ARE, but
not with the globin or globin-TNFα-CDE mRNAs (Figure 2.9C). The T7-tag
alone did not bind to any of the reporter mRNAs. These results illustrated
that 4xS1m-mediated RNA affinity chromatography and quantitative MS suc-
cessfully identified at least two novel ARE-BPs in addition to a large number
of known ARE-BPs.
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2.2 Roquin-mediated Constitutive Decay of
CDE-containing mRNAs
The stability of TNFα mRNA is determined by 3’UTR-residing elements such
as miRNA binding sites, the ARE, as well as the CDE. So far, the active CDE
mediating constitutive decay of this mRNA has been mapped to an element
downstream of the ARE (Figure 2.10A). However, no further characteriza-
tion had been performed. Thus, in my PhD thesis I aimed at identifying and
characterizing CDE-interacting proteins to unravel the underlying mechanism
that the CDE employs for its function [246].
2.2.1 The CDE is a Conserved Stem-Loop Motif
Previously, the CDE had been mapped to an 80 nt long sequence in the mouse
TNFα 3’UTR by Stoecklin et al. (2003) [62], which was named KΔAU. In
his PhD thesis, B. Rattenbacher [145] was able to narrow down the element
to a 37 nt long fragment using decay assays with globin-TNFα reporter tran-
scripts which I reproduced in stably transfected NIH3T3 cells (Figure 2.10A).
I referred to that element as CDE37 which corresponds to the 3’ most por-
tion of the 80 nt-long KΔAU element (Figure 2.10B). When I compared
TNFα CDE sequences from 19 mammalian species as annotated in NCBI, the
CDE37 region was found to be especially highly conserved in primary sequence
(Figure 2.11A).
When I cloned CDE37 in different sequence and structure contexts I observed
that this strongly influenced the decay activity of the respective variants (com-
pare version V2 and V3 in Suppl. Figure 5.3A and B, and Suppl. Table
5.1), suggesting that the CDE might be a structured element. To address
its structure experimentally, I collaborated with the Ming Hammond lab at
UC Berkeley to subject these varying RNAs to in-line probing [315]. This
is an RNA cleavage assay in which base-paired or structurally constrained
nucleotides are protected from spontaneous phosphodiester bond hydrolysis.
The cleavage reaction (Suppl. Figure 5.3C) revealed that the highly active
CDE37-V3 RNA folds into a P2-L2 stem-loop, which is flanked by an inter-
nal L1 loop followed by a P1 stem (Figure 2.11B, Suppl. Figure 5.3C,
middle panel). Regions protected from cleavage precisely correspond to the
base-paired regions of the P1 and P2 stems, whereas cleavage sites (circled in
Figure 2.11B) were observed at most nucleotides in the L1 and L2 loops.
This is in well agreement with the Mfold bioinformatic structure prediction
[316] I performed for the mouse CDE (Figure 2.11B). In contrast, the less
active CDE37-V2 RNA, in which a 2 nt insertion disrupted the continuity be-
tween the cloning stem and P1, showed a diffuse cleavage pattern that could
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Figure 2.10: Mapping of the Mouse TNFα CDE. (A) Schematic representation of
the mouse TNFα 3’UTR. CDE-containing TNFα sequences were inserted into the 3’UTR
of a globin reporter gene. Reporter genes were stably transfected into NIH3T3 cells, and
degradation of the reporter mRNAs was measured upon treatment with 5 µg/ml actD.
Total RNA was extracted at regular time intervals, resolved on 1.1% agarose gels, and
subjected to Northern blot analysis. Globin mRNA signals normalized to nucleolin (ncl)
mRNA were used for calculation of mRNA half-lives (t1/2). (B) Sequence of the mouse
TNFα 3’UTR (755 nt). Regulatory elements are highlighted in color: miR-125b binding
site (purple), ARE (blue), CDE150 (yellow), KΔAU (grey), CDE37 (red) and the minimal
CDE17 stem-loop (green). The stop-codon and the poly(A)-signal are marked in red.
Nucleotides are numbered according to the CDE150 fragment (nt 1-150). Reproduced
with permission from Cell, Elsevier.
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not be assigned to a predominant structure (Suppl. Figure 5.3C, right
panel). Ming Hammond then performed in-line probing of a 150 nt long RNA
containing the CDE in its native TNFα sequence context (CDE150). This also
resulted in a diffuse cleavage pattern (Suppl. Figure 5.3C, left panel). Like
CDE37-V2, CDE150 was less active in mediating mRNA decay than CDE37-
V3 (Suppl. Figure 5.3B). The stem-loop structures in both CDE37-V2 and
CDE150 also provide a much smaller decrease in free energy (ΔG, kcal/mol)
as compared to CDE37-V3 (Suppl. Figure 5.3A), which is indicative of a
less strong tendency to contain structured regions. I concluded that the highly
active CDE37-V3 adopts a stable structure, whereas the less active CDE37-V2
and CDE150 appear to fluctuate between alternative or unstructured confor-
mations.
Importantly, I found that the human CDE sequence can fold into a similar
P1-L1-P2-L2 structure that differs primarily in the P1-L1 region when bioin-
formatically predicted with Mfold (Figure 2.11C). Like the mouse CDE, it
causes rapid degradation of reporter mRNAs at a comparable rate (Figure
2.11D). Based on the TNFα CDE alignment of 19 mammalian species I could
show that the P2-L2 stem-loop is conserved to nearly 100% with few varia-
tions in the lower P2 and only one C/U variation in L2 (red in Figure 2.11A),
whereas the P1 and L1 sequences are more divergent (Figure 2.11A).
2.2.2 The P2-L2 Stem-Loop is Sufficient for CDE-mediated
mRNA Decay
Next, I investigated sequence substitution analysis in which I mutated nu-
cleotides along the CDE structure on one side or on both sides of a stem to
disrupt or reconstitute the stem, respectively. This approach tested whether
the CDE requires structure only or sequence specificity as well. Similarly, nu-
cleotides in the loop regions were exchanged to analyze their contribution for
CDE decay activity. These CDE-mutants were generated and tested with con-
tribution of Sonja Reitter. The mutagenesis results are summarized in Suppl.
Table 5.1. This analysis revealed that mutations within the P1 stem or the
L1 loop did not affect CDE-mRNA decay (Figure 2.12A–C). In contrast,
all mutations disrupting P2 or L2 inactivated the CDE, pointing towards the
importance of the highly conserved P2-L2 stem-loop.
I then tested by mutagenesis whether the CDE’s ability to fold into a stem-loop
is required for mRNA decay. All mutations disrupting the P2 stem (M16, M19,
M21, M22) abrogated CDE37 activity (Figures 2.12D and 2.13A). While
compensatory mutations restoring the apical part of P2 remained inactive
(M23, M27), compensatory mutations in the basal part of the stem rescued
CDE37 activity (M20, M26; Figure 2.12D). Importantly, the compensatory
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Figure 2.11: The Active TNFα CDE is a Conserved RNA Stem-Loop Motif.
(A) Schematic representation of the mouse TNFα 3’UTR along with an alignment of 19
mammalian TNFα CDE sequences. Nucleotides are color-coded according to conservation
as indicated in the box; R, purine; Y, pyrimidine. Numbers refer to nucleotide positions
within the CDE150 fragment. (B) Secondary structure model of the mouse TNFα CDE37
RNA derived from in-line probing. Nucleotides 5’ to cleavage sites are circled, pairing
elements P1 and P2 are shaded in blue and green, respectively, and nucleotides are color-
coded according to conservation. (C) Secondary structure model predicted for the human
TNFα CDE37 RNA by thermodynamic modeling. (D) Globin reporter genes containing
no insert in the 3’UTR, mouse CDE37-V3 or human CDE37-V3 were transiently trans-
fected into NIH3T3 cells. Upon treatment with actD, total RNA was extracted at 2 hour
intervals, resolved on 1.1% agarose gels, and subjected to Northern blot analysis. Globin
mRNA signals normalized to nucleolin (ncl) were used for calculation of average mRNA
half-lives (t1/2) ± SD, n ≥ 3. Reproduced with permission from Cell, Elsevier.
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Figure 2.12: Mutational Analysis of the Mouse TNFα CDE. (A) Schematic rep-
resentation of substitution mutations mapped onto the mouse TNFα CDE structure.
CDE37 mutants active in mRNA decay (t1/2 < 6.0 hrs) are labeled "+", inactive mu-
tants (t1/2 > 9.0 hrs) are labeled "–". For comparison, decay of globin-CDE37-WT-V3
was measured in transiently transfected NIH3T3 cells. (B) The same substitution mu-
tations as is the left panel of A were mapped onto the linear TNFα CDE, t1/2 ± SD (n
≥ 3) of the reporter mRNAs is given. (C) The effect of the CDE37 mutations (in the
V3 cloning context) on mRNA degradation was measured by transient transfection of the
globin reporter genes into NIH3T3 cells. (D) P2 stem mutations were introduced into
the TNFα CDE37-V3, either in one strand to disrupt P2, or as compensatory mutations
in both strands to restore P2. Globin reporter mRNA decay was measured in transiently
transfected NIH3T3 cells by Northern blot analysis, average t1/2 ± SD, n ≥ 3. Northern
blot analysis was carried out as in Figure 2.11D. The mutgenesis analysis was performed
with the assistance of Sonja Reitter. Reproduced with permission from Cell, Elsevier.
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mutation M20 was also able to restore the activity of CDE150 (Figure 2.13B),
demonstrating the existence of a functional P2 stem in the context of the native
TNFα 3’UTR. Taken together, both stem structure and nucleotide identity in
the apical three base-pairs of P2 are essential for CDE activity, whereas base-
pairing alone is sufficient in the basal part of P2.
Analysis of the trinucleotide L2 loop revealed that changing its middle position
(nt 67) from G to A did not abrogate CDE37 activity (M24, Figure 2.13C).
Variation is also tolerated at position 66, where the human CDE has a C as
opposed to a U in the mouse L2 loop (Figure 2.11B–D). Indeed, position 66
is the only nucleotide in the upper P2-L2 that is not 100% conserved among
the mammalian TNFα sequences analyzed, differing, for instance, between the
closely related human and chimpanzee. However, decay activity was lost when
the entire UGU loop was replaced by ACA (M25, Figure 2.13C), indicating
that the CDE allows only for limited nucleotide variation in the L2 loop.
Interestingly, the P2-L2 stem-loop in isolation was sufficient to promote rapid
mRNA degradation when I provided an open, single-stranded (ss) conforma-
tion at the base of the P2 stem (CDE17-ss, Figure 2.13D). In CDE17-ss flank-
ing XbaI-AgeI sites mimic the open conformation of the L1 loop. In contrast,
the CDE was inactive when I terminally elongated the P2 stem by base-pairing
sequence (CDE17-ds), suggesting that the L1 loop at the base of P2 is also an
important structural feature of the active CDE providing unpaired sequences
in the natural context of the TNFα 3’UTR. From these experiments I con-
cluded that the 17 nt long P2-L2 stem-loop with unpaired flanking nucleotides
is the minimal element sufficient to induce CDE-mediated mRNA decay.
2.2.3 Identification of CDE-binding Proteins
As demonstrated in the previous chapter, I developed 4xS1m-mediated mRNP
purification with the aim to identify specific RNA-BPs to RNA elements of in-
terest. One major motivation for this project was to find CDE-binding proteins
(CDE-BPs), as functional interaction partners were previously not known.
Thus, I applied my optimized technique to the CDE by constructing 4xS1m-
tagged CDE37 RNAs for protein pulldown. Importantly, prior to up-scaled
purifications, I confirmed that 4xS1m alone in context of an mRNA reporter
does not induce mRNA decay. It does also not interfere with CDE-mRNA de-
cay in transiently and stably transfected NIH3T3 cells (Figure 2.14A). Next,
in vitro transcribed CDE37-4xS1m and control 4xS1m RNAs were coupled
to SA for affinity purification of proteins from NIH3T3 cell lysates (Figure
2.14B). While most purified proteins were associated with both RNAs, I was
able to identify proteins specifically enriched with CDE37-4xS1m by MS based
on peptide counts (Figure 2.14C). Strongest peptide enrichment was ob-
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Figure 2.13: Mutational Analysis of the TNFα CDE Stem-Loop. (A) Summary
of P2 stem mutations introduced into the TNFα CDE, either to disrupt or compensate
P2 structure as in Figure 2.12. The mutated CDE37 in the V3 context were cloned
into the globin reporter gene 3’UTR, and mRNA decay was measured in transiently
transfected NIH3T3 cells, average t1/2 ± SD, n ≥ 3. (B) P2 disrupting mutation M16
and compensatory mutation M20 were introduced into globin-TNFα-CDE150, and mRNA
decay was measured in transiently transfected NIH3T3 cells by Northern blot analysis,
average t1/2± SD, n ≥ 3. (C) L2 loop mutations were introduced into globin-TNFα-
CDE37-V3, and mRNA half-lives (average t1/2 ± SD, n = 4) were measured as in B. (D)
The TNFα P2-L2 stem loop (CDE17) was tested in two different cloning contexts that
provide a ss or ds conformation at the base of P2. Reporter mRNA half-lives (average
t1/2 ± SD, n = 3) were measured as in B. The mutgenesis analysis was performed with
the assistance of Sonja Reitter. Reproduced with permission from Cell, Elsevier.
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served for Roquin (Rc3h1, RING finger and CCCH zinc finger protein 1).
Its paralog Rc3h2, which I refer to as Roquin2, was also purified specifically
with CDE37-4xS1m. Roquin has previously been described as a protein that
prevents autoimmunity by destabilizing the mRNA encoding ICOS [225] and
thus seemed to be a very promising candidate regulator important for CDE-
mediated mRNA decay.
2.2.4 Roquin and Roquin2 Specifically Bind to the CDE
I obtained a plasmid encoding EGFP-Roquin from the Vigo Heissmeyer group.
In parallel, Sonja Reitter generated the according EGFP-Roquin2 plasmid
based on a cDNA clone. With these tools on hand I performed RNA-IP. By
RNA-IP using EGFP-binder beads, I could show that EGFP-Roquin strongly
associated with globin-CDE37 reporter mRNA, but not with the globin mRNA
alone (Figure 2.15B). I obtained the same results with EGFP-Roquin2. I
then investigated the two inactive CDE37-mutants M7 and M9 in EGFP-
Roquin RNA-IP (Figure 2.15B). M7 was bound equally well compared to
the WT CDE37, while M9 did not interact. In M7, base-pairing of 2 nts is
disrupted in the basal part of the P2 stem. Roquin seemed to still be able
to associate with this mutant. The M9, in which a 4 nt mutation affects the
apical P2 stem and the L2 loop however, is altered too much to be recognized.
Of note, both CDE37-M7 and -M9 did not induce mRNA decay in the absence
of exogenous Roquin in NIH3T3 cells as seen in the EGFP control (Figure
2.15C). Interestingly, decay of the CDE37-M7 mRNA was activated by co-
expression of EGFP-Roquin, whereas the CDE37-M9 mRNA remained stable.
This suggested that Roquin may interact with the apical part of P2-L2, and
that overexpression of EGFP-Roquin might be sufficient to stabilize M7 in the
active conformation.
By RNA-IP, I verified that EGFP-Roquin and -Roquin2 strongly associate
with globin-CDE150 reporter mRNA as well (Figure 2.16A). Disrupting the
P2 stem in the CDE mutant M16 in context of CDE150 dramatically reduced
binding to EGFP-Roquin, while restoring the stem through a compensatory
mutation in M20 rescued Roquin-binding (Figure 2.16A). Thus, this showed
that Roquin recognizes the CDE as a stem-loop motif. It also indicated that
the CDE stem-loop forms in context of its native UTR sequence which is bound
by Roquin. Additionally, Fabian Pötz could show by in vivo crosslinking, sub-
sequent EGFP-Roquin-IP and urea washes that the Roquin-CDE association
occurs inside cells [246].
Roquin has been reported to localize in P-bodies in T cells [226], cytoplasmic
foci in which most enzymes required for mRNA degradation are concentrated
[219]. By immunofluorescence microscopy, Sonja Reitter could clearly visualize
59
Chapter 2 Results
Figure 2.14: CDE RNA Affinity Purification of CDE-BPs Enriches for Roquin
and Roquin2. (A) NIH3T3 cells were transiently (upper panel) and stably (lower panel)
transfected with globin reporter genes containing either the TNFα CDE37, the improved
SA-binding aptamer 4xS1m, or both, in their 3’UTR. Reporter mRNA decay measure-
ments by Northern blot analysis was done as in Figure 2.11D. (B) For purification of
CDE-BPs, RNAs containing the 4xS1m alone or CDE37-4xS1m were transcribed in vitro,
coupled to SA Sepharose beads, and incubated with cytoplasmic NIH3T3 cell extracts.
After washing, proteins were eluted from the matrix using RNase A, resolved by PAGE
and visualized by colloidal Coomassie blue staining. MWM, molecular weight marker.
(C) Out of the 252 proteins identified by MS, I only list those for which the peptide
count in the CDE-4xS1m purification was ≥ 3 times higher than in the control 4xS1m.
Reproduced with permission from Cell, Elsevier.
60
2.2 Roquin-mediated Constitutive Decay of CDE-containing mRNAs
Figure 2.15: Roquin Binding and Overexpression Analysis of CDE-mutants
M7 and M9. (A) Schematic representation of mouse TNFα CDE-mutants M7 and M9
mapped onto the CDE37 stem-loop structure. (B) Binding of Roquin to CDE37-M7 and
-M9 was analyzed by RNA-IP as in Figure 2.6A showing that the CDE37-M7 reporter
mRNA binds to Roquin almost as efficiently as the WT CDE37 reporter mRNA while
CDE37-M7 does not bind. (C) The effect of EGFP-Roquin overexpression on degradation
of the control globin reporter mRNA lacking an insert (-) as well as mutant globin-TNFα-
CDE37-M7 and -M9 mRNA was examined by transient transfection in NIH3T3 cells, as
described in Figure 2.11D. mRNA half-lives are given as average values ± SD, n = 3.
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co-localization of EGFP-Roquin and EGFP-Roquin2 with the P-body marker
Rck in distinct cytoplasmic foci in HeLa, NIH3T3 and Huh7 cells (Figure
2.16C). In the meantime, this finding has been confirmed in HEK cells by
others [239]. Roquin-induced mRNA deadenylation may thus be linked to
relocalization of targeted mRNAs to P-bodies.
Roquin contains a RING finger, a ROQ domain, a ZF and a poorly defined
C-terminal, proline-rich domain (Figure 2.16B). Since ZFs are frequently in-
volved in RNA binding, as seen for many well-studied RNA-BPs like TTP
[129], Sonja Reitter examined if the Roquin ZF domain is important for its
function. She was able to show that mutation of the ZF domain in Roquin
(C419R) [246] and Roquin2 (C416R) did neither alter their ability to associate
with globin-CDE37 mRNA to accelerate CDE mRNA degradation, nor their
localization to P-bodies. Fabian Pötz then conducted domain-function analy-
ses by investigating Roquin deletion mutants (Figure 2.16B). While deletion
of the RING domain (ΔRING) had no effect compared to the WT, deletion of
the ROQ domain (ΔROQ) prevented binding to the CDE37 reporter mRNA,
decay activity and P-body localization. In line with this result, Roquin N-term
as well as the ROQ domain alone were able to associate with globin-CDE37
mRNA, whereas Roquin C-term was not. Of all these truncation mutants
only ΔRING was found to localize in P-bodies. I also tested the activity of
fulllength Roquin containing the sanroque mutation harboring a single amino
acid substitution (M199R) due to which sanroque mice display a lupus-like
autoimmune syndrome [227]. This is believed to be caused by increased ICOS
mRNA expression due to impaired Roquin function while RNA binding ac-
tivity does not change [245]. With regard to RNA-IP and decay promoting
activity, Roquin-M199R interacted with the CDE and mediated decay as WT
Roquin (data not shown). Thus, I did not further investigate the sanroque
mutation. These results are summarized in the table in Figure 2.16C.
By EMSA, I then examined whether Roquin interacts directly with the CDE
RNA in vitro. First, I purified recombinant Roquin-N protein (amino acids
2–440, Suppl. Figure 5.4A) already described in Glasmacher et al. (2010),
which could be obtained in a highly pure form (Suppl. Figure 5.4B).
Roquin-N was found to efficiently bind to a 23 nt long CDE stem-loop RNA
(CDE23), which consists of the P2-L2 stem-loop plus three adjacent nucleotides
of L1 at each end, with an apparent Kd of 92 nM (Figure 2.17). In contrast,
the mutant CDE23-M23 harboring a compensatory 2 base-pair mutation in the
functionally important apical part of P2 did not associate with Roquin-N, and
an unstructured ARE RNA of identical length did not bind either (Figure
2.17). In summary, from these experiments I concluded that Roquin recog-
nizes the CDE stem-loop with high specificity both in vitro and inside cells.
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Figure 2.16: Specific Binding of Roquin to the CDE Inside Cells. (A) Binding
of Roquin to the mouse TNFα CDE150 was analyzed by RNA-IP. HEK293 cells were
transiently transfected with EGFP, EGFP-Roquin or -Roquin2 together with a globin
reporter lacking an insert (-), globin-TNFα-CDE150, or the corresponding M16 and M20
mutants. Upon IP, EGFP-tagged proteins were monitored by anti-GFP Western blot
analysis. Associated reporter mRNAs were visualized by Northern blot analysis, ncl
mRNA serves as negative control. The fraction of mRNA bound by IP is given as %
of the input. (B) Schematic representation of mouse Roquin domains; ZF, zinc finger.
Deletion mutants are depicted below the fulllength protein. Numbers indicate amino
acid positions, M199 refers to the position mutated to R in sanroque mice. (C) Table
summarizing structure-function analysis of Roquin fulllength and fragments with respect
to CDE decay activity as well as CDE and Caf1/Not1 interaction. The majority of the
domain analysis was performed by Fabian Pötz, while ZF mutants and Roquin2 construct
generation, as well as localization analysis was done by Sonja Reitter. Reproduced with
permission from Cell, Elsevier.
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Figure 2.17: Specific Binding of Roquin to the CDE in vitro. Binding of re-
combinant Roquin-N (aa 2–440) to the CDE23 RNA was examined in vitro by EMSA.
Radiolabeled CDE23, CDE23-M23 and TNFα-ARE RNAs were incubated with increasing
concentrations of Roquin-N. Free RNA (black arrow) was separated from RNA-protein
complexes (white arrow) by native PAGE. The apparent dissociation constant Kd ± SE
was calculated from quantification of three independent experiments. Reproduced with
permission from Cell, Elsevier.
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2.2.5 Roquin and Roquin2 Promote CDE-mediated mRNA
Decay
As a first test for Roquin function, EGFP-Roquin or -Roquin2 were ectopi-
cally expressed (Figure 2.18) in HeLa and NIH3T3 cells to examine whether
Roquin and Roquin2 are important for CDE-mediated mRNA decay. By West-
ern blot analysis (Figure 2.18A), I showed that in both cell lines, the amount
of overexpressed EGFP-Roquin is highly increased with respect to endogenous
Roquin levels. Roquin2 could not be detected due to lack of a specific anti-
body. I found both overexpressed EGFP-Roquin and -Roquin2 to accelerate
degradation of globin-CDE150 mRNA up to 4-fold compared to the EGFP
control in NIH3T3 cells (Figure 2.18B). This effect was less pronounced for
globin-CDE37 mRNAs as its decay in the absence of excess Roquin was al-
ready very fast. The reporter mRNA lacking a CDE remained stable (Figure
2.18C). In HeLa cells, that generally do not mediate CDE mRNA decay, el-
evated expression of Roquin accelerated CDE-mediated mRNA decay even
more strongly. Degradation of globin-CDE37 (Figure 2.18D) and globin-
CDE150 (Figure 2.18E) reporter mRNA was induced by overexpression of
EGFP-Roquin and -Roquin2. Hereby, Roquin2 appeared to be less effective in
decay induction, possibly because EGFP-Roquin2 is expressed at lower levels
than EGFP-Roquin in HeLa cells with identical amounts of plasmid trans-
fected (Figure 2.18A). This analysis indicated that in both NIH3T3 and
HeLa cells, mRNA decay of CDE-containing mRNAs can be accelerated by
ectopical overexpression of Roquin and Roquin2.
Taking the opposite approach, I then examined the effect of knocking down
Roquin and Roquin2. In NIH3T3 cells, knockdown (kd) of either protein
alone (Suppl. Figure 5.5A) caused a modest 2-fold stabilization of globin-
CDE37 mRNA, whereas the simultaneous kd of both proteins led to a 7-fold
stabilization (Figure 2.19A and (Suppl. Figure 5.5B). Fabian Pötz then
constructed an siRNA-resistant Roquin cDNA that cannot be recognized by
siRNA Roquin (B) (si(B)-res) and thus rescues Roquin expression after si-
Roquin (B) kd in HEK and NIH3T3 cells as validated by Western blot anal-
ysis (Suppl. Figure 5.5C). Expression of si(B)-res Roquin cDNA restored
degradation of the CDE37 reporter mRNA after kd of endogenous Roquin and
Roquin2 (Figure 2.19B), demonstrating the specificity of the Roquin kd ef-
fect on CDE mRNA decay.
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Figure 2.18: Roquin Overexpression Accelerates CDE-mediated mRNA
Degradation. (A) Equal amounts of plasmid encoding EGFP, EGFP-Roquin or EGFP-
Roquin2 were transiently transfected into HeLa and NIH3T3 cells, corresponding to the
amounts used for the experiments in B-E. Upper panel, proteins were detected by anti-
GFP Western blot analysis, tubulin serves as a loading control; middle panel, endogenous
Roquin and EGFP-Roquin were detected using an anti-Roquin antibody, HuR serves
as a loading control; bottom panel, same analysis in NIH3T3 cells. (B) NIH3T3 cells
were transiently transfected with EGFP, EGFP-Roquin or -Roquin2 together with globin-
TNFα-CDE150. Reporter mRNA degradation was measured as in Figure 2.11D, average
t1/2 ± SD, n ≥ 3. Right panel, decay curves show average globin reporter mRNA levels
normalized to ncl mRNA as % of the initial value (± SD), plotted against time. (C)
The effect of EGFP-Roquin overexpression on degradation of the control globin reporter
mRNA as well as globin-TNFα-CDE37-V3 mRNA was examined by transient transfection
in NIH3T3 cells, as described in Figure 2.11D, average t1/2 ± SD, n = 3. (D) HeLa cells
were transiently transfected with EGFP, EGFP-Roquin or EGFP-Roquin2 together with
globin-TNFα-CDE37-V3. Left panel, degradation of the reporter mRNA was measured as
in Figure 2.11D, average t1/2 ± SD, n ≥ 3. Right panel, decay curves as in B. (E) The
same analysis as in D with the globin-TNFα-CDE150 reporter. Overexpression analysis
was performed with the assistance of Sonja Reitter. Reproduced with permission from
Cell, Elsevier.
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Figure 2.19: Roquin is Required for CDE-mediated mRNA Degradation. (A)
Knockdown of Roquin and Roquin2, either alone or in combination, and transient ex-
pression of globin-TNFα-CDE37-V3 in NIH3T3 cells. Reporter mRNA decay rates were
quantified from Northern blots (depicted in Suppl. Figure 5.6B), average t1/2 ± SD, n
≥ 3. The p-value (one-sided T-test) is given for t1/2 of double Roquin/Roquin2 kd and
combined controls. (B) EGFP or EGFP-Roquin-si(B)-res was transfected into NIH3T3
cells one day after transfection of control siRNA C2 or Roquin-siRNA (B). Degradation
of globin-TNFα-CDE37-V3 reporter mRNA was measured on day 2 as in Figure 2.11D.
(C) RAW264.7 cells were transfected twice over a period of 2 days with water (H2O), con-
trol siRNA (C2), or two different siRNAs against Roquin (Roquin (A) and Roquin (B)).
Roquin protein levels were assessed by Western blot analysis. (Figure legend continued
on next page)
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Figure legend continued: (D) RAW264.7 cells were transfected with siRNAs as in C, and
stimulated with LPS (100 ng/ml) for 2 hours prior to addition of actD. Endogenous TNFα
mRNA decay was measured by Northern blot analysis, ribosomal protein S7 mRNA serves
as loading control; average t1/2 ± SD, n = 3. (E) TNFα mRNA expression in response to
LPS was analyzed by Northern blot in RAW264.7 cells subjected to Roquin or control kd.
Right panel, quantification of average TNFα mRNA levels normalized to S7 mRNA (± SD, n
= 3). (F) Synthesis of mTNFα and sTNFα in response to LPS was analyzed by Western blot
in RAW264.7 cells subjected to Roquin or control kd. Quantification of mTNFα normalized
to tubulin is shown. (G) TNFα secretion was measured by ELISA in the supernatants of
RAW264.7 cells treated as in E. The graph shows normalized TNFα levels (average ± SE, n
= 3). (H) Degradation of TNFα mRNA was measured in resting RAW264.7 macrophages
by RT-qPCR after normalization to NupL1 mRNA. Shown are average values ± SD, n = 3.
Data in H was obtained by Sonja Reitter. Reproduced with permission from Cell, Elsevier.
These results were corroborated in LPS-stimulated RAW264.7 macrophages,
where kd of Roquin by two different siRNAs ((A) and (B)), as monitored by
Western blot analysis (Figure 2.19C), led to a 2- to 4-fold stabilization of
endogenous TNFα mRNA (Figure 2.19D) as shown by Northern blot analy-
sis. Importantly, Roquin kd by siRNA (A) and (B) prevented rapid clearance
of TNFα mRNA during prolonged exposure of macrophages to LPS up to
12 hours (Figure 2.19E). In stimulated macrophages, after a sharp early in-
crease, TNFαmRNA levels would normally decrease with time due to activated
anti-inflammatory pathways as seen for the si-C2 control. When I examined
TNFα protein levels, I observed that Roquin kd caused elevated levels of both
membrane-bound (m) and secreted (s)TNFα, as shown by Western blot anal-
ysis and ELISA (Figures 2.19F–G). Of note, the simultaneous kd of Roquin
and Roquin2, as seen to be necessary for a full response in NIH3T3 cells before,
did not cause a further increase in TNFα mRNA (Suppl. Figure 5.5D) or
protein (Suppl. Figure 5.5E) levels in macrophages as compared to kd of
Roquin alone. This was presumably because Roquin depletion was less effi-
cient in the double kd condition (Suppl. Figure 5.5F). In addition, Sonja
Reitter detected that in unstimulated macrophages, TNFα mRNA was also
stabilized upon kd of Roquin (Figure 2.19H). Taken together, these results
demonstrate that Roquin, by binding to the CDE and accelerating mRNA
decay, is crucial for limiting TNFα production in both resting and activated
macrophages.
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2.2.6 Roquin Promotes CDE-mRNA Deadenylation by
Recruitment of Ccr4-Caf1-Not
To further explore the mechanism of Roquin-induced mRNA decay, Sonja Re-
itter stably expressed EGFP, EGFP-Roquin and EGFP-Roquin2 in HEK293
cells and affinity-purified them via the GFP-binder. By MS, this revealed
Not1 to be strongly associated with both Roquin and Roquin2 [246]. Not1
is the scaffold subunit of the Ccr4-Caf1-Not complex, a major deadenylase in
eukaryotic cells [317, 163]. Indeed, virtually all the other subunits of the com-
plex including Not2, Not3, Not10, TAB182, Ccr4b, Caf1a and Caf1b were
enriched in the Roquin and Roquin2 purifications. By co-IP, I confirmed
that EGFP-Roquin and -Roquin2 interact with endogenous Not1 and Caf1a
(Figure 2.20A), which Fabian Pötz also confirmed to be occurring in an RNA-
independent manner [246]. He also found that it is the C-terminal domain of
Roquin that associates with Not1 and Caf1a (Figure 2.16C, [246]).
A previous study suggested that Roquin may activate ICOS mRNA degrada-
tion by interacting with enhancers of mRNA decapping [226]. However, and
in line with the finding that Roquin interacts with the deadenylase complex,
I noticed that EGFP-Roquin primarily enhanced deadenylation of a CDE-
containing mRNA (Figure 2.18C). I thus tested Caf1a-AA, a dominant-
negative mutant of the deadenylase Caf1a, generated in the Stoecklin lab be-
fore [131]. I found that its overexpression fully blocked both deadenylation and
degradation of globin-CDE37 mRNA as observed on higher resolution North-
ern blots (Figure 2.20B). As opposed to Caf1a-AA, overexpression of neither
Caf1a-WT (Figure 2.20C) nor of the dominant-negative decapping enzyme
Dcp2-AA (Figure 2.20B) affected CDE-mRNA decay showing that CDE re-
porter mRNA is deadenylated before the body of the mRNA is degraded. The
strong inhibitory effect of dominant-negative Caf1a-AA indicated that dead-
enylation is the first step in CDE-mediated mRNA degradation. These data
provide strong evidence that Roquin recruits the Ccr4-Caf1-Not complex and
thereby induces rapid deadenylation and subsequent degradation of its target
mRNAs.
2.2.7 ICOS mRNA Contains a Functional CDE
Roquin was reported to enhance the degradation of ICOS mRNA [227, 225],
yet the exact binding motif was unknown. By empirically inspecting the ICOS
sequence, I found a highly conserved CDE-like element in the 3’UTR of human
and mouse ICOS (Figure 2.21A), as well as other mammals, as annotated
in NCBI (Figure 2.21B). I saw that while the stem in the ICOS element
is 2 base-pairs shorter than the P2 stem in the TNFα CDE, the functionally
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Figure 2.20: The CDE Induces Caf1-dependent mRNA Deadenylation. (A)
HEK293 cells were transiently transfected with EGFP, EGFP-Roquin or -Roquin2. After
EGFP-IP from cytoplasmic lysates endogenous Not1 and Caf1a were detected by Western
blot analysis. (B) NIH3T3 cells were transiently transfected with globin-TNFα-CDE37-
V3 together with a vector control, dominant-negative Dcp2-AA or dominant-negative
Caf1a-AA. Reporter mRNA degradation was analyzed as in Figure 2.11D, except that
RNA was resolved on a higher resolution 1.6% agarose gel. dT, treatment of RNA with
oligo-dT and RNase H to remove poly(A) tails, average t1/2 ± SD, n = 3. Bottom panel,
deadenylation was visualized by quantifying the signal intensity (A.U., arbitrary units)
of the reporter mRNA along the length of the signal, plotted against mRNA size; A+,
polyadenylated; A-, deadenylated mRNA. (C) NIH3T3 cells were transiently transfected
with globin-TNFα-CDE37-V3 together with either vector control, WT Caf1a or Caf1a-
AA. mRNA degradation was analyzed as in B. Reproduced with permission from Cell,
Elsevier.
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important apical part of the stem is identical in sequence. When I cloned it into
the ss globin 3’UTR context, ICOS CDE17-ss induced reporter mRNA decay,
which was further accelerated by overexpression of EGFP-Roquin (Figure
2.21C). These results imply that Roquin recognizes the ICOS mRNA via a
functional CDE-like stem-loop motif.
2.2.8 Roquin Recognizes a Conserved Class of
CDE-containing mRNAs
With the aim to predict CDE-containing mRNAs genome-wide, Johanna
Schott combined our experimental mutagenesis data and derived a structure-
and sequence-based CDE consensus motif (Figure 2.22A). CDEs were defined
by a trinucleotide pyrimidine-purine-pyrimidine loop and a 5–8 base-pairs long
stem whose apical 3 base-pairs match the consensus in the TNFα and ICOS
CDE. For bioinformatics analyses, her CDE conservation criteria only classified
detected stem-loops as CDEs that were conserved in >10/46 vertebrate species
based on the UCSC 46 vertebrate genome alignment [318]. When she searched
all 3’UTRs of the mouse transcriptome, she identified 109 putative CDEs in
108 genes [246]. Notably, 56 of the identified CDEs were highly conserved in
>10 out of 46 vertebrate species (Figure 2.22C, [246]). She further showed
that the corresponding genes are preferentially associated with regulation of
development, transcription, nucleic acid metabolism and T cell differentiation
based on Gene Ontology (GO)-term analysis [246].
I next aimed at experimentally determining Roquin target mRNAs. Thus,
I immunoprecipitated endogenous Roquin from cytoplasmic lysates of LPS-
stimulated macrophages (Figure 2.22B) and identified Roquin-associated
mRNAs (Suppl. Table 5.2) by deep sequencing of RNA samples. The
bioinformatics analysis of deep sequencing data was all performed by Johanna
Schott. Importantly, the three biological replicates were highly reproducible
(Suppl. Figure 5.6). Remarkably, 15 mRNAs with conserved CDEs in the
3’UTR, based on our criteria, showed a strong and highly significant enrich-
ment in the Roquin-IP (red in Figure 2.22D, frequency of association in
Figure 2.22C). There were four mRNAs enriched that contain a CDE in the
ORF, as well as additional 76 enriched mRNAs that lack a CDE. However,
the group of mRNAs that were highest enriched were at the same time the
ones harboring conserved CDEs. This major finding strongly supported our
previous data and demonstrateed that Roquin target mRNAs preferentially
contain a conserved and thus putative functional CDE.
For the highest enriched Roquin target mRNA candidates, I derived a sec-
ondary structure consensus for their respective CDEs based on conservation
data provided in the UCSC Genome alignment (Figure 2.23A). The top
71
Chapter 2 Results
Figure 2.21: ICOS mRNA Contains a Functional CDE. (A) Schematic represen-
tation of the human and mouse ICOS 3’UTRs. The CDE-like stem-loop in the mouse
ICOS 3’UTR and the mouse TNFα CDE17 are shown within the ss-cloning context. Nu-
cleotides are color-coded according to conservation, as in Figure 2.11. (B) Sequence
conservation of the ICOS CDE based on the alignment of seven mammalian species, num-
bers refer to nucleotide positions in the mouse ICOS 3’UTR. Color-code according to
conservation as in Figure 2.11, pairing elements (green). (C) NIH3T3 cells were tran-
siently co-transfected with EGFP or EGFP-Roquin together with globin-TNFα-CDE17-ss
or globin-ICOS-CDE17-ss. Reporter mRNA decay was measured as in Figure 2.17B, av-
erage t1/2 ± SD, n ≥ 3. Reproduced with permission from Cell, Elsevier.
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Figure 2.22: Genome-wide Identification of CDEs and Roquin Target mRNAs.
(A) Consensus CDE stem-loop motif used for bioinformatics prediction of CDE-containing
mRNAs generated by Johanna Schott. (B) Endogenous Roquin (Roq) was immunopre-
cipitated from cytoplasmic lysates of RAW264.7 macrophages ± stimulation with LPS
(100 ng/ml) for 2 hours. HA-antibody was used for control (ctrl) IP. Roquin-IP was mon-
itored by Western blot analysis, RNA-binding proteins G3BP and HuR serve as controls
for specificity. (C) Numbers of genes predicted to contain a CDE and corresponding mR-
NAs significantly enriched by Roquin-IP from LPS-stimulated RAW264.7 macrophages.
Significant enrichment is defined by a p-value ≤ 0.005 (Roquin-IP vs control-IP) and fold
enrichment (Roquin-IP / control-IP) > 8.0. pfreq represents the hypergeometric probabil-
ity of randomly finding the observed number of mRNAs enriched by Roquin-IP in each of
the four groups of mRNAs, given the overall frequency of 95 significantly enriched mRNAs
in a total of 13,759 mRNAs. Analysis performed by Johanna Schott. (D) mRNAs associ-
ated with Roquin in LPS-stimulated RAW264.7 macrophages were recovered by RNA-IP
and identified by RNA-Seq, n = 3. Left: average enrichment (Roquin-IP / control-IP)
is plotted for all RefSeq-annotated transcripts that were identified, grouped according to
the bioinformatics prediction of CDEs. Right: enrichment over input is depicted for the
same transcripts. The color code refers to C. Analysis performed by Johanna Schott.
Reproduced with permission from Cell, Elsevier.
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Roquin target (475-fold enrichment) was Nfkbid mRNA, which also represents
the only mouse transcript that contains a tandem CDE stem-loop motif in its
3’UTR (Figure 2.23A). The mRNAs encoding Roquin and Roquin2 them-
selves contain conserved CDEs and were enriched by Roquin-IP, suggesting
that Roquin proteins may regulate their own mRNAs as part of a feedback
loop. Consistent with my previous results, TNFα and ICOS mRNA were
strongly enriched by Roquin-IP. Thus, an unbiased RNA-IP approach provided
compelling evidence that CDE-containing mRNAs are the primary targets of
Roquin.
I then verified binding of several mRNAs containing conserved CDEs (Figure
2.23A) by IP of endogenous Roquin from macrophages followed by RT-qPCR.
TNFα mRNA was found to associate with Roquin to a similar degree in resting
and stimulated macrophages (Figure 2.23B, left panel). Like TNFα mRNA,
several of the candidate CDE mRNAs, especially immune regulators as Nfkbiz
and Ier3, were induced in expression upon LPS treatment of macrophages and
were hardly detected in resting cells (Suppl. Figure 5.7A). In contrast to
four control mRNAs lacking a CDE, six out of seven mRNAs with conserved
CDEs were strongly enriched (≥20-fold) by Roquin-IP from LPS-stimulated
RAW264.7 macrophages (Figure 2.23B, right panel). For target mRNAs
detectable also in resting macrophages, all data are summarized in Suppl.
Figure 5.7B. Together, these data suggested that all putative Roquin targets
tested could be confirmed to specifically associate with Roquin in RAW264.7
cells.
I further investigated, with the help of Johanna Schott, whether Roquin con-
trols the degradation of newly identified, CDE-containing target mRNAs. In-
deed, kd of Roquin and Roquin2 led to the stabilization of Nfkbiz, Ier3,
Ppp1r10 and Hmgxb3 mRNA in NIH3T3 cells while ectopic expression of
siRNA-resistant Roquin impressively restored the degradation of these mR-
NAs (Figure 2.23C). Nfkbid mRNA could not be analyzed in NIH3T3 cells
due to its low expression level in these cells, but was as well found to be sta-
bilized by kd of Roquin in RAW264.7 macrophages (Figure 2.23D). These
results demonstrate that Roquin not only associates with CDE mRNAs but in
fact regulates the degradation of numerous mRNAs containing CDE stem-loop
motifs.
2.2.9 Interference with CDE-Roquin Binding Alleviates
TNFα Suppression
Finally, I explored whether Roquin-mediated mRNA regulation could be
blocked with a trans-acting antisense morpholino (MO) that interferes with
CDE stem-loop formation. CDE-MO-1 and -2 were designed to base-pair with
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Figure 2.23: Confirmation of CDE-containing mRNAs as Roquin Targets. (A)
Secondary structures predicted for conserved CDEs representing the mouse CDE. Nu-
cleotides are color-coded according to conservation (UCSC genome alignment) as in Figure
2.11. (B) Binding of mRNAs by Roquin RNA-IP. Left: TNFα mRNA was quantified by
RT-qPCR after IP of Roquin from RAW264.7 macrophages ± stimulation with LPS (100
ng/ml) for 2 hours. The signal was divided by the amount of TNFα mRNA in the control
IP, and expressed as fold enrichment (average ± SE, n ≥ 7). Right: average enrichment
± SE (n ≥ 3) of 4 control mRNAs and 7 mRNAs containing conserved CDEs. (C) Degra-
dation of the CDE-containing Nfkbiz, Ier3, Ppp1r10 and Hmgxb3 mRNAs was measured
by RT-qPCR in NIH3T3 cells after control kd (siRNA C2), kd of Roquin/Roquin2, and
rescue by siRNA-resistant Roquin. All mRNA levels were normalized to NupL1 mRNA,
average t1/2 ± SE, n = 3. (D) Degradation of the tandem CDE-containing Nfkbid mRNA
was measured by RT-qPCR in RAW264.7 macrophages after stimulation with LPS (100
ng/ml) for 2 hours. Nfkbid mRNA levels were normalized to NupL1 mRNA, average t1/2
± SE, n = 3. Data in C and D were generated with the assistance of Johanna Schott and
Sonja Reitter. Reproduced with permission from Cell, Elsevier.
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Figure 2.24: Interference with CDE-Roquin Binding Elevates TNFα Expres-
sion. (A) Schematic representation of antisense moropholinos Ctrl-MO, CDE-MO-1,
CDE-MO-2 and UTR-MO interacting with the TNFα 3’UTR. (B) MOs were transfected
into HEK293 cells together with EGFP-Roquin and globin-TNFα-UTR containing the
entire mouse TNFα 3’UTR. Proteins were monitored after EGFP-IP by anti-GFP West-
ern blot analysis. Reporter mRNA binding was monitored as in Figure 2.15A. (C) One
day after MO delivery into RAW264.7 macrophages using 2 µM Endo-Porter, cells were
stimulated with LPS (100 ng/ml) for 6 hours. Rck, TNFα and Nfkbid mRNA levels were
measured by RT-qPCR and normalized to NupL1; average values ± SE, n = ≥6; * indi-
cates p < 0.05 by two-tailed, paired T-test. (D) Ctrl-MO and CDE-MO-2 were delivered
into primary mouse BMDM as in C. Left: average mRNA values ± SE, normalized to
NupL1, n = 9, were measured by RT-qPCR. Right: mTNFα protein was assessed by
Western blot analysis; quantification of mTNFα normalized to tubulin is depicted below
the blot, average values ± SE, n = 6. Reproduced with permission from Cell, Elsevier.
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the left and right arm of the TNFα CDE stem-loop, respectively (Figure
2.24A). As controls, I used a provided Ctrl-MO lacking any target sequence
and UTR-MO, a morpholino designed to base-pair with the TNFα 3’UTR
downstream of the CDE. RNA-IP of EGFP-Roquin in HEK cells showed that
CDE-MO-2 reduces binding of Roquin to the 3’UTR of TNFα mRNA by 4-
fold (Figure 2.24B). In contrast, CDE-MO-1 was not able to compete with
CDE-Roquin binding, presumably because the portion that needs to invade the
P2-L2 stem-loop is shorter in CDE-MO-1 (7 nt) than in CDE-MO-2 (11 nt).
When introduced into RAW264.7 macrophages and upon LPS stimulation for
6 hours, I saw that CDE-MO-2 specifically increased the expression of endoge-
nous TNFα mRNA by 1.5-fold (Figure 2.24C), whereas it did not affect two
control mRNAs: Rck, which does not contain a CDE, and Nfkbid, whose tan-
dem CDEs lack sequence complementarity to CDE-MO-2 outside of the stems.
The extent to which CDE-MO-2 increased TNFα mRNA expression was sim-
ilar to the effect of Roquin kd on TNFα mRNA steady-state levels (1.7-fold,
[246]). Importantly, CDE-MO-2 also elevated expression of TNFα mRNA and
protein in mouse primary bone marrow-derived macrophages (BMDM, Figure
2.24D). Since the morpholino approach was effective in primary cells, inter-
fering with structured RNA motifs in trans may represent a future strategy to
influence inflammatory responses in a therapeutic setting.
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3 Discussion
In my PhD thesis, I unravelled the mechanism of how Roquin proteins regulate
decay of CDE-containing mRNAs [246]. For that, I first improved an in vitro
approach for mRNP purification. I developed the optimized SA-binding RNA
aptamer 4xS1m and demonstrated that it is successful in purifying novel ARE-
BPs [303]. With this method, I identified Roquin and Roquin2 to specifically
recognize the CDE. I found that the CDE is a structured RNA motif that folds
into a stem-loop. Roquin then attracts the Ccr4-Caf1-Not deadenylase com-
plex to degrade the mRNA from the 3’ end. Initially discovered in the TNFα
mRNA 3’UTR [62], I now show that functional CDEs represent a whole class
of novel decay elements in the 3’UTR of many mRNAs of physiological impor-
tance. This demonstrates the importance of regulatory RNA structures bound
by RNA-BPs in mammals for the control of critical processes like the immune
response. Additionally, the ability to interfere with the Roquin-CDE interac-
tion using a morpholino approach provides a means of possible applicability
in a therapeutic setting. By this, I hope to initiate future investigations that
discover and decipher the function of regulatory mRNA structures in higher
eukaryotes to highlight their contribution to posttranscriptional control of gene
expression.
3.1 An Optimized RNA Aptamer for mRNP
Purification
The ability to capture a snapshot of an mRNP’s composition remains a chal-
lenge but offers important insight into how complex cellular machineries work.
Here, I present an in vitro purification approach that makes use of the opti-
mized SA-aptamer tag 4xS1m developed herein [303].
3.1.1 The 4xS1m Aptamer is More Efficient than S1
In this study I improved a structured SA-binding RNA aptamer. RNA struc-
ture is critical for aptamer function as the tag might adopt flexible confor-
mations that do not recognize its target. For S1m, I aimed at stabilizing the
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terminal S1 RNA structure by elongating the basal stem of the original S1 ap-
tamer [291] by eight base-pairs (in yellow) (Figure 2.1A). I also stabilized its
structure by point mutations (in red) similar to the design in Xu et al. (2009)
that cause perfect strand complementarity [306]. Thereby, the SA-binding
portion of the aptamer would further protrude from the mRNP into the cyto-
plasm. I chose to introduce the aptamer 3’ to the reporter gene and regulatory
element instead of internally, as previously reported [126, 291], in order not
to disrupt RNA structure. When I inserted multiple consecutive copies of
S1m into the reporter gene, I included a 21 nts long linear linker sequence in
between individual motifs to prevent structural hindrance. Thereby, a syner-
gistic avidity effect of the elements may further increase binding efficiency. For
4xS1m, I concatemerized four aptamers in a single tag.
With the optimized 4xS1m aptamer, the recovery of a reporter mRNA ex-
pressed in cells was increased by 15-fold (Figure 2.1). In my hands, 4xS1m
was also more efficient than the MS2 and PP7 systems (Figure 2.4). SA-
binding aptamers offer several advantages such as straight-forward one-step
purification without the need for recombinant protein production, readily avail-
able matrices, no restrictions regarding antibody availability, the applicability
to any RNP complex, as well as the possibility for scaled-up approaches. More-
over, the user has the option to either tag in vitro transcribed RNAs or RNAs
expressed in cells. A previous report has compared S1 to the use of internally
biotin-labelled ribonucleotides, and addition of biotin-ATP or biotin-dATP,
respectively, and found the S1 aptamer to be superior [300]. In addition,
S1-attachment to an RNA element results in identical bait RNAs. Other in-
vestigators also found that elongating the basal stem of S1 increases binding
to SA [306, 296]. Moreover, stabilizing S1 by adding a tRNA scaffold increased
binding efficiency 10-fold [298]. This tRNA-modified S1 tag proved useful for
identification of RNA-BPs and miRNA-RNA interactions from lysates [319].
However, Iioka et al. (2011) also tested six tandemly repeated S1 motifs, yet
found the 6-fold repeat to be much less efficient than a single S1 aptamer. In
contrast, my most efficient construct, 4xS1m, clearly benefits from an avidity
effect. Additionally, in an in vitro EMSA approach, the S1m RNA as a single
motif bound with 2-fold higher affinity to SA than the original S1 aptamer
(Figure 2.5). Thus, elongation of the basal stem in S1m might induce a ster-
ically favorable conformation that stabilizes the apical binding portion of the
aptamer. This helps the binding portion to further protrude from the mRNP:
both would facilitate retention on SA Sepharose beads.
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3.1.2 Successful 4xS1m-mediated RNP Purification
I established an improved purification protocol that allows for proteome-wide
discovery of RNA-BPs that recognize a specific RNA. This allows to further
understand the function, composition and dynamics of RNPs. Optimized pa-
rameters include mechanical lysis with a tissue-lyser to avoid detergent in the
lysis buffer [305], a pre-block step of the lysate with avidin-beads to remove
biotinylated cell material [294, 320], as well as usage of RNA/DNA-low bind
tubes to reduce unspecific RNA-binding to the tube walls.
With this on hand, my next goal was to purify mRNPs from stably transfected
cells using 4xS1m. However, MS of these purifications showed high levels of
contaminating proteins, mostly cytoskeleton components, and did not yield
the expected pattern of RNA- and ARE-BPs (data not shown). One impor-
tant limitation is that even with the optimized 4xS1m aptamer, I could only
retrieve 4.5% of the tagged reporter mRNA from cells (Figure 2.1E). Over-
all, identification of protein components of endogenously assembled RNPs by
RNA aptamers have only been used with limited success, especially for mRNA
complexes [320]. I am aware of one example where the S1 aptamer was used
successfully for purification of a cellular mRNP from transfected cells [126]. In
that case, additional crosslinking to preserve an ARE RNP and gel filtration
steps increased purification specificity. Here, reversible in vivo formaldehyde
crosslinking [259] was necessary to identify specific interaction partners by
MS. Of note, crosslinking can also cause artefacts when proteins are fixed non-
specifically to mRNPs due to close proximity. I envision that the improved
4xS1m aptamer may also offer an advantage in such a combined protocol. Ar-
guing in favor of crosslinking, the transient interactions of ARE-BPs can not
only cause loss during purification from cells [321]. Limited ARE-BPs can also
be competed off the ARE by other abundant RNA-BPs during lysis or along
the purification procedure. It has indeed been reported that RNP composition
can change post lysis [322].
With this in mind, I favored an in vitro approach. I was aware of the possibility
that this protocol is partially limited by in vitro reconstruction of RNPs on pre-
coupled RNA. They may not represent authentic RNPs as they exist in living
cells. Synthetic RNA may not fold properly and non-specific RNA-protein
interactions may form during cell lysis and purification. However, the example
of the TNFα ARE purification provided evidence that this approach identified
established RNA-protein interactions of biological importance, as well as new
candidate RNA-BPs (Figure 2.8D). This strongly implicates non-artificial
interactions while most of the highest enriched proteins are RNA-BPs.
I also decided to use the 4xS1m aptamer for purification of ARE-BPs from cel-
lular extracts because the binding efficiency of in vitro transcribed 4xS1m RNA
to SA was very high (Figures 2.6B and 2.8A). After incubating cell lysates
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with the ARE-4xS1m-coupled matrix and subsequent washing, I eluted RNA-
associated proteins with RNase A. This was more efficient than elution with
biotin (Figure 2.6B). It was also much more specific than elution with SDS,
which also released contaminating sticky proteins from the beads [323] (Figure
2.8B). Additionally, a near-complete but specific elution is crucial to obtain
reasonable levels of protein for MS. Notably, even though I favored RNase
A elution, the S1 aptamer-based approach alternatively allows for elution of
S1-tagged RNPs with biotin as described before [300, 291, 294, 126, 299, 297].
This is as well possible with 4xS1m (Figure 2.6B). Despite its lower elution
efficiency, this can be important for purifications that require an intact, native
RNP conformation, investigate RNA components of a complex, or aim for a
second purification step.
3.1.3 4xS1m Pulldown of Established and Novel ARE-BPs
On ARE-4xS1m RNA, in addition to specific ARE-BPs interacting with the
ARE, the structured aptamers and linker sequences offer binding sites for gen-
eral RNA-BPs recognizing certain sequence or double-stranded stretches. That
is why 4xS1m alone is an important control which allows for discrimination of
exclusively enriched proteins on ARE-4xS1m. Thus, key to successful identifi-
cation of ARE-BPs was the direct comparison of the ARE-4xS1m and 4xS1m
whole-protein samples by quantitative MS using differential dimethyl peptide-
labeling [307]. This approach is advantageous over stringent washes followed
by individual band isolation, as the latter favors identification bias of high-
affinity and high-abundant binders visible on a gel. In my case, about 200
proteins were co-purified with similar efficiencies in both samples (enrichment
0.5–2.0-fold, peptide coverage >5%), which is also reflected in the similar pat-
terns of protein bands in the eluates of the two purifications (Figure 2.8C).
In contrast, only 16 proteins were enriched with the TNFα ARE (enrichment
>8-fold, Figure 2.8D) including most of the established TNFα ARE-BPs:
HuR, TIAR, AUF1, BRF1 and BRF2. I was surprised by the near complete
list of known TNFα ARE-BPs that resulted from the ARE RNP purification,
especially as highly dynamic ARE-BPs have rapid off-rates. In related terms,
it would be interesting to investigate whether there is a quantitative correla-
tion between the expression level of certain ARE-BPs and their enrichment on
the ARE. This analysis would show how ARE-BPs compete for ARE-binding.
This could unravel the impact of the different affinities of ARE-BPs to the
ARE. Thereby, differential ARE-BP expression levels and affinities determine
the overall ARE mRNA stability in a certain cell type. In fact, only two of the
major TNFα ARE-BPs, TTP and KSRP, were not enriched in my purification.
However, TTP expression is very low in resting NIH3T3 fibroblasts used [324].
It is only induced upon immune stimulation. Two additional proteins, FUBP3
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and DAZAP1, had previously been purified with the TNFα ARE [308, 309].
However, their function in regulating ARE mRNAs has not been established.
Thus, I am confident that this assay is able to identify crucial RNA regula-
tors. Taken together, my results demonstrate that purification via 4xS1m was
efficient at identifying specific, bona fide RNA-interacting proteins.
3.1.4 Confirmation of Rbms1 and Roxan as ARE-BPs
In addition to known ARE-BPs, I also identified five RNA-BPs that had pre-
viously not been associated with AREs. They included two proteins of the U2
snRNP (A’ and B’’) and a general snRNP protein (Sm-D2), suggesting that
the ARE-4xS1m RNA might base-pair with U2 snRNA and retain U2 snRNPs.
Alternatively, ARE-4xS1m may fold into a motif with similarity to U2 snRNA
and thus binds U2-associated proteins directly. While the interaction of these
proteins was not studied further, I confirmed binding of Rbms1 and Roxan
to the ARE by RNA-IP (Figure 2.9). Rbms1 has so far not been studied
with respect to its RNA-binding function. Yet, the reported connections to
c-Myc [310, 312] pose the question whether Rbms1 might bind to the ARE lo-
cated in the 3’UTR of c-Myc mRNA. Roxan has been implicated in rotavirus
mRNA translation [313]. It will be interesting to determine whether Roxan
might also contribute to the ability of AREs to repress translation of cellu-
lar mRNAs. Thereby, Roxan and Rbms1 represent novel ARE-BPs identified
by S1m-mediated RNP purification. Additional proteins enriched in the ARE
RNP remain to be confirmed as true ARE-BPs, which will further increase the
repertoire of functional ARE regulators.
3.1.5 Understanding mRNPs Through RNA Affinity
Purification
I have demonstrated that in vitro 4xS1m purification can successfully identify
relevant RNA-BPs for a regulatory RNA element. It is still unclear, however,
to which extent an in vitro assembled RNP on synthetic RNA resembles the
respective endogenous mRNP formed in vivo (Figure 3.1). Besides specific
RNA-BPs recognizing the fused RNA motif of choice, the in vitro RNP bound
to SA via 4xS1m contains common RNA-BPs and RNAs that interact with
aptamers and linkers which can be discriminated due to the 4xS1m control.
The endogenous mRNP however, beside all these factors, contains additional
cellular RNA-BPs and RNAs, regulatory proteins and miRNAs, as well as
translating ribosomes and protein nacent chains bound by associated factors.
Moreover, the UTR regions, as well as the cap and the poly(A)-tail, harbor
their own set of regulatory components. This highlights that a cellular mRNP
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is much more complex and dynamic than an in vitro reconstituted RNP. This
is especially the case as external and internal stimuli such as e.g. stress, nu-
trient availability, or cell cycle stage, can influence and demand mRNP re-
organization in order for the cell to adapt. Thus, to capture a snapshot of a
dynamic mRNP, crosslinking may be required.
Figure 3.1: Schematic Comparison of in vitro and in vivo S1m-mediated RNP
Purification. Left: In vitro transcribed 4xS1m-tagged RNAs are coupled to SA
Sepharose beads and incubated with a highly concentrated cellular extract. RNP com-
plexes formed contain RNA-BPs specific to the RNA element (red), as well as common
RNA-BPs and RNAs that interact with aptamers and linkers. Right: In vivo formed
mRNPs on endogenous 4xS1m-tagged mRNAs, harboring an RNA element of interest,
contain all the components present in the in vitro RNP complex. In addition, they com-
prise factors such as translating ribosomes with nacent polypeptide chains, regulatory
proteins and RNAs interacting with the poly(A)-tail, the cap, as well as the UTRs. The
mRNP is much more complex and dynamic than the in vitro formed RNP.
Interestingly, the before mentioned study by Vasudevan et al. (2007) performed
S1-pulldown of TNFα ARE mRNPs upon in vivo crosslinking from serum-
starved cells [126]. Upon starvation-induced cell-cycle arrest, the ARE acts as
a translation enhancer. They found the two proteins FXR1 and Ago2, which
previously were considered effectors of translation repression, to exclusively
associate with the ARE during translation activation upon starvation and to
function together to activate translation. Important in this context is that
they MS- or Western blot-identified enriched proteins bound to the ARE by
analyzing extra bands on a gel compared to a control. This obtained JNK2,
Tob1, GSTPI, FXR1, Ago2, as well as HuR and TTP [126]. This list is much
shorter than the candidate ARE-BP list I obtained (Figure 2.8D) due to
its limited resolution. A different study investigated ARE RNP complexes by
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affinity purification of proteins on immobilized TNFα ARE RNA oligos from
RAW macrophages and obtained a less biased list [308, 309]. This included
TIA, TIAR, AUF1, several hnRNP proteins, as well as FUBP3 and DAZAP1,
also found in my study. Notably, despite using RAW macrophages as protein
source, they did not find HuR, BRF1 and BRF2 included in my purification,
or TTP and KSRP. Thus, my presented technique is highly specific and is able
to identify almost the complete set of well-known RNA-BPs for a certain RNA
motif.
Recently, I applied 4xS1m-mediated RNA affinity chromatography to identify
Roquin as the major protein that interacts with the CDE [246]. In the future,
the optimized 4xS1m aptamer tag should also be applied for mRNP purifica-
tion from cells with 4xS1m providing 15-fold higher binding efficiency than S1.
In conclusion, I developed an improved technique for RNA-based identifica-
tion of specific RNA-protein interactions from crude cell lysates in a one-step
affinity purification approach [303]. I anticipate that 4xS1m will continue to
be useful for identifying RNA-protein interactions to help uncover the intricate
nature of mRNP complexes.
3.2 Roquin-mediated Constitutive Decay of
CDE-containing mRNAs
In this study, I define CDEs as a novel class of regulatory motifs that mediate
mRNA degradation through their interaction with Roquin proteins and provide
a detailed analysis of the CDE RNA structure. I also present evidence for the
physiological importance of the CDE for TNFα expression [246].
3.2.1 The CDE in the TNFα 3’UTR
The following presents the starting point for my study highlighting the im-
portance to further investigate the CDE. TNFα plays a major role in medi-
ating inflammation and immunity in the early response to infection. As its
systemic secretion by LPS-stimulated macrophages can cause autoimmunity,
septic shock and chronic inflammation [7, 325], TNFα synthesis is subject to
tight control. Posttranscriptional regulation of this potentially harmful cy-
tokine includes a variety of ARE-BPs [107] that bind the ARE in the TNFα
3’UTR. This orchestrates mRNA export, decay rate, and translation efficiency
[326, 327, 328, 329]. Besides miRNA binding sites [76, 141], the TNFα 3’UTR
harbors the CDE downstream of the ARE, that induces rapid mRNA decay
[62]. Initially, Stoecklin et al. (2003) observed that the entire TNFα 3’UTR
was still capable to stimulate mRNA decay in AMD-deficient mutant cells [62],
85
Chapter 3 Discussion
which proposed the existence of a second, AMD-independent mRNA decay
pathway [145]. Importantly, the presence of more than one decay element and
miRNA binding site in the TNFα 3’UTR allow for differential regulation under
various physiological conditions. This highlights the need to understand the
individual mechanistic contribution of the CDE to the overall TNFα mRNA
stability.
3.2.2 The CDE is not a miRNA Binding Site
Many 3’UTRs are targets of miRNAs which leads to suppression of mRNA
stability and/or translation [64]. Thus, it was initially tested whether the
observed CDE-mediated mRNA decay activity was due to the CDE serving as a
linear miRNA binding site, before even considering it to be a structured motif.
Johanna Schott analyzed CDE-mediated mRNA decay in Dicer knockout (–/–)
mouse embryonic fibroblasts (MEFs) [226] generated in the Gregory Hannon
lab (CSHL, USA). These MEFs express a truncated Dicer protein that lacks
most of the RNase III domain and fail to generate mature miRNAs from
pre-miRNA precursors, as exemplified for miR-16 [246]. A reporter mRNA
containing green fluorescent protein (GFP) fused to globin and the TNFα
CDE was degraded with similar half-lives in the Dicer+/+ (t1/2 = 2.2 ± 0.2
hours) and Dicer–/– MEFs (t1/2 = 1.5 ± 0.3 hours) [246]. Almost all miRNAs
require Dicer for their maturation. Since CDE-mRNA decay was not affected
by knockout of Dicer, we concluded that the CDE is unlikely to represent a
miRNA binding site.
Roquin was previously found to suppress the expression of ICOS mRNA by ac-
celerating its degradation [226, 225]. Whereas Yu et al. (2007) proposed that
Roquin suppresses ICOS mRNA in association with miR-101, Glasmacher et
al. (2010) found that Roquin acts independently of miRNAs. Our observa-
tion that CDE-mediated mRNA decay is Dicer-independent would also argue
against the involvement of miRNAs in Roquin-mediated suppression. This lead
to the idea that the CDE might fold into a specific structure that is important
for its decay activity.
3.2.3 Established Structured RNA Degradation Motifs
There is a small but growing set of structured RNA elements that control
mRNA stability in eukaryotes for which few examples exist. Beyond these
individual examples, computational approaches suggest that structured mRNA
motifs are more abundant and form large and distinct families [330, 153].
In histone mRNAs, a highly conserved stem-loop at the end of the 3’UTR is
recognized by the stem-loop binding protein SLBP, which is required for rapid
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histone mRNA degradation at the end of S-phase [331]. SLBP recruits factors
for oligo(U) tail addition to histone mRNA 3’ ends before mRNA degradation
occurs through both 5’-3’ and 3’-5’ pathways [332]. However, oligouridylation
initiates degradation, whereby the 3’-5’ degradation machinery stalls [333]. It
was recently shown that exoRNase Eri1 binds to the stem-loop and 3’-trims
histone mRNAs. The oligo(U) tail of histone mRNAs is recognized by the
Lsm1-7 heptamer which interacts with Eri1, whose catalytic activity is then
able to stepwise degrade the stem-loop [334].
There are also stem-loop recognition elements in Drosophila maternal mRNAs
that interact with Smaug which induces Ccr4-dependent transcript degrada-
tion [335]. This also regulates translation of nanos mRNA in flies [335]. An-
other example is Staufen, an RNA-BP that targets mRNAs for degradation
by binding to long base-paired sequences [336, 337]. Hereby, STAU1 binds
to dsRNA regions of the 3’UTR and interacts with the main NMD factor
UPF1 to elicit mRNA decay. STAU1 binding sites are formed by imperfect
base-pairing between a 3’UTR Alu element and another Alu element in a cy-
toplasmic, polyadenylated long non-coding RNA (lncRNA). Thereby, binding
of STAU1 to mRNAs can be transactivated by lncRNAs [336].
A very direct mechanism for destabilizing mRNAs was discovered in IL-6
mRNA. A conserved stem-loop of about 30 nts within its 3’UTR is recog-
nized by the endonuclease Regnase-1 (Zc3h12a), a ZF protein that directly
cleaves its target mRNA [214, 215]. Interestingly, Regnase-1 binds to a similar
stem-loop in its own mRNA as part of a negative feedback loop. Thereby, it
prevents excessive translation of Regnase-1 and degradation of cytokine mR-
NAs [214, 338]. Initially, LPS-stimulated macrophages from Regnase-1−/−
mice showed increased production of IL-6 and IL-12b, but not TNFα. In accor-
dance, IL-6 mRNA decay was severely impaired in these cells [214]. Regnase-
1−/− mice develop a severe systemic inflammation, characterized by production
of autoantibodies. Thus, Regnase-1 exploits its RNase activity to cleave IL-6
mRNA by recognizing a stem-loop structure and thereby prevents autoimmu-
nity [215].
As part of the regulatory circuit of the cellular iron metabolism, in iron-
deficient cells, cis-regulatory hairpin structures, called iron-responsive ele-
ments (IREs), in the UTRs of mRNAs encoding proteins involved in iron
transport and storage, are bound by iron regulatory protein 1 (IRP1) or IRP2
[339, 340]. The binding of IRPs to single IREs in the 5’UTR of target mR-
NAs inhibits their translation. However, IRP interaction with multiple 3’UTR
IREs in the transferrin receptor 1 (TfR1) transcript increases its stability. As
a consequence, TfR1-mediated iron uptake increases whereas iron storage in
ferritin and export via ferroportin decrease [341].
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3.2.4 The CDE Folds into a Conserved Stem-Loop Motif
The first indication that structure is important for CDE function arose from
the observation that CDE activity was influenced by different cloning contexts
it was inserted in. This either favored or prevented formation of base-paired
regions (Suppl. Figure 5.3). The initial P1 stem was stabilized by two
introduced base-pairing nucleotides which facilitated folding into an overall
stabilized structure. By conservation analysis of mammalian TNFα 3’UTR
sequences and thermodynamic modelling, I then derived a structure model for
the CDE (Figure 2.11). This approach is challenging in higher eukaryotes.
On the one hand, regulatory motifs acquire relatively minor sequence changes
during evolution. This enhances their discovery by conservation-based bioin-
formatics approaches. On the other hand, co-evolution of primary sequence is
not very frequent. This is in contrast to rapidly evolving bacterial genomes.
This facilitates determination of conserved structures. This is exemplified by
the rather straight-forward discovery of riboswitches in prokaryotes, regula-
tory RNA structures that control gene expression [148, 342]. Thus, due to the
comparably small number of available mammalian genome sequences and more
complex genomes, it is hard to identify functional RNA structures in higher
eukaryotes. I suppose that regulatory RNA elements in mammals are more
likely to rely on RNA-protein interactions rather than metabolite-binding due
to the increased importance of proteins as gene expression regulators in higher
eukaryotes.
The active CDE stem-loop motif was determined in vitro by in-line prob-
ing of variants that differ in their decay activity (Suppl. Figure 5.3) in
the Hammond lab and by my functional analysis of compensatory mutations
(Figures 2.12D, 2.13A and 2.13B). In fact, by thermodynamic modeling
based on Mfold [316], we calculated a ΔG = -6.7 kcal/mol for the mouse TNFα
CDE37 (Figure 2.11B) and aΔG = -9.0 kcal/mol for the human CDE37 RNA
(Figure 2.11C), whereas the lowest ΔG = -18.7 kcal/mol was obtained for
the mouse CDE37-V3 (Suppl. Figure 5.3A). This indicated that the most
active V3 variant also has the highest capacity to fold into the presented struc-
ture. Notably, the CDE stem-loop was not observed by in-line probing of the
TNFα CDE150 RNA, where the stem-loop is embedded in its natural sequence
context (Suppl. Figure 5.3C). In fact, ΔG of the stem-loop in its natural
context is predicted to be only -6.7 kcal/mol. This suggested that this region
of the 3’UTR does not fold into a single structure, but samples different con-
formations. Inside cells, binding of Roquin is likely to stabilize the CDE in the
stem-loop conformation. My finding that the CDE37-M7 mutant, which has a
destabilized P2 stem, can be activated by overexpression of Roquin (Figure
2.15C), supports the notion that binding of Roquin stabilizes the CDE in its
active conformation.
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Alternatively, RNA structure can be investigated by dimethyl sulphate (DMS)
probing. This relies on in vitro transcription termination by 32P-primer exten-
sion of an RNA whose unpaired As and Cs were in vitro or in vivo methylated
by DMS beforehand. In addition, the SHAPE (selective 2’-hydroxyl acyla-
tion analyzed by primer extension) technique enables quantitative chemical
probing of RNA structures in living cells. This reveals tertiary contacts and
RNA-protein interactions [343, 344]. Recently, SHAPE was combined with
RNA-Seq for high-throughput analysis [345]. These approaches allow to asses
RNA structure inside cells to map native RNA-protein architectures.
Despite its low thermodynamic stability, the CDE bears features that are char-
acteristic for trinucleotide hairpins. First, stable trinucleotide loops have a
strong preference for Us at each position of the loop [346]. Indeed, UGU is
by far the most frequently observed CDE loop according to our bioinformatics
prediction [246]. Precisely, mutants and evolutionary sequence conservation
revealed that the first nucleotide in the CDE loop is a pyrimidine, the sec-
ond is a purine and the third nucleotide is U in all CDEs we tested (Figures
2.11 and 2.13). Although Johanna Schott allowed for either U or C in the
bioinformatics search, all 56 highly conserved putative CDEs have a U at this
position [246]. Second, the closing base-pair below the loop has an overwhelm-
ing preference for C–G in stable trinucleotide hairpins with a ΔG three times
greater than that of the next best closing base-pair G–C [346]. Since the clos-
ing base-pair in the CDE needs to be C–G according to our mutational analysis
(Figures 2.12D and 2.13A), it matches the thermodynamically most stable
configuration of trinucleotide hairpins.
3.2.5 Roquin and Roquin2 Specifically Bind to the CDE
I applied the before mentioned 4xS1m tag fused to the CDE to find CDE-BPs
by RNA affinity purification. This identified Roquin to be the highest en-
riched protein (Figure 2.14C). Interestingly, among other RNA-BP enriched
>3-fold, Roquin2 was found at position four on that list. This already hinted
at the Roquin family of proteins representing promising candidate CDE-BPs.
A first indication of a specific Roquin-CDE interaction came from RNA-IP
experiments (Figures 2.15B and 2.16A). They showed that EGFP-Roquin
binds to CDE37- and CDE150-bearing reporter mRNAs in cells. I also con-
firmed specific binding of Roquin2 to CDE37- and CDE150-mRNAs. One con-
cern is that RNP re-organization upon lysis can occur [322]. Thus, Fabian Pötz
tested by in vivo crosslinking whether the Roquin-CDE association occurs in-
side cells, and not post-lysis [246]. This showed that in the absence of formalde-
hyde crosslinking, EGFP-Roquin associated with globin-CDE37 mRNA under
non-denaturing, but not under denaturing conditions (4 M urea). When cells
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were crosslinked prior to lysis, globin-CDE37 mRNA remained associated with
EGFP-Roquin under denaturing conditions. Also, EGFP-Roquin did not bind
globin mRNA lacking a CDE under either condition. In addition, my EMSA
experiments showed that Roquin binds directly and with high specificity and
affinity to the CDE stem-loop (Figure 2.17). Consistent with previous re-
ports [245, 226], we saw that the ROQ domain is responsible for RNA binding
(Figure 2.16C). Thus, these experiments demonstrated specific and direct
association of Roquin with CDE-mRNA inside cells and in vitro.
3.2.6 Roquin is a Suppressor of TNFα Expression
While overexpression of Roquin or Roquin2 in NIH3T3 and HeLa cells accel-
erates CDE-mediated mRNA decay (Figure 2.18), the simultaneous kd of
both proteins is neccessary to effectively prevent CDE-mRNA degradation in
NIH3T3 cells (Figure 2.19A and Suppl. Figure 5.5B). This indicates
that the two proteins can induce mRNA degradation independently in these
cells and therefore demonstrate a certain level of redundancy. It has recently
been shown in T cells that Roquin and Roquin2 indeed have redundant func-
tions in promoting mRNA decay and in controlling TFH cell differentiation
[236]. In LPS-stimulated RAW264.7 macrophages, kd of Roquin alone is suf-
ficient to cause stabilization and prolonged production of endogenous TNFα
mRNA, which translates into elevated synthesis of TNFα (Figure 2.19C–G).
In macrophages, double kd of Roquin and Roquin2 did not show a greater
effect (Suppl. Figure 5.5D–F). This suggested that the relative importance
of Roquin and Roquin2 may differ between cell types. By introducing an anti-
sense morpholino that targets the TNFα CDE and interferes with Roquin bind-
ing in trans, I observed specifically elevated expression of TNFα mRNA and
protein, not of any other CDE-containing mRNA, in RAW264.7 macrophages
and primary BMDM (Figure 2.24). Taken together, these results demon-
strate that Roquin acts through the CDE as a suppressor of TNFα expression
in macrophages. This might be different in T cells, where overexpression of
Roquin was found to cause elevated levels of numerous pro-inflammatory cy-
tokines including TNFα [347].
In accordance with CDE activity, it was found that TNFα mRNA remains
labile in LPS-stimulated macrophages [348, 104, 349]. In a mouse model [13],
the ARE and the 18 nt AU-rich stretch of the fragment K was specifically
deleted from the TNFα locus whereas KΔAU was retained (TNFα-ΔARE).
Primary macrophages derived from these mice showed excessive TNFα mRNA
and protein levels upon LPS-stimulation. Net mRNA levels suggested that
the TNFα-ΔARE transcript was stable in the presence of LPS, precluding
the existence of a second, ARE-independent decay pathway. However, TNFα
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ARE mRNA declined to baseline levels in 6 hours after accumulation. This
is in agreement with the prolonged expression of TNFα mRNA in Roquin kd
cells upon LPS stimulation (Figure 2.19E). This highlights the impact of the
CDE on TNFα mRNA half-life rather than on steady-state levels. Also, ARE-
dependent decay was inhibited in trans in TTP-knockout mice (TTP-/-) [107,
350]. In TTP-/--mice, TNFα mRNA half-lives increased 2-fold in LPS-treated
macrophages and a bit more than 2-fold in LPS-treated bone marrow stromal
cells. The fact that TNFα mRNA was still fairly labile in TTP-/- cells could be
either due to the activity of TTP-related proteins, or to the CDE acting in an
ARE-independent manner. Thus, the TTP knockout model is fully consistent
with the CDE contributing to TNFα mRNA turnover. One interesting idea
is that regulation of Roquin binding to the CDE is dependent on affinity:
when TNFα mRNA levels increase upon stimulation, Roquin binding might
be overcome as a result of titration, whereby the amount of Roquin protein
present sets a dynamic threshold that determines the CDE-mRNA decay rate.
3.2.7 Roquin Recruits the Ccr4-Caf1-Not Complex for
mRNA Deadenylation
My study also provided insight into the mechanism of CDE-dependent mRNA
degradation. Previous work suggested that Roquin may activate ICOS mRNA
degradation via interaction with decapping enhancers [226]. In contrast, by
affinity purification of Roquin and Roquin2 from stably transfected HeLa cells,
Sonja Reitter found that both proteins associate with the entire Ccr4-Caf1-Not
complex [246]. We did not detect any decapping components. Co-IP experi-
ments revealed that the interaction with Not1, the scaffold protein of the Ccr4-
Caf1-Not deadenylation complex, and with the deadenylase Caf1a, is RNA-
independent and occurs through the C-terminal region of Roquin (Figure
2.20, [246]). Importantly, a catalytically inactive Caf1a mutant was able to
potently inhibit CDE-mRNA deadenylation and degradation. Thus, I propose
that Roquin and Roquin2 serve as adaptor proteins that specifically recognize
CDE-like RNA stem-loops via the ROQ domain. They destabilize their target
mRNAs by recruitment of the Ccr4-Caf1-Not deadenylase complex (Figure
2.20), possibly through an interaction with Not1, via the C-terminal effector
domain (Figure 3.2).
Several other mRNA decay pathways employ a similar mechanism. In case of
TTP-bound ARE-mRNAs, TTP recruits the Ccr4-Caf1-Not complex to the
mRNA through its association with Not1 [131]. miRNA-mediated mRNA
degradation requires argonaute proteins to interact with TNRC6/GW182
adaptor proteins, which in turn recruits the Ccr4-Caf1-Not complex through
direct association with Not1 [71, 351, 352]. Thus, Not1 may provide a plat-
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form where mRNAs containing different destabilizing elements are regulated
in a coordinated manner. Given that several immunity-related factors (e.g.
TNFα, IL-6, VEGF and G-CSF) contain more than one destabilizing element
in their mRNAs [57], it may be advantageous to coordinate access of RNA-BPs
to the mRNA decay machinery.
3.2.8 Structure-Function Analysis of Roquin Domains
Fabian Pötz examined the role of the RING and ROQ domains as well as
of the N- and C-termini of Roquin, summarized in Figure 2.16C. Whereas
deletion of the RING domain had no effect, the Roquin-ΔROQ mutant was
deficient in CDE RNA-binding [246], failed to accelerate CDE-mRNA decay
upon overexpression and lost its ability to localize to P-bodies (Figure 2.16,
[246]). Notably, the ROQ domain within the N-terminus of Roquin was suffi-
cient to bind globin-CDE mRNA, whereas the C-terminal domain was found
to associate with Not1 and Caf1a (Figures 2.16C and 2.17, [246]). When
Fabian expressed the individual N-terminal domain, the C-terminal domain
or the ROQ domain alone, this strongly reduced the degradation rate of the
CDE reporter-mRNA in comparison to expression of EGFP alone. This sug-
gested that these Roquin fragments have dominant-negative activity [246].
This could be explained by a competition of endogenous Roquin with the N-
terminal ROQ domain for CDE-mRNA binding. Likewise, endogenous Roquin
may compete with the C-terminal fragment for binding to the Ccr4-Caf1-Not
complex. Taken together, these results demonstrate that the ROQ domain
of Roquin is responsible for RNA-binding, whereas the C-terminal fragment
contains the effector domain that recruits the Ccr4-Caf1-Not complex.
Localization of Roquin to P-bodies was found to be non-uniform in different
cell types [226, 245]. When Sonja Reitter investigated P-body localization of
Roquin and Roquin2, she found that both localize to P-bodies in HEK293,
NIH3T3, as well as Huh7 cells (Figure 2.16C). For Roquin2, this had only
recently been reported in HEK cells [239]. When she tested the ZF mutants
of Roquin and Roquin2, she found that oth mutants efficiently localized to
P-bodies. This was consistent with their CDE-binding activity and acceler-
ation potential of CDE-decay upon overexpression compared to WT. Of the
truncation mutants presented, only Roquin-ΔRING behaved as WT, while all
others were found to be cytoplasmic or even reduced the P-body number per
cell. This can be explained by either misfolding and inactivity of the protein
domain, interference with function due to the attached EGFP-tag or an overall
stress response of the cell to overexpression. All this can lead to mislocalization
and can even induce a decrease in P-body numbers [353]. In all, this highlights
that Roquin and Roquin2 localize to P-bodies, for which the ZF and RING
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domain are not essential. Moreover, for efficient P-body localization, Roquin
is likely to require both the N- and C-terminal domain.
3.2.9 Roquin Recognizes a Conserved Class of
CDE-containing mRNAs
When Johanna Schott applied her consensus CDE sequence and structure
model (Figure 2.22A) derived from our experimental data by searching all
3’UTRs of the mouse transcriptome, she identified 56 highly conserved CDEs
in 55 vertebrate genes [246]. This identified a total 109 putative CDEs in
108 genes, and an additional 91 in ORFs. This was opposed to 55 CDEs
that would have been expected to occur randomly. By an in silico approach,
Parker et al. (2011) predicted novel families of structured motifs within mR-
NAs based on the conservation of potentially structured RNA sequences in-
cluding several stem-loops that correspond to CDEs [153]. This provided in-
dependent evidence for the notion that the CDE is a widespread regulatory
element. Through the genome-wide identification of Roquin target mRNAs
by Roquin-IP and RNA-Seq (Figure 2.22B–D, Suppl. Table 5.2), we
found that mRNAs with conserved CDEs are strongly enriched by Roquin-IP
(Figure 2.22C–D). In fact, highest enrichment was observed for the only
mouse mRNA (Nfkbid) that contains a tandem CDE motif in its 3’UTR.
Similarly, the only two mouse mRNAs containing two CDEs in their ORF
(D5Ertd579e and Ipo11) showed strongest enrichment by Roquin-IP among
all mRNAs with ORF CDEs. These results demonstrate that the CDE is the
principal Roquin binding element.
3.2.10 Physiological Consequences of the Roquin-CDE
Interaction
Roquin was previously found to suppress ICOS expression by accelerating its
mRNA degradation [226, 225]. I could now show that a ICOS 3’UTR motif
recognized by Roquin is indeed a conserved CDE-like motif (Figure 2.21).
Sanroque mutant mice display a severe, lupus-like autoimmune syndrome due
to the mutant Roquin protein which harbors a single amino acid substitu-
tion (M199R). This phenotype was shown to result from elevated ICOS ex-
pression [227]. I did not observe a difference between WT Roquin and the
M199R mutant with regard to CDE-binding or acceleration of CDE-mRNA
decay (Figure 2.16C). Sanroque Roquin has also been reported to not affect
binding to the ICOS 3’UTR [245]. Also, a more recent study reported that
the knockout of Roquin in the hematopoietic system did not cause autoim-
munity, but a more inflammatory phenotype [241]. Our genome-wide iden-
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tification of Roquin targets (Suppl. Table 5.2) revealed several immunity
and inflammation-related mRNAs including TNFα and three regulators of the
NFκB-mediated transcription pathway: Nfkbid, a member of the IκB family
of NFκB inhibitors, Nfkbiz, a nuclear member of the same family, and Ier3, a
protein that suppresses activation of NFκB by stabilization of IκBα [354, 355].
Given that an estimated additional 50 mRNAs are likely to contain functional
CDEs (Suppl. Table 5.2), and that 95 mRNAs were significantly enriched by
Roquin-IP (Suppl. Table 5.2), I postulate that the complex phenotypes of
the hematopoietic Roquin knockout and sanroque mice may in fact arise from
the simultaneous deregulation of multiple mRNAs in the immune system.
In addition, the target spectrum detected from stimulated macrophages does
not reflect the whole pool of Roquin target mRNAs, as only the transcripts
expressed in that cell type can be found. Given that some of the Roquin-
associated mRNAs were strongly induced by LPS whereas others were not
(Suppl. Figure 5.7), Roquin appears to bind to both newly synthesized
and constitutively expressed CDE-containing mRNAs. IP and RNA-Seq of
ubiquitously expressed Roquin from different tissues will increase the num-
ber of specifically enriched transcripts. Moreover, we monitored 76 highly
enriched mRNAs lacking a CDE which indicates, on the one hand, that our
mutagenesis-derived criteria for functional CDEs was limited and highly re-
strictive. Thus, transcripts with more divergent CDE-like motifs were missed.
On the other hand, these enriched mRNAs might contain additional common
Roquin binding sites beside CDEs, representing a different class of Roquin
recognition motifs. However, with respect to conservation, CDEs were the
main class of conserved 3’UTR elements found.
The complete knockout of Roquin causes perinatal lethality and malformations
of the tail and spinal column [241]. This phenotype may be linked to our obser-
vation that 13 mRNAs encoding regulators of development, including Wnt3a
and the bone morphogenic protein receptor Bmpr1a, contain highly conserved
CDEs [246]. Six of these mRNAs, including Bmpr1a, were also enriched by
Roquin-IP (Suppl. Table 5.2). Interestingly, 10 of the CDEs we identified
are conserved between fish and mammals, suggesting that Roquin-mediated
mRNA regulation is maintained among vertebrates. Additionally, we found
the Roquin protein to be present from human and mouse down to sponges
(see the Roquin protein alignment in the Supplemental Data). The sequence
alignment indicates a particular conservation of the N-terminal portion con-
taining the RNA-binding domain. The high conservation of Roquin in lower
and higher metazoans, together with CDEs in higher metazoans, hints at a
potential conservation of the Roquin-CDE system as a decay signal and/or a
function in development. Since Roquin homologs are found in all branches
of metazoan evolution, Roquin-CDE interactions may have an ancient role in
multicellular organisms.
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3.3 Summary and Model
In this study, I describe the regulatory mechanism of CDE-mediated mRNA
decay. I focused on identification and characterization of critical RNA-binding
proteins that mediate CDE activity. For that, I first established an improved
mRNP purification protocol [303] and identified novel protein regulators bound
to the TNFα ARE. This included the development of a modified SA-binding
aptamer, S1m, which has higher affinity for SA than the original S1, binds
with highest avidity to SA in a four-repeat conformation (4xS1m), and is more
efficient than the MS2 and PP7 systems. I applied the optimized 4xS1m tag
fused to the ARE for purification of the ARE-RNP. This allowed me to detect
most of the well-known ARE-BPs [87] and to determine novel ones. I confirmed
Roxan and Rbms1 as new TNFα ARE-BPs, both of which have previously not
been associated with AREs. Thereby, I established 4xS1m as an efficient and
powerful tool for the isolation and identification of RNP-associated proteins.
Figure 3.2: Roquin Promotes Constitutive Decay of CDE-containing mRNAs.
Model of CDE-mediated mRNA degradation. Roquin and Roquin2 bind to CDE RNA
stem-loops via the ROQ domain. The Ccr4-Caf1-Not complex is recruited through the
C-terminal effector domain. This causes Caf1a-dependent deadenylation and consecutive
degradation of CDE-containing mRNAs, many of which encode proteins important for
development as well as inflammation and immunity. Reproduced with permission from
Cell, Elsevier.
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Moreover, I demonstrate that the CDE is a structured motif that folds into an
RNA stem-loop in its active conformation. The minimal active CDE forms a
17 nt hairpin with sequence and structure requirements for function. When I
applied my optimized 4xS1m protocol to the TNFα CDE, I purified Roquin and
its paralog Roquin2 as stem-loop specific CDE-binding proteins [246] (Figure
3.2). Roquin is required for CDE-mediated mRNA decay and suppression of
TNFα production in macrophages. I further show that Roquin proteins cause
mRNA deadenylation by recruiting the Ccr4-Caf1-Not complex. Here, the
ROQ domain in the N-terminus provides the RNA-recognition site, while the
C-terminus interacts with components of the decay machinery. Furthermore, I
discovered target mRNAs of Roquin on a transcriptome-wide scale. Thereby,
CDE-containing mRNAs were found to be the primary targets of Roquin in
macrophages. These data provide evidence that Roquin controls the degrada-
tion of more than 50 vertebrate mRNAs with highly conserved CDE stem-loop
motifs. Many of these transcripts encode regulators of development and in-
flammation. Finally, my data imply that morpholino-mediated interference
with CDE structure formation alleviates TNFα supression which represents a
promising strategy for therapeutic applications.
My study defines CDEs as a conserved class of abundant regulatory RNA stem-
loop motifs that mediate mRNA deadenylation through their association with
Roquin proteins. This emphasizes the importance of structured RNA elements
in the complex network of cis- and trans-acting factors regulating mRNA sta-
bility. As exemplified by TNFα, the presence of multiple regulatory elements
in the same mRNA may allow for the integration of regulatory cues from var-
ious signaling pathways. Similar to promoter regions that offer binding sites
for different TFs, the UTRs of mRNAs are increasingly recognized as versatile
regulatory platforms. In all, comprehensive analysis of CDE-mediated mRNA
decay provides a near complete picture of how the CDE conveys constitutive
mRNA decay. This is important for limiting the TNFα-mediated inflammatory
response and for the regulation of numerous CDE-containing mRNAs. This
adds an important component to the regulation of posttranscriptional control
of gene expression.
96
3.4 Outlook
3.4 Outlook
3.4.1 S1m is a Powerful Tool for mRNP Analysis
Purification of intact mRNPs from cells has always been technically challeng-
ing. The improved 4xS1m aptamer offers an efficient tool to isolate complex
RNPs via RNA. It has proven successful for retaining established and novel
ARE-BPs on 4xS1m-tagged TNFα ARE RNA in vitro [303]. It remains to be
investigated which function the confirmed, new ARE-BPs Roxan and Rbms1
have upon binding to the ARE. Other RNA-BPs enriched on the ARE also
remain to be explored. In the future, I suspect a broad spectrum of appli-
cations for the 4xS1m-tag. These include identification of RNA-associated
proteins important in RNA metabolism from splicing to decay, as well as in-
teraction partners of non-coding RNAs. Besides, RNA components of an RNP
can be assessed by RNA-Seq or microarray analysis upon biotin elution of
4xS1m. The biggest advantage of the presented in vitro pulldown approach is
the available amount of in vitro transcribed RNA compared to the levels of
mRNA expressed in cells. This is important for the detection of small amounts
of RNA-BPs eluted by MS. While 30 µg 4xS1m RNA and highly concentrated
protein extracts were applied in an in vitro approach, I observed that a lysate
of Cos7 cells transiently expressing 4xS1m-containing mRNAs of a confluent
10-cm dish yielded total 300 ng 4xS1m RNA (or 250,000 copies/cell). The large
difference in numbers is critical for successful RNP isolation. This could ex-
plain the few reports for successful isolation of cellular mRNPs. Nonetheless,
an approach employing cell lines stably expressing 4xS1m-containing RNAs
would allow for purification of authentic endogenous mRNPs in their preserved
composition upon formaldehyde crosslinking (Figure 3.1). Moreover, I find
that with short RNA motifs, like the TNFα ARE (53 nt) [303] or CDE (37
nt) [246], one obtains a short list of specifically enriched RNA-BPs. These can
be clearly discriminated from general RNA-BPs by comparison to the impor-
tant aptamer-only control. Affinity purification of long RNAs will increase the
total number of enriched RNA-BPs, which impedes determination of crucial
regulators. I therefore recommend to previously map an RNA element to its
core activity. With the interest shown by many labs to date, I assume that
the 4xS1m aptamer will be of broad use in many areas of RNA research in the
future.
3.4.2 The Roquin-CDE Complex and Roquin/2 Targets
In my thesis, I define the minimal TNFα CDE as a 17 nt long stem-loop
structure. I showed by RNA-IP and EMSA that the CDE is specifically and
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directly recognized by the ROQ domain in the N-terminal portion of Roquin
(Figures 2.16 and 2.17, [246]). The ROQ domain lacks an established RNA-
recognition motif but represents a novel RNA-binding domain. It would be
interesting to investigate the structure of the Roquin-CDE complex by crys-
tallography or NMR in order to obtain a clear picture of how the ROQ domain
recognizes the CDE hairpin. It has been reported that the ROQ domain binds
the ICOS 3’UTR to suppress ICOS mRNA [245, 226]. Interestingly, the ICOS
3’UTR may contain multiple cis-acting Roquin binding sites. This includes a
47 nt long sequence adjacent to the miR-101 site at the 3’ end of the 3’UTR
[225, 245], and a 100 nt long sequence located 100-200 nts downstream of the
stop codon [226, 236]. The CDE in the ICOS 3’UTR that I identified in my
thesis does not overlap with any of these sites. Thus, it will be important to
investigate whether Roquin has different binding sites that play distinct roles
in target mRNA regulation. I suggest to obtain Roquin CLIP data in order to
decipher its exact binding sites, which might reveal several recognition motifs
in one mRNA.
It is not yet fully understood why the sanroque mutation in the ROQ do-
main induces autoimmunity by causing increased ICOS expression [227], while
it does not affect ICOS 3’UTR binding [245]. In agreement with this, my
EMSA data show that sanroque Roquin-N-M199R binds to the CDE with equal
affinity as WT Roquin-N (data not shown). It was suggested that sanroque
Roquin binding sequesters Roquin mRNA targets, but impairs their degrada-
tion, which hinders Roquin2 to compensate for Roquin activity [236, 239]. This
results in Roquin/2 target mRNA stabilization and aberrant TFH cell devel-
opment. However, I did not see a difference between sanroque and WT Roquin
regarding their activity to accelerate CDE-mediated mRNA decay upon over-
expression (Figure 2.16). It was shown that sanroque Roquin localizes to SGs
and P-bodies [239]. It should be tested by FISH whether sanroque Roquin se-
questers its target mRNAs and thereby blocks their degradation in P-bodies.
Also, the structural change in sanroque Roquin that mediates its impaired
activity should be addressed by crystallography or NMR. It will also be inter-
esting to challenge the proposed redundancy of Roquin and Roquin2. They
may have a different target mRNA spectrum in different cell types. This can
be addressed by Roquin- and Roquin2-IP prior to RNA-Seq from cells of dif-
ferent tissues, as performed for Roquin from RAW macrophages in this study
(Figure 2.22). I suspect that Roquin mRNA targets differ already from T
cells to macrophages, as for example ICOS is not well expressed in macrophages
in which TNFα is a more important target. I propose that the sanroque phe-
notype is a result of increased expression of many Roquin targets at the same
time. This should also be studied in the context of the observed developmental
defects of Roquin KO mice, such as tail and spinal column defects [241]. This
is in agreement with our finding that regulators of development like Bmpr1a
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mRNA contain conserved CDEs and are bound by Roquin (Figure 2.22 and
2.23).
3.4.3 Regulation of Roquin Proteins
Differential expression of Roquin/2 is important in the context of the proposed
redundancy of Roquin and Roquin2 function in different tissues, as demon-
strated in T cells [236, 239]. Both are expressed in many different tissues, while
Roquin2 is mostly expressed at lower levels than Roquin [236]. By kd experi-
ments, I observed that in NIH3T3 cells, Roquin/2 act in a redundant fashion to
suppress CDE-containing mRNAs. In RAW264.7 macrophages, kd of Roquin
alone is sufficient to stabilize them (Figure 2.19 and Suppl. Figure 5.5).
It will be interesting to see how Roquin proteins are regulated in different tis-
sues, which is not known so far. Roquin protein levels remain unchanged upon
LPS-stimulation of macrophages (data not shown). Also, CDE-containing re-
porter mRNAs were found to be resistant to AMD-inhibiting stimuli such as
LPS, ionomycin or TPA, and constitutive active variants of PI3K, MEK6 or
v-H-ras1 [62]. Therefore, I so far have no evidence that Roquin-mediated CDE-
mRNA decay is regulated. Roquin and Roquin2 mRNAs themselves contain
a CDE and were both enriched in the Roquin-IP from macrophages. This
suggests a negative feedback loop wherein Roquin proteins destabilize their
own transcripts to dampen their own expression. This needs to be studied fur-
ther. Roquin is a new member to the set of CCCH-type ZF proteins, including
Regnase-1 and TTP (Figure 3.3), that regulate mRNA decay of transcripts
encoding cytokines and immune mediators. They all recognize different classes
of RNA motifs and have a distinct immune-relevant phenotype in mice. Fu-
ture investigation should aim at revealing whether Roquin proteins, as seen
for Regnase-1 and TTP, are regulated by posttranslational modifications; a
common means to regulate immune effectors essential for mRNA decay.
Figure 3.3: Characteristics of CCCH-type Zinc Finger Proteins in mRNA De-
cay. Comparison of Regnase-1, TTP and Roquin features. Roquin features in bold are
based on my thesis. Figure modified from Uehata and Akira 2013 [215].
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Due to its RING domain, Roquin and Roquin2 are predicted E3 ubiquitin
ligases. For the C. elegans Roquin homolog RLE-1, which initiates DAF-16-
degradation by by ubiquitination [244], E3 ligase activity was shown. Based
on my data, the RING domain in Roquin does not play a role in CDE-mRNA
decay. It is possible that Roquin, in addition to its function in mRNA decay,
mediates ubiquitination of substrate proteins which needs further investiga-
tion. I suggest to study in an in vitro setting whether Roquin is capable of
autoubiquitination, commonly seen for E3 ligases. This would give a first hint
for E3 ligase activity of the RING finger in Roquin.
3.4.4 Regulatory RNA Structures in Mammals
In addition to the CDEs representing a conserved class of structured elements
in mammals, I speculate that there are many unknown classes of regulatory
RNA structures in higher eukaryotes that may play a role in posttranscrip-
tional control. High conservation on primary sequence in UTR regions is
an important indicator for a potential regulatory element, a fact we used to
search for CDEs bioinformatically [246]. Co-variation of sequences with respect
to structure conservation can additionally help to identify functional motifs.
With increasing importance of regulatory RNA-protein systems in vertebrates,
complicated networks have evolved to control gene expression. These systems
integrate inputs from different regulatory pathways. One may speculate that
two or more distinct elements in one 3’UTR, as seen for the TNFα ARE and
CDE, might also be functionally linked. As mentioned before, the ICOS 3’UTR
is likely to even contain different Roquin binding motifs, including the CDE.
Moreover, there is a class of mRNAs that are enriched in the Roquin-IP that
do not contain a conserved CDE as we define it (Figure 2.22). This suggests
that Roquin is able to bind other distinct recognition motifs or weaker CDEs.
This can either be addressed experimentally by performing Roquin CLIP ex-
periments or bioinformatically by determining a further common motif in these
3’UTRs.
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4.1 Materials
Detailed lists of the materials, chemicals and technical equipment used in this
study can be found in the Appendix.
4.2 Methods
All commercial kits and reagents were used according to the manufacturer’s
instructions unless otherwise stated.
4.2.1 Cell Culture and Transfection
Cell lines used in this study are listed in Table 4.1.
Table 4.1: Cell Lines Used in this Study.
Cell line Description and ATCC Number
COS7 African green monkey (Cercopithecus eathiops) kidneyfibroblast-like cell line (CRL-1651)
NIH3T3 B2A2
Mouse (Mus musculus) NIH 3T3 fibroblast clone B2A2
cell line (Ann-Bin Shyu lab, 1998) is a stable
transfectant of plasmid pUHD15-1 (Prof. H. Bujard)
encoding hybrid transactivator protein (tTA)
HeLa Human (Homo sapiens) epithelial cervicaladenocancinoma cell line (CCL-2)
HEK293 Hypotriploid human embryonic kidney cell line(CRL-1573)
RAW264.7 Mouse Abelson murine leukemia virus transformedmacrophage cell line (TIB-71)
COS7 as well as NIH3T3, HeLa, HEK293T and RAW264.7 cells were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco) supplemented
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with 10% fetal calf serum (PAA Laboratories), 2 mM L-glutamine, 100 U/ml
penicillin and 0.1 mg/ml streptomycin (all PAN Biotech) at 37°C in 5% CO2.
Cells were trypsinized using trypsin-EDTA (PAN biotech). BMDM were iso-
lated from the femur and tibia of WT C57BL/6 mice as described previously
[356]. BMDM were cultured for 10–12 days in DMEM supplemented with
10% fetal calf serum (Sigma), 20 mM HEPES (PAA), 2 mM L-glutamine
(PAN Biotech) essential and nonessential amino acids (Invitrogen), 55 µM 2-
mercaptoethanol (Sigma), 100 units/ml penicillin (PAN Biotech), 100 µg/ml
streptomycin (PAN Biotech) and 20% conditioned medium from L929 cells as
a source of macrophage colony-stimulating-factor. NIH3T3 B2A2 cells [357]
were a generous gift from Ann-Bin Shyu (University of Texas-Houston Medi-
cal School). NIH3T3, HeLa, HEK293T cells were seeded in 10-cm dishes and
transfected the following day with 9–12 µg of plasmid using polyethyleneimine
(PEI, Polysciences Europe, 1 mg/ml, pH 7.0) at a ratio of 1:2 (DNA:PEI)
in serum-free and antibiotic-free DMEM. In case Tet-inducible vectors were
transfected, 6 µg pTet reporter plasmid was co-transfected with 3 µg pTet-
Off (p2249), and media containing 10% (v/v) Tet-negative fetal calf serum
(PAA) was used. The medium was changed to regular DMEM 4–6 hours af-
ter transfection. Stable NIH3T3 cell lines were generated by PEI transfection
and subsequent selection with puromycin (4–6 μg/ml, Applichem) as given in
Table 4.2. Mass cultures were used for mRNA decay assays. Where indi-
cated, RAW264.7 cells were treated with LPS (100 ng/ml, Sigma, L2630, E.
coli serotype O111:B4).
4.2.2 Plasmid Construction
The following plasmids have been described previously: pTet-7B-ARE (pTet-
7B-TNFα-ARE53, p2260) containing a Tet-inducible promoter and a T7-tagged
rabbit β-globin reporter gene with the 53 nt ARE of mouse TNFα in its
3’UTR [136]; puroMXβglobin (p2220, also referred to as puroMXβ) con-
taining the β-globin reporter gene driven by the Moloney murine leukemia
virus (MMLV) promoter [304]; puroMXβ-TNFα-ARE (p2225) [304]; puroMXβ-
TNFα-KΔAU (p2230) [62]; pEGFP-N1 (Clontech/ BD Biosciences); pLNCX2-
EGFP-Roquin (p2838) encoding EGFP-tagged full-length mouse Roquin and
pETM11-Roquin-N (p2940) for expression of His-Roquin-N (aa 2-440) [226];
TOPuro-Caf1a-mycSG (p2485) and TOPuro-Caf1a-AA-mycSG (p2737) en-
coding human WT Caf1a and the dominant negative D40A/E42A mutant,
respectively; pcDNA3-Flag (p2002) and pcDNA3-Flag-Dcp2-AA (p2798) har-
boring the E147A/E148A Dcp2 mutant [196]; as well as pCMV-Flag-Not1
(p2556) encoding Not1 [358]. pcDNA3-hygro-T7tag (p3203) and pcDNA3-
hygro-T7tag-Roxan (p3204) [313] were kindly provided by Didier Poncet
(CNRS, Gif sur Yvette, France), and pGEX-2T-MS2cp (p2809) was a kind
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Table 4.2: Stable Cell Lines Generated in this Study. All cell lines were generated
by PEI transfection and selection with puromycin to a mass culture stage.
Cell line Plasmid Selection
NIH3T3 B2A2-puroMXß p2220 puromycin
NIH3T3 B2A2-puroMXß-CDE p2812 puromycin
NIH3T3 B2A2-puroMXß-TNF-KΔAU p2230 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V1 p2813 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V2 p2814 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3 p2818 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M1 p2820 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M2 p2821 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M3 p2822 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M4 p2823 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M5 p2824 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M6 p2825 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M7 p2826 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M8 p2827 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M9 p2828 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M10 p2829 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M11 p2830 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-hCDE p2831 puromycin
NIH3T3 B2A2-puroMXß-4xS1m p2824 puromycin
NIH3T3 B2A2-puroMXß-TNF-ARE-4xS1m p2891 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-4xS1m p2856 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M7-4xS1m p2857 puromycin
NIH3T3 B2A2-puroMXß-CDE37-V3-M9-4xS1m p2858 puromycin
gift from Stephen Wax and Paul Anderson (Brigham and Women’s Hospital,
Boston, USA). pTet-Off (p2249) was purchased from Clontech.
For the S1 and S1m-containing pTet-7B-TNFα-ARE reporter constructs,
oligonucleotides containing the S1 (G1779/G1780) or S1m (G1850/G1851) ap-
tamer sequence (see Suppl. Figure 5.1A, Suppl. Table 5.7, all oligonu-
cleotides were purchased from Invitrogen or Eurofins MWG Operon) were an-
nealed, concatemerized via their 5’BamHI- and 3’BglII-compatible ends and
ligated. Head-to-head and tail-to-tail conformations were suppressed by cleav-
age with BglII and BamHI, while BglII/BamHI fusion sites in head-to-tail
conformations gave rise to multimers. Fragments containing 1 to 7 consecu-
tive repeats of the S1 or S1m aptamer were then cloned into the BglII site of
pTet-7B-ARE (p2260). Thereby, the following series of pTet vectors was gener-
ated: pTet-7B-TNFα-ARE-1xS1 (p2775), -2xS1 (p2776), -3xS1 (p2777), -4xS1
103
Chapter 4 Materials and Methods
(p2778), -5xS1 (p2779), -6xS1 (p2780), -7xS1 (p2788); pTet-7B-TNFα-ARE-
1xS1m (p2781), -2xS1m (p2782), -3xS1m (p2783), -4xS1m (p2784), -5xS1m
(p2785), -6xS1m (p2786), -7xS1m (p2787). Plasmid puroMXβ-4xS1m (p2824)
was generated by PCR-amplifying 4xS1m from pTet-7B-TNFα-ARE-4xS1m
(p2784) using the forward BglII-mismatch repair primer G1919, which recon-
stitutes a BglII site from the BglII/BamHI fusion site, and reverse primer
G1918. The amplicon was then digested with BglII and inserted into the BglII
site of puroMXβ (p2220). The same 4xS1m fragment was cloned into the
BglII site of puroMXβ-TNFα-ARE (p2225) to generate puroMXβ-TNFα-ARE-
4xS1m (p2891), and into the BglII site of pSP73 (Promega) to generate pSP73-
4xS1m (p2880) (see Suppl. Figure 5.1 and 5.2). For pSP73-4xS1 (p3278),
a 4xS1 fragment with flanking BglII sites was PCR-amplified from pTet-
7B-TNFα-ARE-4xS1 (p2778) with primers G1919/G1918, BglII-digested, and
cloned into the BglII site of pSP73. For pSP73-TNFα-ARE-4xS1m (p2881), the
ARE-4xS1m fragment was PCR-amplified from puroMXβ-TNFα-ARE-4xS1m
(p2891) using the forward BamHI-mismatch repair primer G2247, which re-
constitutes a BamHI site from the BglII/BamHI fusion site, and reverse primer
G2235. Thereupon, the 5’BamHI- and 3’BglII-flanked insert was cloned into
the BglII site of pSP73. In analogy, for pSP73-TNFα-ARE-4xS1 (p3279), an
ARE-4xS1 fragment with flanking BamHI/BglII sites was PCR-amplified from
pTet-7B-TNFα-ARE-4xS1 (p2778) with primers G2247/G2235, BamHI/BglII-
digested, and inserted into the BglII site of pSP73. The PP7bs was synthe-
sized by annealing oligonucleotides G95 and G96, and concatemerized using
the same BamHI/BglII strategy as described above for S1/S1m. A 6-fold
head-to-tail repeat of PP7bs was then cloned into pSP73, and transferred as
a BamHI-BglII fragment into the BglII site of pTet-7B-ARE (p2260) [136]
to generate pTet-7B-TNFα-ARE-6xPP7bs (p2259). For pTet-7B-TNFα-ARE-
6xMS2bs (p2258), a 6-fold repeat of MS2bs was amplified by PCR using
primers G37 and G38 from plasmid b-6bs [274] and cloned as a BamHI-BglII
fragment into the BglII site of pTet-7B-ARE (p2260) [136].
For the expression of GST-tagged recombinant proteins, a 5’BamHI-, 3’EcoRI-
linkered TEV sequence encoding ENLYFQG was first synthesized by anneal-
ing oligos G1875/G1876, and ligated into the BamHI/EcoRI sites of pGEX-
4T-3 to generate pGEX-4T-3-TEV (p2772). The PP7cp sequence was then
PCR-amplified with oligos G1859/G1860 from pc-HA-PP7cp (p2211) [197]
and inserted into the EcoRI/XhoI sites of pGEX-4T-3-TEV (p2772) to gener-
ate pGEX-4T-3-TEV-PP7cp (p2773). Using the same strategy, oPP7cp [286]
was PCR-amplified from pET28-ZZ-TEV-oPP7cp-His6 (p2770), a kind gift
from Kathy Collins (University of California Berkeley, USA), using oligos
G1860/G1861, and inserted into the EcoRI/XhoI sites of pGEX-4T-3-TEV
(p2772) to generate pGEX-4T-3-TEV-oPP7cp (p2774). A TEV-linked ver-
sion of GST-MS2cp was generated by inserting two consecutive BamHI/BglII-
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linked TEV sites (G1852/G1853) into the BamHI site of pGEX-2T-MS2cp
(p2809), resulting in pGEX-2T-TEV-TEV-MS2cp (p2810).
For pcDNA3-GFβ (p2732), which encodes a GFP/β-globin fusion protein,
EGFP was amplified with primers G1612/G1613 and cloned as a HindIII–KpnI
fragment into the HindIII/KpnI sites of pcDNA3-7B (p2308) [196]. pcDNA3-
GFβ-TNFα-CDE (p2730), was generated by insertion of annealed oligonu-
cleotides spanning a 14 nt linker (NheI, AgeI sites) and the 40 nt CDE of
mouse TNFα (see Suppl. Table 5.1 for all CDE inserts). The oligonucleotides
were designed with BamHI- and BglII-compatible ends, 5’-phosphorylated us-
ing T4 polynucleotide kinase (Promega) and annealed prior to ligation into
the BglII site of pcDNA3-GFβ (p2732), whereby a 5’-BamHI/BglII fusion
site (AGATCC) and a 3’-BglII site were created. For puroMXβ-TNFα-CDE
(p2812), the CDE was excised as an EcoRI–BglII fragment from pcDNA3-
GFβ-TNFα-CDE (p2730) and ligated into the EcoRI/BglII sites of puroMXβ
(p2220).
By the same BamHI-BglII strategy, annealed oligonucleotides were inserted
into the BglII-site of puroMXβ (p2220) to generate the following plasmids:
puroMXβ-TNFα-CDE37-V2 (p2814), -V3 (p2823), -V3-M1 (p2825), -V3-M2
(p2826), -V3-M3 (p2827), -V3-M4 (p2828), -V3-M5 (p2829), -V3-M6 (p2830),
-V3-M7 (p2831), -V3-M8 (p2832), -V3-M9 (p2833), -V3-M10 (p2834), -
V3-M11 (p2835), -V3-M12 (p2859), -V3-M13 (p2860), -V3-M14 (p2861), -
V3-M15 (p2862), -V3-M16 (p2863), -V3-M17 (p2864), -V3-M18 (p2944), -
V3-M19 (p2945), -V3-M20 (p2959), -V3-M21 (p2946), -V3-M22 (p2947), -
V3-M23 (p2960), -V3-M24 (p2961), -V3-M25 (p2948), -V3-M26 (p2967), -
V3-M27 (p2968), puroMXβ-TNFα-CDE17-ds (p2966) and puroMXβ-human-
TNFα-CDE37-V3 (p2836). All CDE sequences and corresponding mRNA half-
lives are summarized in Suppl. Table 5.1.
In order to generate puroMXβ-TNFα-CDE17-ss (p2965) and puroMXβ-ICOS-
CDE17-ss (p2991), puroMXβ was engineered to contain an XbaI, AgeI and
NheI site between the β-globin stop codon and the BglII site, and CDE17-
containing oligos with XbaI- and AgeI-compatible ends were ligated into the
XbaI/AgeI sites. For puroMXβ-TNFα-CDE150 (p2969), a 150 nt fragment of
the mouse TNFα 3’UTR containing the CDE in its center was amplified us-
ing BamHI- and BglII-linkered primers (G2495/G2496) and cloned into the
BglII site of puroMXβ (p2220). Mutations in puroMXβ-TNFα-CDE150-M16
(p2970) and puroMXβ-TNFα-CDE150-M20 (p2972) were generated by the fol-
lowing PCR strategy: up- and downstream portions of the CDE150 were
amplified using mutation-bearing primers (G2495/G2498 and G2497/G2496
for M16, G2495/G2502 and G2501/G2496 for M20), annealed, and the full
CDE150 fragment was reamplified with G2495/G2496 prior to insertion into
the BglII site of puroMXβ (p2220). The TNFα mouse 3’UTR was ligated into
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puroMXβ (p2220) as a SalI/BglII fragment from pBABEpuro-GFP-TNFα-
UTR (G. Stoecklin, unpublished) to generate puroMXβ-TNFα-3’UTR (p2914).
A point mutation in the Roquin2 cDNA obtained from Imagenes was re-
placed with a WT fragment amplified by PCR from mouse cDNA with primers
G2421/G2427. The fulllength Roquin2 cDNA was then cloned as a SalI/ClaI
fragment into pLNCX2 (Clontech) to generate pLNCX2-Roquin2 (p2984).
For pLNCX2-EGFP-Roquin2 (p2985), EGFP was excised using SalI from
pLNCX2-EGFP-Roquin (p2838) and inserted into the SalI site of pLNCX2-
Roquin2 (p2984).
The Roquin and Roquin2 ZF mutants were generated replacing the first cys-
teine in the CCCH-type zinc finger domains of both proteins with an arginine,
resulting in a RCCH motif (Roquin-C419R and Roquin2-C416R). Mutagenesis
was carried out using a dual PCR approach, as follows: Two PCR fragments
each were amplified for Roquin (G2623/G2577, G2576/G2579) and Roquin2
(G2556/G2555, G2554/G2622), annealed and used as DNA templates for a
second PCR with the outer primer pairs (Roquin, G2623/G2579; Roquin2,
G2622/G2556). The secondary PCR fragments spanning the mutations were
exchanged with the original sequence by restriction digest and subsequent
ligation. DraIII was used for pLNCX2-EGFP-Roquin-C419R (p3013), and
MfeI/BstXI were used for pLNCX2-EGFP-Roquin2-C416R (p3014).
To facilitate cloning of Roquin fusion proteins, the EGFP coding sequence
was excised from pLNCX2-EGFP-Roquin (p2838) using SalI and replaced by
a PCR-amplified EGFP fragment containing a unique AgeI site downstream of
the EGFP sequence, yielding pLNCX2-EGFPA-Roquin (p3090). For the plas-
mids encoding the N-terminal portion (N-term) of Roquin (pLNCX2-EGFPA-
Roquin-2-441aa; p3124) or the ROQ-domain (pLNCX2-EGFPA-Roquin-131-
360aa; p3153), the Roquin coding sequence was excised from p3090 as a
AgeI/ClaI fragment and replaced with corresponding PCR-amplified inserts
coding for N-term (G2788/G2840) or ROQ (G2855/G2856). For pLNCX2-
EGFPA-Roquin-442-1130aa (p3125) encoding the Roquin C-terminus (C-
term), a larger N-terminal portion of Roquin was excised as an AgeI/PmlI
fragment from pLNCX2-EGFPA-Roquin (p3090) and replaced by a shorter
PCR-amplified fragment (G2842/G2843). pLNCX2-EGFPA-Roquin-S060r
(p3101) encoding an siRNA s060 (si-Roquin (B))-resistant version of Roquin
was generated using the above described dual PCR approach with primers
G2788/G2791, G2789/G2790 and G2788/G2789. The resulting fragment har-
boring four silent point mutations in the s060 seed sequence were cloned into
the AgeI/MfeI sites of pLNCX2-EGFPA-Roquin (p3090). Flag-tagged Roquin-
fusion constructs pCI-neo-Flag-Roquin (p3061), pCI-neo-Flag-Roquin-ΔRING
(p3062), and pCI-neo-Flag-Roquin-ΔROQ (p3063) were kindly provided by
Nancy Kedersha and Paul Anderson (Harvard Medical School, Boston, MA).
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4.2.3 Oligo Phosphorylation and Ligation
In case oligos were used as inserts for cloning, they were 5’-phosphorylated
in a kination reaction using T4 polynucleotide kinase (PNK, NEB). A 20 µL
reaction contained oligonucleotides at a concentration of 20 pmol/µL, 1x T4
kinase buffer, 1 mM ATP and 5 U T4 PNK. After incubation at 37°C for 30
minutes, sense and antisense oligos were mixed for annealing. Upon heating at
95°C for 15 minutes for denaturation, the mixture was slowly cooled down by
incubation in a beaker of 500 ml boiling water and cooled to RT. The annealed
oligos were nucleotide-purified (Nucleotide Purification Kit, QIAgen), eluted
in 30 µl H2O and ligated for 30 minutes at RT in a 40 µl reaction applying
5 U T4 DNA ligase (Rapid DNA Ligation Kit, Fermentas) This generated
head-to-tail linked oligo chains. After nucleotide removal and elution in 40 µl
H2O, in cases where BamHI- and BglII-sites were attached, the inserts were
BglII/BamHI-digested in a 50 µl reaction using 1 U restriction enzyme (NEB)
each, for 1 hour at 37°C. This prevented links other than head-to-tail. The
samples were resolved on a 1% agarose gel and ligation products of correct
size were gel-extracted (QIAquick Gel Extraction Kit, QIAgen) and eluted
in 30 µl H2O. Inserts were further applied for ligation with plasmid DNA.
Where only one copy of an oligo served as insert, annealed olignucelotides were
nucleotide-purified, digested with the respective enzymes to reverse multimer-
ization, and again nucleotide-purified before subjection to plasmid ligation.
All oligonucleotide sequences are provided in Suppl. Table 5.1. Mutations,
cloning boundaries and coding sequences were systematically verified by DNA
sequencing (GATC Biotech).
4.2.4 Polymerase Chain Reaction (PCR)
In case plasmid construction included insert amplification by PCR, a 100 µl
reaction was performed as given in Table 4.3 with the PCR program given
in Table 4.4. Screening of colonies upon E. coli transformation by colony
PCR was performed as exemplified for puroMXβ constructs using primers
G1854/G1855 in a downscaled 25 µl reaction in analogy to as presented in
Table 4.3. For that cells of a single colony were picked and used as template,
increasing the initial denaturation time to 10 minutes. 10 µl of the PCR re-
action was loaded onto a 1 or 2% agarose gel and analyzed with a UV Gel
Documentation device.
4.2.5 mRNA Decay Assay
For mRNA decay experiments, NIH3T3 B2A2 or HeLa cells were stably or
transiently transfected with puroMXβglobin reporter plasmids. 24 hours post
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Table 4.3: PCR Reaction.
Amount Component
0.5-1 µg plasmid DNA
10 µl 10x Taq polymerase buffer (QIAgen)
200 nM dNTPs (dATP, dTTP, dGTP, dCTP, Fermentas; 10 mM each)
400 nM forward primer G1854 (40 mM)
400 nM reverse primer G1855 (40 mM)
2 U Taq polymerase (QIAgen)
ad 100 µl water
Table 4.4: PCR Program.
Temperature (°C) Duration (minutes) Cycles
95 3 1
95 0.5
3555-60 0.5
72 0.5-1.5
72 10 1
4 ∞ 1
transfection, 5 µg/ml actinomycin D (actD, Applichem, Cat. No. A1489) was
added to the medium for the indicated time intervals before harvesting cells
and extracting total RNA using the Genematrix universal RNA purification
kit (Eurx, Roboklon). RNA was extracted from Trifast (PeqLab) samples
by phase-separation using chloroform and precipitated with isopropanol. The
RNA pellet was washed with ice-cold 70% ethanol and resuspended in RNase-
free water. RAW264.7 cells were stimulated for 2 hours with LPS (100 ng/ml)
before addition of actD. mRNA levels were determined either by Northern
blot or by quantitative reverse transcription (RT)-PCR analysis. mRNA half-
lives were calculated assuming a first order decay rate. After background
subtraction, mRNA signals were normalized to the signal of the loading control
and plotted against time. Curves with the following equation were fitted to
the data points by linear regression: y = a × e(b × t), where y stands for the
relative mRNA signal and t for the time. mRNA half-lives were calculated as
follows: t1/2 = ln(2) / ln(b).
4.2.6 Northern Blot Analysis
5–15 µg of RNA was resolved by 1.1% agarose/2% formaldehyde/MOPS
(morpho-linepropanesulfonic acid) gel electrophoresis and blotted over night
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with 8x saline-sodium citrate (SSC) buffer (1x contains 0.15 M NaCl and
0.015 M sodium citrate) onto Hybond-N+ Nylon membranes (Amersham, GE
Healthcare). Membranes were hybridized overnight at 55°C with digoxigenin-
labelled RNA probes synthesized in vitro using Sp6 polymerase (Fermentas)
and DIG RNA labelling mix (Roche). 500 ng RNA probe was diluted in 10 ml
hybridization buffer containing 50% formamide, 5x SSC, 5x Denhard’s solu-
tion, 5 mM EDTA, 10 mM PIPES pH 7.0 at 25°C, 0.4 mg/ml torula yeast RNA
(US Biological) and 1% SDS. Membranes were washed twice with 2x SSC/ 0.1%
SDS for 5 minutes, and twice with 0.5x SSC/ 0.1% SDS for 20 minutes at 65°C.
Alkaline phosphatase-coupled anti-digoxigenin Fab fragments and CDP-Star
substrate (both Roche) were used for detection according to the manufac-
turer’s instructions. Templates for RNA probes were generated by PCR using
the following primers: G1000/G1001 (probe against exon 1 and 2 of rabbit
β-globin), G83/G1009 (probe against human nucleolin), G078/G1008 (probe
against mouse S7), and G314/G316 (probe against mouse TNFα). Deadeny-
lated mRNA was generated using RNase H (NEB) and oligo-dT as described
[131]. 1.6% agarose gels were used to resolve poly(A) tails, and the correspond-
ing signals were quantified using ImageJ software.
4.2.7 Western Blot Analysis
Proteins were resolved on 5–20% polyacrylamide gradient Tris-glycine gels and
transferred onto 0.2 µm pore size nitrocellulose membranes (Peqlab). Protein
loading was assessed by Ponceau Red staining. Membranes were then blocked
in phosphate buffered saline (PBS) containing 0.1% sodium azide and 5%
horse serum or milk powder, incubated with antibodies diluted in the same
solution for 1 hour at room temperature or over night at 4°C, and washed in
150 mM NaCl, 50 mM Tris-HCl (pH 7.5 at 25°C), 1% Tween-20. Horseradish
peroxidase-coupled secondary antibodies (Jackson Immunoresearch) in combi-
nation with Western Lightning enhanced chemiluminescence substrate (Perkin
Elmer) and X-ray films (FujiFilm) were used for detection. Films were docu-
mented using an EPSON scanner. For the detection of Roquin and TNFα in
RAW264.7 macrophages, cells were harvested, washed once in PBS, solubilized
in RNA-IP lysis buffer, and cytoplasmic lysates were supplemented with 2x
SDS sample buffer containing 100 mM Dithiothreitol (DTT) prior to Western
blot analysis.
4.2.8 Antibodies
A list of all primary antibodies and dilutions used in this study for Western
blot analysis can be found in the Appendix. Antibodies received from others
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include polyclonal rabbit anti-GST antibody which was kindly provided by
Ludger Hengst (Innsbruck Medical University, Austria) and Frauke Melchior
(ZMBH, University of Heidelberg, Germany). Polyclonal rabbit anti-Caf1a
antibody was kindly provided by Ann-Bin Shyu (University of Texas-Houston
Medical School).
4.2.9 Recombinant Protein Purification
For expression of the recombinant fusion proteins GST-T-PP7cp, GST-T-
oPP7cp, GST-MS2cp, and GST-TT-MS2cp, pGEX-based plasmids described
above were transformed into BL21 (DE3) codon+ E. coli. Cells were cultured
in 1 l Luria-Bertani medium supplemented with 100 µg/ml ampicllin at 37°C to
an OD600 of 0.5 and protein expression was induced by addition of 1 mM IPTG.
The culture was incubated for additional 16 hours at 21°C before cells were
collected at 4°C, washed once with ice-cold phosphate buffered saline (PBS),
and resuspended in 10 ml PBS-MEC (PBS, 0.1% (v/v) β-mercaptoethanol
(ME), 1 tablet/10 ml Mini Complete Protease Inhibitors, EDTA-free (Roche))
and lysed in PBS-ME using a microfluidizer (Emulsiflex, Avestin). The lysate
was supplemented with 1% Triton-X-100, insoluble debris was removed by
centrifugation and the supernatant was incubated under rotation with Glu-
tathione (GSH) Sepharose High Performance 4B (GE Healthcare) beads for 1
hour at 4°C. Beads were washed five times for 10 minutes with PBS-ME and
transferred to a Poly-Prep column (Biorad) with a frit. PBS-ME was drained
by gravity, and recombinant protein was eluted in 2 ml of elution buffer (50
mM glutathione, 50 mM Tris-HCl (pH 8.0), 10% glycerol, 1 tablet/10 ml Mini
Complete Protease Inhibitors, EDTA-free (Roche), 0.1% (v/v) β-ME) for 2
hours at 4°C under rotation. Eluted protein was dialyzed against dialysis
buffer (50 mM Tris-HCl (pH 8.0), 0.1% (v/v) β-ME) for 6 hours at 4°C, ex-
changing the buffer every 2 hours. The eluate was recovered, supplemented
with 20% glycerol, and protein concentration was determined by Nanodrop
measurement and SDS-PAGE using a BSA standard.
4.2.10 Cellular RNP Purification via S1/S1m Aptamers
One day after transient transfection of 1.2x106 COS7 cells per 10-cm dish,
cells were washed once with PBS, and the cell pellet was snap frozen in liquid
nitrogen. By addition of a 5 mm steel bead, the cell pellet was homogenized
by cryomilling using a tissue lyser (QIAgen TissueLyser II) at 25 Hz for 15
seconds.
For SA-pulldown of S1 and S1m-tagged RNAs, the homogenate was solubilized
in 500 μl ice cold SA-RNP lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM
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NaCl, 1.5 mMMgCl2, 2 mM DTT, 2 mM vanadylribonucleosid complex RNase
inhibitor (NEB), 1 tablet/10 ml Mini Complete Protease Inhibitors, EDTA-
free (Roche)). Lysates were first incubated with avidin agarose beads (Thermo
Pierce) for 10 minutes at 4°C as a blocking step before cell debris was removed
by centrifugation for 5 minutes at 2000 rpm (~400 x g) at 4°C. The pre-cleared
lysate was transferred to a fresh tube, and 1:10 was saved as RNA input, mixed
with 500 µl TriFast (PeqLab) and stored at -20°C for later RNA extraction.
Lysates were incubated with Streptavidin Sepharose High Performance (GE
Healthcare) beads for 4 hours at 4°C under rotation before washing five times
for 5 minutes at 4°C with SA-RNP wash buffer (20 mM Tris-HCl (pH 7.5),
300 mM NaCl, 5 mM MgCl2, 2 mM DTT). For the last wash, beads were
transferred to a fresh tube, and RNA was eluted from the beads using 500 µl
TriFast reagent (PeqLab) according to the manufacturer’s instructions. 15 µg
GlycoBlue (Ambion) was added to the RNA samples prior to precipitation.
Subsequently, RNA was resolved on denaturing agarose gels for Northern Blot
analysis to determine RNA binding efficiency to SA-beads.
4.2.11 Cellular RNP Purification via GST
COS7 cells were transfected, harvested and homogenized as described for SA-
pulldown above. Homogenates were solubilized in 500 µl ice cold GSH-RNP
lysis buffer (50 mM Tris-HCl (pH 8.0 at 25°C), 150 mM NaCl, 1 mM MgCl2,
10% v/v glycerol, 2 mM DTT, 1 tablet/10 ml Mini Complete Protease In-
hibitors, EDTA-free (Roche), 2 mM vanadylribonucleosid complex RNase in-
hibitor (NEB)), tumbled for 10 minutes at 4°C and cell debris was removed by
centrifugation. The lysate was transferred to a fresh tube, and 1:10 was saved
for extraction of input RNA using TriFast (PeqLab). Lysates were pre-cleared
with Glutathione Sepharose High Performance 4B (GE Healthcare) beads for
2 hours at 4°C. The supernatant was then transferred to a new tube, and 1:10
was saved for extraction of pre-clear RNA. 2 µg of recombinant GST-tagged
proteins was added to the pre-cleared lysates for 3 hours at 4°C prior to in-
cubation with Glutathione Sepharose High Performance 4B (GE Healthcare)
for another 3 hours. The beads were then washed six times for 5 minutes at
4°C with GSH-RNP lysis buffer. For the last wash, beads were transferred to
a fresh tube, and protein was eluted from 10% of the beads using SDS sample
buffer. RNA was eluted from 90% of the beads using 500 μl TriFast (PeqLab).
4.2.12 In vitro Transcription
Four RNAs were synthesized by in vitro transcription: ARE-4xS1 and ARE-
4xS1m RNA containing a single copy of the 53 nt long TNFα ARE attached
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to 4 copies of the S1 or S1m aptamer, respectively, as well as 4xS1 and 4xS1m
alone as negative control RNAs. Since amplification of the highly structured
4xS1 and 4xS1m tag by PCR was problematic, linearized pSP73 plasmids
or excised fragments from plasmids containing the ARE and 4xS1/4xS1m
sequences served as templates. To this end, plasmids pSP73-4xS1 (p3278),
pSP73-4xS1m (p2880), pSP73-TNFα-ARE-4xS1 (p3279), and pSP73-TNFα-
ARE-4xS1m (p2881) were linearized at the EcoRV-site downstream of the
4xS1m sequence, purified with the QIAquick PCR Purification Kit (QIAgen)
and used as DNA templates for run-off in vitro transcription using SP6 RNA
polymerase. Alternatively, plasmids were digested for 6 hours with NdeI and
EcoRV to release SP6-tagged DNA templates that were gel-extracted with
the QIAquick Gel Extraction Kit (QIAgen). A 50 µl transcription reaction
contained the components given in Table 4.5.
Table 4.5: In vitro Transcription Reaction.
Amount Component
8 µg linear DNA template
1x 5x SP6 Transcription Buffer (Fermentas)
4 mM NTPs (ATP, UTP, GTP, CTP, Fermentas, 10 mM each)
0.5 U yeast pyrophosphatase (Sigma)
50 U RNasin RNase inhibitor (Promega)
400 U SP6 RNA Polymerase (Fermentas)
ad 50 µl water
After incubation for 4 hours at 37°C, DNA was digested by addition of 5 U RQ1
DNase (Promega) for 15 minutes at 37°C. In cases where higher RNA yields
were needed, the MEGAscript SP6 Kit (Invitrogen, Life Technologies) was
used for transcription and DNase digestion according to the manufacturer’s
instructions. Synthesized RNA was purified by gel filtration using pre-packed
G-50 Mini Quick Spin Sephadex RNA columns (Roche) according to the manu-
facturer’s instructions, and RNA concentration was determined by Nanodrop.
One reaction typically yielded 25–50 µg of RNA.
4.2.13 In vitro RNP Purification via S1m
For the following procedures, DNA/RNA LoBind tubes (Eppendorf) were used
to reduce the degree of unspecific binding. Per sample, 100 µl 50% slurry of
Streptavidin Sepharose High Performance (GE Healthcare) beads were washed
three times with 1 ml of SA-RNP lysis buffer (20 mM Tris-HCl (pH 7.5), 150
mM NaCl, 1.5 mM MgCl2, 2 mM DTT, 2 mM vanadylribonucleosid complex
RNase inhibitor (NEB), 1 tablet/10 ml Mini Complete Protease Inhibitors,
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EDTA-free (Roche)). At each step, beads were gently pelleted at 500 rpm
(~20 x g) for 1 minute at 4°C. 30 µg of the in vitro transcribed 4xS1m or
ARE-4xS1m RNAs was renatured in 50 µl SA-RNP lysis buffer by heating at
56°C for 5 minutes, 10 minutes at 37°C and incubation at room temperature
for several minutes to refold RNA structures. The RNA was added to the
100 µl SA Sepharose slurry together with 3 µl RNasin (120 U, Promega),
and 10 µl of the supernatant (10%) was saved for extraction of input RNA
using TriFast (PeqLab). The mixture was incubated at 4°C for 2–3 hours
under rotation to permit binding of the RNA to the column. After that,
beads were sedimented and a 10 µl sample of the supernatant (10%) was saved
for extraction of unbound RNA using TriFast (PeqLab), while the remaining
supernatant was discarded. Input and unbound RNA samples were compared
side by side through 6% polyacrylamide/TBE/urea gel electrophoresis and
methylene blue staining to assess the efficiency of RNA coupling.
Cellular extracts were prepared from 40 confluent 15-cm dishes of untransfected
NIH3T3 B2A2 cells. A total of 3.5 g cells was collected, washed once in PBS,
divided into 300 mg portions and aliquoted in 2 ml safe-lock tubes (Eppendorf).
The cell pellets were then snap frozen in liquid nitrogen, homogenized by
cryomilling after addition of a 5 mm steel bead using a tissue lyser (QIAgen
TissueLyser II) at 25 Hz for 15 seconds 4–6 times, and the powder was either
processed directly or stored in liquid nitrogen. The frozen homogenate of one
aliquot (300 mg) was solubilized by the addition of 300 µl ice-cold RNP lysis
buffer and allowed to thaw for 5 minutes at room temperature. Cell debris
was removed by centrifugation for 10 minutes at 17.000 x g at 4°C, resulting
in a supernatant of ~500 µl. The protein concentration in the extract was
determined by Nanodrop to be ~70 mg/ml.
Next, the extract (~500 µl) was pre-cleared by addition of 25 µl of a 50%
slurry of Avidin Agarose (Thermo Pierce) beads and tumbling for 30 minutes
at 4°C. The supernatant was transferred to a fresh tube and tumbled with 50
µl of a 50% slurry of SA Sepharose beads for an additional 2–3 hours. Beads
were discarded, and the pre-cleared lysate was supplemented with 1.5 µl (60
U) of RNasin (Promega), added onto the freshly prepared, RNA-coupled SA
Sepharose matrix and incubated at 4°C for 3–4 hours under rotation. Beads
were washed 6 times for 2–5 minutes with 1 ml SA-RNP wash buffer (20
mM Tris-HCl (pH 7.5), 300 mM NaCl, 5 mM MgCl2, 2 mM DTT) supple-
mented with 2 mM vanadylribonucleosid complex RNase inhibitor (NEB) and
1 tablet/50 ml Complete Protease Inhibitors, EDTA-free (Roche). After the
last wash, beads were transferred to a fresh tube and RNA-bound proteins were
eluted by addition of 5 µg RNase A (Genomed) in 100 µl Low Salt Buffer (20
mM Tris-HCl (pH 7.5), 30 mM NaCl, 5 mM MgCl2, 2 mM DTT, 1 tablet/10
ml Mini Complete Protease Inhibitors, EDTA-free (Roche)) for 10 minutes at
4°C. The RNase A eluate was recovered and concentrated by vacuum centrifu-
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gation from 100 µl to 30 µl. 10 µl of the eluate was analyzed by SDS-PAGE and
colloidal Coomassie staining while 20 µl were used for subsequent LC-MS/MS
analysis. After RNase A elution, the beads were extracted with 30 µl 2x SDS
sample buffer, 10 µl of which were analyzed by SDS-PAGE.
4.2.14 In vitro RNP Purification via S1m and Biotin Elution
Where indicated, elution of RNA-protein complexes with biotin was carried
out using 10 mM biotin (50 mM stock, Invitrogen, Life Technologies) in SA-
RNP lysis buffer for 1 hour at 4°C. For initial small-scale experiments aimed
at quantifying binding and elution efficiencies, (and protein analysis), 20%
of the RNA at each step was analysed by 6% polyacrylamide/TBE/urea gel
electrophoresis and methylene blue staining. For that, the before mentioned
protocol was adjusted as follows. Per sample, 20 µl (50 µL) washed 50%
slurry of Streptavidin Sepharose High Performance (GE Healthcare) beads
were incubated with 5 µg (15 µg) of in vitro transcribed RNA and 0.5 µl
(2 µl) RNasin (20 U, Promega) in 50 µL SA-RNP lysis buffer. 10 µl of the
supernatant (20%) was saved as input RNA, the RNA was coupled to beads at
4°C for 1–2 hours under rotation, and 10 µl of the supernatant (20%) was saved
as unbound RNA. Cellular extracts of 30–50 mg/ml protein concentration
were prepared from frozen NIH3T3 cell homogenates in ice-cold SA-RNP lysis
buffer, pre-cleared with SA and avidin beads for 30 minutes at 4°C, and 50 µl
(250 µl) lysate supplemented with RNasin was incubated with RNA-resins for
1–2 hours at 4°C. Upon three washes with SA-RNP lysis buffer (SA-RNP wash
buffer when monitoring protein), RNA-protein complexes were eluted either
with 10 mM biotin (50 mM stock, Invitrogen, Life Technologies) in 40 µl lysis
buffer for 1 hour at 4°C or with 1 µg (2.5 µg) RNase A (Genomed) in 40 µl
lysis buffer (50 µL wash buffer) for 10 minutes at 4°C. 10 µL (20%) of each
biotin and RNase A elution sample was saved. Residual RNA on beads was
extracted using TriFast (PeqLab). For protein analysis, after RNase A elution,
the beads were extracted with 40 µl 2x SDS sample buffer. 23% of RNase A
elutions and SDS bead elutions was analyzed by SDS-PAGE and Western blot.
4.2.15 Mass Spectrometry
Mass spectrometry analysis was carried out at the Mass Spectrometry Core
Facility of the ZMBH (Zentrum für Molekulare Biologie der Universität Hei-
delberg). Proteins eluted from the RNA affinity matrix were shortly run into
a 10% polyacrylamide Tris-glycine gel (NuPAGE, Novex/Invitrogen), and pro-
teins were stained by colloidal Coomassie blue. For each sample, the entire
lane was cut into 3–4 gel slices including the wells. After in-gel digestion
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with trypsin, the supernatant was dried in a speed vac and solubilized in
55 µl of dimethyl labeling reaction mixture (50 µl 100 mM TEAB, 2 µl 150
mM NaBH3CN) and 2 µl formaldehyde for light labeling and 2 µl deuterated
formaldehyde for medium labeling [307]. After 1 hour at 25°C, the reaction
was stopped with 1.6 µl 5% NH4OH and acidified with 4 µl 50% formic acid 10
minutes later. NanoUPLC-MS/MS analysis (LTQ Orbitrap XL, Thermo Sci-
entific) was carried out as described in more detail previously [131]. Database
search was done using Mascot in the framework of ProteomeDiscoverer (PD1.3;
ThermoScientific) with carbamidomethyl cysteine as fixed modification, and
deamidation (NQ) and oxidation (M) as variable modification against the
NCBI database (taxonomy: mus). Light and medium dimethylation at K and
the N-terminus were searched as static modifications in two different nodes of
PD1.3.
4.2.16 In-Line Probing
In-line probing was performed as described previously [315]. Mouse TNFα-
CDE RNA (CDE37-V2, CDE37-V3 and CDE150) was transcribed in vitro using
T7 RNA polymerase, dephosphorylated and radiolabelled with [γ-32P]ATP.
T7-linkered primers (G2234/G2235, Suppl. Table 5.7) were used to am-
plify the DNA sequence of TNFα-CDE37-V2 (92 nt) and TNFα-CDE37-V3
(94 nt) from plasmid templates. For the CDE150 DNA template, primers
G2332/G2333 and plasmid puroMXß-TNFα-3’UTR (p2914) containing the
full-length 3’UTR of mouse TNFα were used. After gel-extraction of the DNA
templates, RNAs were prepared by in vitro transcription using T7 RNA poly-
merase (NEB) in a solution containing 40 mM Tris-HCl (pH 7.9 at 25°C), 6 mM
MgCl2, 2 mM spermidine, and 10 mM dithiothreitol (DTT). The transcrip-
tion products were subjected to denaturing 8 M urea/6% polyacrylamide gel
electrophoresis (PAGE) for purification. The RNA transcripts were dephos-
phorylated using calf intestinal phosphatase (Roche) and radiolabeled with
[γ-32P]ATP using T4 polynucleotide kinase (NEB) in 70 mM Tris-HCl (pH 7.6
at 25°C), 10 mM MgCl2, 5 mM DTT. The radiolabeled RNA was purified us-
ing denaturing 6% PAGE. The purified RNA was subsequently incubated for
45 hours at room temperature in a solution containing 50 mM Tris-HCl (pH
8.3 at 25°C), 20 mM MgCl2, and 100 mM KCl. Reactions were quenched with
urea and EDTA prior to loading. Products of spontaneous in-line cleavage
were resolved next to a no reaction (NR) control, a partial RNase T1 digest
(T1), and a partial alkaline digest (-OH) of the same RNA by denaturing 10%
urea PAGE. Gels were dried and visualized using a GE Typhoon laser scanner
under the phosphorimager setting.
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4.2.17 Quantitative RT-PCR
For reverse transcription-quantitative PCR (RT-qPCR) analysis, cDNA was
synthesized from 1–2 µg of total RNA using random hexamer primers (Fer-
mentas) and Transcriptor reverse transcriptase (Roche) according to the man-
ufacturer’s instructions in an RT reaction. Prior to RT, residual DNA was
removed from RNA samples in a DNase treatment step. 16 µl total RNA
in a 20 µl DNase reaction was incubated with 2 U RQ1 DNase (1 U/µl)
and 1x RQ1 DNase Buffer (both Promega) and incubated at 37°C for 30
minutes before inactivation of the DNase by addition of 2 µL RQ1 stop
solution and incubation at 65°C for 10 minutes. DNase-treated RNA was
then used for RT. The RT reaction mixture given in Table 4.6 was incu-
bated for 30 minutes at 55°C for cDNA synthesis and the reverse transcrip-
tase was inactivated at 85°C for 5 minutes. The generated cDNA was di-
luted 1:5 in water prior to PCR. qPCR reactions were assembled in 384-well
plates using 1:20 of a cDNA reaction, 400 nM of each target-specific primer
and the DNA SYBR Green I Master kit (Roche) in a final volume of 10
µl per well. qPCR was performed on the Lightcycler 480 system (Roche)
applying the program given in Table 4.7. Mouse gene-specific primer se-
quences used for detection of mRNAs encoding nucleolin (G1706/G1707),
Ier3 (G1712/G1713), TNFα (G1844/G1845), Gapdh (G2053/G2054), Nfk-
biz (G2181/G2182), Nfkbid (G2199/G2200), NupL1 (G2364/G2365), Roquin
(G2392/G2393), Roquin2 (G2394/G2395), Ppp1r10 (G2592/G2593), Bmpr1a
(G2723/G2724), Pdia6 (G2729/G2730), Hmgxb3 (G2737/G2738) and Rck
(G2747/G2748) are given in Suppl. Table 5.7.
Table 4.6: RT Reaction for cDNA Synthesis.
Amount Component
1–2 µg total RNA (DNase-treated)
4 µl 5x Transcription Buffer (Roche)
2 µl dNTPs (dATP, dTTP, dGTP, dCTP, Fermentas; 10 mM each)
2 µl 100 mM DTT
0.01 μg Random hexamer primers (Fermentas)
1 µl RNasin RNase inhibitor (Promega)
10 U Transcriptor Reverse Transcriptase (Roche)
ad 20 µl water
4.2.18 Protein-IP
HEK293T cells were transiently transfected 24 hours prior to lysis. Cells of a
confluent 10-cm dish were washed once with PBS, collected in a 2 ml reaction
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Table 4.7: qPCR Program.
Program Target (°C) Acquisit. Mode Hold Ramp Rate
Pre-Incubation 95 none 5 min 4.4
95 none 10 sec 4.4
Amplification 55 none 15 sec 2.5
72 single 25 sec 4.8
95 none 5 sec 4.8
Melting curve 60 none 1 min 2.5
97 continuous - 0.11
Cooling 40 none 10 sec 2
tube, and the cell pellet was disrupted mechanically with a tissue lyser (QIAgen
TissueLyser II). The lysate was solubilized in 400 µl ice-cold RNP lysis buffer
(20 mM Tris-HCl (pH 7.5 at 25°C), 100 mM KCl, 1.5 mM MgCl2, 1 mM DTT,
1 tablet/10 ml Mini Complete Protease Inhibitors, EDTA-free (Roche)), and
cell debris was removed by centrifugation. 1:20 of the lysate was saved as input
before EGFP-tagged proteins were purified using the GFP-binder as described
previously [359]. Lysates were incubated with sepharose-coupled GFP-binder
for 1–3 hours at 4°C, followed by two washes with lysis buffer and 3–4 washes
with RNP wash buffer (20 mM Tris-HCl (pH 7.5 at 25°C), 150 mM KCl,
2.5 mM MgCl2, 1 mM DTT). Proteins were eluted from the beads with 1%
SDS-containing sample buffer.
4.2.19 RNA-IP
Cells grown in 10-cm dishes were mechanically disrupted as described above
for protein-IP, and solubilized in 400 µl RNA-IP lysis buffer (20 mM Tris-
HCl (pH 7.5 at 25°C), 150 mM NaCl, 1.5 mM MgCl2, 1 mM DTT, Mini
Complete protease inhibitors (Roche), 2 mM vanadylribonucleosid complex
RNase inhibitor (NEB) or 0.2 U/ml RNasin (Promega)). 1:13 of the lysate
was saved as RNA input, 1:40 for protein input. For IP of EGFP-tagged
proteins, lysates were bound to GFP-binder beads for 2–4 hours at 4°C before
washing twice with RNA-IP lysis buffer and four times with RNA-IP wash
buffer (20 mM Tris-HCl (pH 7.5 at 25°C), 300 mM NaCl, 2.5 mM MgCl2,
1 mM DTT, 2 mM vanadylribonucleosid complex RNase inhibitor (NEB)).
Protein was eluted from 1:5 of the beads using SDS sample buffer; RNA was
eluted from 4:5 of the beads using 500 µl TriFast reagent (PeqLab) according
to the manufacturer’s instructions. 15 µg GlycoBlue (Ambion) was added to
the RNA prior to precipitation.
For RNA-IP of endogenous Rbms1 from HEK293T, cell lysates were pre-
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cleared with Protein A/G UltraLink Resin (Thermo Pierce) for 1 hour at
4°C. 3 μg of Rbms1 antibody (ab150353, Abcam) or myc control antibody
(Santa Cruz sc-789) were added for 2 hours at 4°C prior to incubation with
protein A/G beads for another 2 hours. For RNA-IP of T7-tagged Roxan, 1
µg of T7 antibody (Novagen, 69522-3) was used instead. For RNA-IP of en-
dogenous Roquin from RAW264.7 macrophages, lysates were pre-cleared with
Protein A/G UltraLink Resin (Thermo Pierce) for 1 hour at 4°C. 4 µg Roquin
antibodies (rabbit polyclonal, Bethyl, 514A and 515A, 2 µg each) or HA con-
trol antibody (mouse monoclonal, Covance Innovative Antibodies MMS-101P)
were added for 2 hours at 4°C prior to incubation with protein A/G beads for
another 2 hours. Flag-IPs were carried out using Flag antibody (M2, F3165,
Sigma). For qPCR analysis following RNA-IP, a fixed volume of RNA ex-
tracted from IP and input samples was used for RT.
4.2.20 Electromobility Shift Assay (EMSA)
To express a recombinant N-terminal His-tagged fragment of Roquin (aa
2-440, Roquin-N), plasmid pETM11-Roquin-N (p2940, a kind gift of Vigo
Heissmeyer, Helmholtz Center Munich, Germany) was transformed into BL21
codon+ E. coli cells. Cells were cultured in LB medium at 37°C to an OD600
of 0.5, and protein expression was induced by addition of 1 mM IPTG. The
culture was then incubated for additional 16 hours at 21°C before cells were
lysed using a microfluidizer (Emulsiflex, Avestin). The recombinant protein
was purified on Ni-Sepharose 6FastFlow beads (GE-Healthcare) under non-
denaturing conditions and eluted in elution buffer (20 mM Tris-HCl (pH 8.0
at 25°C), 1 mM MgCl2, 200 mM NaCl, 270 mM imidazole (pH 8.0 at 25°C),
0.1 % NP-40, 10 % glycerol, 1 tablet/10 ml Mini Complete Protease Inhibitors,
EDTA-free (Roche)). For S1/S1m EMSAs, recombinant streptavidin protein
was purchased from Life Technologies (43-4301) and reconstituted to 1 mg/ml
in PBS.
The EMSA was performed according to [360] with the following modifications:
RNA was prepared by 5’ end-labeling 200 pmol of commercially synthesized
RNA oligonucleotides (23 nt, Biomers.net, Germany; or IDT Inc) with [γ-
32P]-ATP using T4 polynucleotide kinase (NEB) as described above for in-line
probing. Labelled RNA was separated from unincorporated nucleotides by
column purification (QIAquick Nucleotide Removal Kit, QIAgen) and adjusted
with H2O to 1 pmol/µl. Prior to binding reactions, a mastermix containing
500 pM labeled RNA (10 fmol per 20 µl reaction), 1x binding buffer (20 mM
Tris-HCl (pH 7.5 at 25°C), 50 mM KCl, 5 mM MgCl2, 20 µM ZnSO4, 10%
glycerol), 2 mM DTT, 0.1 mg/ml BSA, 3.75 µg/ml tRNA and 5 µg/ml heparin
was heated at 55°C for 3 minutes and cooled down at room temperature for 5
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minutes to promote RNA folding. In parallel, a dilution series of 10x protein
stocks was prepared in 1x protein dilution buffer (1x binding buffer, 5 µg/ml
heparin, 0.2 U/ml RNasin (Promega), 1 tablet/10 ml Mini Complete Protease
Inhibitors, EDTA-free (Roche)). For each binding reaction, 2 µl of the 10x
protein stock was added to 18 µl of the mastermix at room temperature for 10
minutes. Reactions were then supplemented with 4 µl of 6x loading buffer (30%
glycerol, bromphenol blue, xylene cyanol) and placed on ice. RNP complexes
were resolved by non-denaturing PAGE (6% polyacrylamide, 0.5x TBE, 20 µM
ZnSO4, 5% glycerol) in ice-cold 0.5x TBE buffer (2 mM EDTA, 20 µM ZnSO4)
at 200 V for 40 minutes at 4°C. Gels were dried at 80°C for 30 minutes and
exposed to a phosphor imager screen. For S1/S1m EMSAs the protocol was
applied as described except that ZnSO4 was omitted in the binding buffer, the
polyacrylamide gel and the TBE running buffer.
To calculate the Kd, the fraction of Roquin-N-bound RNA (specific binding, y
variable) was plotted against the initial concentration of Roquin-N (x variable).
Using Graphpad Prism software, a curve with the following equation was fitted
to the data points: y = ymaxh × xh / (Kdh + xh), whereby ymax is the maximum
specific binding, Kd the dissociation constant, and h the Hill coefficient.
The RNAs used for EMSA were commercially synthesized and correspond to
the sequences given in Table 4.8.
Table 4.8: RNA Oligonucleotides Used in this Study.
Name Length Sequence
CDE23 23 nt 5’-ACAUGUUUUCUGUGAAAACGGAG-3’
CDE23-M23 23 nt 5’-ACAUGUUUAGUGUCUAAACGGAG-3’
TNFα-ARE 23 nt 5’-AUUUAUUAUUUAUUUAUUAUUUA-3’
S1 44 nt 5’-ACCGACCAGAAUCAUGCAAGUGCGUAAGAUAGUCGCGGGCCGGG-3’
S1m 60 nt
5’-AUGCGGCCGCCGACCAGAAUCAUGC
AAGUGCGUAAGAUAGUCGCGGGUCGG
CGGCCGCAU-3’
4.2.21 Knockdown by siRNA
NIH3T3 B2A2 cells were transfected twice with siRNAs at a final concentration
of 100 nM over a time period of four days using Lipofectamine RNAiMAX (In-
vitrogen) and OptiMEM (Gibco) according to the manufacturer’s instructions.
The second siRNA transfection on the third day included plasmid DNA. For
rescue experiments, NIH3T3 cells were transfected with siRNAs on the first
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day, plasmids were transfected using PEI on the second day, and the mRNA
decay assay was performed on the third day. RAW264.7 macrophages were
transfected twice on two consecutive days with siRNAs at a final concentra-
tion of 100 nM over a time period of three days using Lipofectamine LTX
(Invitrogen) and OptiMEM (Gibco) according to the manufacturer’s instruc-
tions. Mouse siRNAs used in this study were synthesized by Eurofins MWG
Operon. They correspond to the sequences (sense strand) given in Table 4.9.
Table 4.9: siRNAs Used in this Study.
Name Target Sequence
D0 (s015) control 5’-GCAUUCACUUGGAUAGUAAdTdT-3’
C2 (s014) control 5’-GCAUUCACUUGGAUAGUAAdTdT-3’
Roquin (A) (s051) Roquin 5’-CCUUCUAUCUGCUGAAAGAdTdT-3’
Roquin (B) (s060) Roquin 5’-CGCACAGTTACAGAGCTCAdTdT-3’
Roquin2 (s055) Roquin2 5’-GGACTTGGCTCATAAATCAdTdT-3’
4.2.22 Enzyme-linked Immunosorbent Assay (ELISA)
After knockdown of Roquin in RAW264.7 macrophages, supernatants were
collected from cells exposed to LPS (100 ng/ml) for different periods of time,
and the concentration of secreted TNFα was measured using the murine TNFα
ELISA development kit (PeproTech, 900-K54) according to the manufacturer’s
instructions. TNFα concentrations were normalized to the amount of total
RNA extracted from the same cells, and the resulting ratio was expressed as
arbitrary units (A. U.).
4.2.23 Morpholino Delivery
For delivery of antisense morpholino oligonucleotides, RAW264.7 cells or
BMDM were seeded into 12-well plates one and 10–12 days prior to trans-
fection, respectively. Morpholinos were stored at 4°C (-20°C for long term
storage) and heated at 65°C for 5 minutes before use. Morpholinos were
added to the medium at a final concentration of 2 µM in the presence of 6
µM Endo-Porter (Gene Tools, LLC) according to the manufacturer’s proto-
col. 24 hours later, cells were stimulated with LPS (100 ng/ml) for 6 hours.
Cells were washed with PBS and either collected by trypsinization for lysis
(RAW264.7) or lysed directly on the dish (BMDM) for total RNA extraction
using the Genematrix universal RNA purification kit (Eurx, Roboklon). For
RNA-IP, HEK293T cells were transfected with 2 µM morpholino and plasmid
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simultaneously using Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s protocol. The 25-mer morpholinos were obtained from Gene
Tools, LLC, and are listed in Table 4.10.
Table 4.10: Morpholinos Used in this Study.
Name Target / Sequence
CDE-MO-1 (m001) left arm of the TNFα CDE5’-GAAAACATGTCTGTCTGAAGACAGC-3’
CDE-MO-2 (m002) right arm of the TNFα CDE5’-GGACAGCTCAGCTCCGTTTTCACAG-3’
UTR-MO (m003) TNFα 3’UTR sequence downstream of the CDE5’-AGCCTGGTCACCAAATCAGCGTTAT-3’
Ctrl-MO (m004) standard control oligo from Gene Tools5’-CCTCTTACCTCAGTTACAATTTATA-3’
4.2.24 Data Sources for Sequence Alignments
For sequence conservation analysis of TNFα and ICOS CDEs, Gen-
Bank mRNA 3’UTR sequences were retrieved for different species from
the NCBI database: TNFα: mouse (Mus musculus; accession num-
ber NM_013693), human (Homo sapiens; NM_000594), chimpanzee (Pan
troglodytes; XM_001152827), orangutan (Pongo abelii; XM_002816720),
macaque (Macaca mulatta; NM_001047149), swine (Sus scrofa; NM_214022),
zebu (Bos indicus; AF011927), cow (Bos taurus; NM_173966), goat (Capra
hircus; X14828), sheep (Ovis aries; NM_001024860), dog (Canis lupus fa-
miliaris; NM_001003244), horse (Equus caballus; NM_001081819), giant
panda (Ailuropoda melanoleuca; XM_002930032), rabbit (Oryctolagus cunicu-
lus; NM_001082263), african elephant (Loxodonta africana; XM_003422213),
rat (Rattus norvegicus; NM_012675), marmot (Marmota monax ; AF096268),
guinea pig (Cavia porcellus; NM_001173025), and chinese hamster (Cricetulus
griseus; XM_003508487); ICOS: mouse (Mus musculus; NM_017480), human
(Homo sapiens; NM_012092), chimpanzee (Pan troglodytes; XM_001173460),
orangutan (Pongo abelii; XM_002812772), macaque (Macaca mulatta;
XM_001104581), swine (Sus scrofa; NM_001044546), and cow (Bos taurus;
NM_001034275). CDE sequence conservation analysis of Nfkbid, Nfkbiz, Ier3,
Roquin, Roquin2, Bmpr1a, Pdia6, Ppp1r10 and Hmgxb3, performed by Jo-
hanna Schott, was based on sequences retrieved from the UCSC whole-genome
alignment of 46 vertebrate organisms [318].
For conservation analysis of Roquin, we retrieved the following protein
sequences from NCBI and aligned them by ClustalW: mouse (Mus muscu-
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lus; NP_001020123.1), chicken (Gallus gallus; XP_001234605.2), African
clawed frog (Xenopus laevis; NP_001084548.1), zebrafish (Danio rerio;
NP_001108155.1), lancelet (Branchiostoma floridae; XP_002588179.1),
sea squirt (Ciona intestinalis; XP_002125601.1), sea urchin (Strongylocen-
trotus purpuratus; XP_780349.3), red flour beetle (Tribolium castaneum;
EFA08769.1), fruit fly (Drosophila melanogaster ; NP_648886.1), water flea
(Daphnia pulex ; EFX88973.1), tick (Ixodes scapularis; XP_002414149.1),
roundworm (Ascaris suum; ADY40466.1; Caenorhabditis elegans,
CCD31104.1), sea anemone (Nematostella vectensis, XP_001626669.1),
hydra (Hydra magnipapillata; XP_002158024.1), and sponge (Amphimedon
queenslandica; XP_003385928.1).
4.2.25 RNA-IP, Library Preparation, Deep Sequencing and
Data Analysis
Endogenous Roquin was immunoprecipitated from lysates of RAW246.7
macrophages that had been grown in two 15-cm dishes and stimulated for
2 hours with LPS (100 ng/ml). Beads alone served as control-IP. The IP was
performed as described in the RNA-IP section. RNA was then extracted from
both the IP and input samples using TriFast (PeqLab). Library preparation
was carried out with Illumina protocols using 50–100 ng RNA making use of
the service of the BioQuant Deep Sequencing Core Facility at the University of
Heidelberg. Sequencing was performed at the EMBL Genomics Core Facility,
Heidelberg, on an Illumina HiSeq2000 instrument, which yielded a raw read
length of 58 bases (52 bases for the fragment plus 6 bases for the barcode).
All sequence analysis was performed by Johanna Schott. Reads were aligned
to the Mus musculus genome (NCBI build 37), and differential expression was
tested using Bioconductor software. A detailed description and references,
as well as statistical procedures, can be found in the Extended Experimental
Procedures of Leppek et al. (2013) [246].
4.2.26 Accession Numbers
RNA sequencing data from Roquin-IP experiments were deposited in the Gene
Expression Omnibus under accession number GSE44775.
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The following abbreviations were used in this study:
Abbreviation Expanded form
-/- knockout
5’ TOP 5’ terminal oligopyrimidine tract
4EBP eIF4E-binding protein
α alpha
A adenine
aa amino acid
Ab antibody
actD actinomycin D
Ago argonaute
AMD adenylate/uridylate-rich element-mediated mRNA decay
ARE adenylate/uridylate-rich element
ARE-BP AU-rich element binding protein
β beta
bp base-paired
BRF1/2 butyrate response factor 1/2
bs binding site
BSA bovine serum albumin
C cytosine
°C degree celcius
Caf1 carbon catabolite repressor protein (CCR4)-associative factor 1
Ccr4 carbon catabolite repressor protein 4
Ccr4-Not Ccr4-Not complex
CDE constitutive decay element
cDNA complementary/copy DNA
CIP calf intestinal phosphatase
Co-IP co-immunoprecipitation
COS7 African green monkey kidney
cp coat protein
cpm counts per minute
Da Dalton
Dcp decapping protein
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Abbreviation Expanded form
DMEM Dulbecco’s modified eagle’s medium
DNA desoxyribonucleicacid
ds double stranded
DTT dithiothreitol
E. coli Escherichia coli
eIF eukaryotic translation initiation factors
Edc enhancer of mRNA decapping
ELAV embryonic-lethal abnormal vision
EMSA electrophoretic mobility shift assay
FCS fetal calf serum
FISH fluorescence in situ hybridization
Flag hydrophilic 8 aminoacid peptide
FMRP fragile X mental retardation protein
FXR1 fragile X mental retardation-related protein 1
γ gamma
G guanine
G3BP RasGAP-SH3-binding protein
GFP green fluorescent protein
GM-CSF Granulocyte macrophage colony stimulating factor
HA hemaglutinin
hDcp1 human decapping enzyme 1
hnRNP heterogeneous nuclear ribonucleoprotein
His histidine
HPLC high performance liquid chromatography
HuR human antigen R
ICOS inducible T cell co-stimulator
IF immunofluorescence
IgG Immunoglobulin G
IKK IκB kinase
IL interleukin
INFγ interferon gamma
IP immunoprecipitation
JNK c-jun-N-terminal kinase
κ kappa
k kilo
Kd dissociation constant
kDa kilo dalton
LPS lipopolysaccharide
Lsm Sm-like protein
mA milli Ampere
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Abbreviation Expanded form
MAPK mitogen-activated protein kinase
MEF mouse embryonic fibroblast
Mg2+ magnesium
miRNA microRNA
MK2 MAPK-activated protein kinase-2
mM milli molar
Mnab membrane-associated nucleic acid binding protein, Roquin2
MO morpholino
mRNA messenger ribonucleic acid
mRNP messenger ribonucleoprotein
MS2 bacteriophage MS2
NB Northern blot
NGD No-go mRNA decay
NF-κB nuclear factor kappa beta
NMD nonsense mediated decay
NMR nuclear magnetic resonance
Not negative regulator of transcription
Not1 negative on TATA, Ccr4-Not complex subunit 1
NSD nonstop mRNA decay
nt nucleotide
PABP poly(A) binding protein
PAGE polyacrylamide gel electrophoresis
PAMP pathogen-associated molecular pattern
PAN poly(A) nuclease
PARN poly(A)-specific ribonuclease
PARP poly ADP-ribose polymerase
P-body processing body
PBS phosphate buffered saline
PCR polymerase chain reaction
Pol Polymerase
poly(A) poly adenosine
PP2A protein phosphatase 2
PP7 bacteriophage PP7
PTC premature stop codon
puro puromycin
qPCR quantitative PCR
RBD RNA-binding domain
Rbms1 RNA binding motif, single stranded interacting protein 1
Rc3h1 RING finger and CCCH-type zinc finger domain-containing
protein 1, Roquin
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Abbreviation Expanded form
Rc3h2 RING finger and CCCH-type zinc finger domain-containing
protein 2, Roquin2
RING really interesting new gene, protein domain
RISC RNA-induced silencing complex
RNA ribonucleic acid
RNAi RNA interference
RNase ribonuclease
rp ribosomal protein
rpm revolutions per minute
RRM RNA recognition motif
RT reverse transcription
S7 ribosomal protein S7
san sanroque allele, Roquin mutation M199R
SD standard deviation
SDS sodium dodecyl sulfate
SE standard error
SG stress granule
siRNA small interfering RNA
ss single stranded
T thymine
t1/2 half-life
TCA trichloracetic acid
Tet tetracycline
TEV tobacco etch virus
TF transcription factor
TFH follicular helper T cells
TIA-1 T cell intracellular antigen-1
TIAR T cell intracellular antigen-1-related
TNFα tumor necrosis factor α
TNFR tumor necrosis factor receptor
TRAF2 TNFα receptor associated factor 2
TTP tristetraprolin
U uracil
UTR untranslated region
UV ultraviolet
V Volt
WB Western blot
WT wild type
XRN1 5’-3’ exoribonuclease 1
ZF zinc finger
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5 Supplemental Data
5.1 Supplemental Figures
The following supplemental figures include data that support and complete
the data shown in the Results.
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Figure 5.1: S1m Sequence and pSP73-4xS1m Plasmid Map. (A) Sequence of
the S1 and S1m aptamers as designed for cloning of tandem repeats. Linear sequences
are shown below the predicted secondary structures. Nucleotides mutated in S1m (red),
nucleotides added to prolong the stem (yellow), core aptamer (blue). (B) Plasmid map
of pSP73-4xS1m (p2880) used for in vitro transcription of RNA for S1m-mediated RNP
purification. The plasmid was linearized with EcoRV downstream of the 3’BglII site,
column-purified and used as template for run-off transcription by SP6. Alternatively, the
template was excised by NdeI/EcoRV digest and gel-purified. 4xS1m can be excised with
BglII. Reproduced with permission from Nucleic Acids Research, Oxford Journals.
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Figure 5.2: Sequence of the pSP73-4xS1m Plasmid. The four S1m aptamer
sequences, separated by 21 nt long spacers, are highlighted in dark blue. The SP6 promoter
is marked in red, BlgII sites in grey, BamHI/BglII fusion sites in light blue, the multi
cloning sequence in yellow, the T7 promoter in pink, and the β-lactamase coding region
in green. Reproduced with permission from Nucleic Acids Research, Oxford Journals.
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Figure 5.3: Secondary Structure Determination and Comparison of TNFα
CDE Variants. (A) Schematic representation of mouse TNFα CDE37 variants V2
and V3, which differ only in the cloning context, and CDE150 spanning a 150 nt region
of the mouse TNFα 3’UTR. The gain in free energy, ΔG, was calculated for the proposed
structures at 37ºC using Mfold version 3.5. (B) Globin reporter genes containing TNFα
CDE37 variants V2 and V3, CDE150 and a control globin reporter lacking an insert were
transiently transfected into NIH3T3 cells. Reporter mRNA degradation was measured as
described for Figure 2.11D. mRNA half-lives are given as average values ± SD, n ≥ 3.
(C) In-line probing analysis of in vitro synthesized, 5’-32P-labeled CDE37-V2, CDE37-V3
and CDE150 RNAs. The RNAs were either loaded directly (NR, no reaction), subjected
to cleavage by RNase T1 or alkaline hydrolysis (–OH), or incubated for 45 hours at room
temperature and pH 8.3 (in-line reaction, Rxn) prior to urea-PAGE. The in-line analysis
was performed by Ming Hammond. Reproduced with permission from Cell, Elsevier.
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Figure 5.4: Purification of Recombinant Roquin-N. (A) Schematic representation
of mouse Roquin domains; ZF, zinc finger. The sequence shows the N-terminal Roquin
fragment used for purification. Numbers refer to amino acid positions. (B) Roquin-
N (amino acids 2–440) was expressed as a His-tagged protein in E. coli and purified
via nickel-Sepharose beads. To determine its purity and concentration, the protein was
resolved by SDS-PAGE next to a dilution series of bovine serum albumin (BSA), and
stained with Coomassie blue. Reproduced with permission from Cell, Elsevier.
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Figure 5.5: Knockdown of Roquin and Roquin2 Prevents CDE-mRNA Degra-
dation. (A) For kd of Roquin and Roquin2, NIH3T3 cells were transfected twice over
a period of four days with either water (H2O), control siRNAs (D0 or C2), or siRNAs
against Roquin (A) or Roquin2, either alone or in combination. Roquin and Roquin2
mRNA levels were measured by RT-qPCR, normalized to ncl mRNA levels, and plotted
as % of the water control (average ± SD, n ≥ 4). (B) Roquin and Roquin2 kd in NIH3T3
cells as in A. The globin-TNFα-CDE37-V3 reporter gene was included in the second trans-
fection, and reporter mRNA decay was measured by Northern blot analysis as described
for Figure 2.11D. Quantification of n ≥ 3 repeat experiments is shown in Figure 2.9A.
(Figure legend continued on next page)
172
5.1 Supplemental Figures
Figure legend continued: (C) Left panel, expression of EGFP-Roquin (WT) and the siRNA-
resistant EGFP-Roquin si(B)-res was examined in HEK293 cells. The Roquin expressing
plasmids were transfected together with the control siRNA C2 or the Roquin-siRNA (B).
Cells were lysed after two days for Western blot analysis using an anti-GFP antibody. Right
panel, EGFP or EGFP-Roquin-si(B)-res were transfected into NIH3T3 cells one day after
transfection of the control siRNA C2 or the Roquin-siRNA (B). Cells were lysed on day two
and Western blot analysis was carried out using an anti-Roquin antibody. (D) TNFα mRNA
expression in response to LPS (100 ng/ml) was analyzed by Northern blot in RAW264.7
cells transfected twice over a period of two days with control siRNA (C2), Roquin-siRNA
(A), Roquin-siRNA (B) or Roquin-siRNA (B) together with Roquin2-siRNA. (E) TNFα
production was analyzed in RAW264.7 cells transfected twice over a period of two days with
control siRNA C2, Roquin-siRNA (B) or Roquin-siRNA (B) together with Roquin2-siRNA.
Cells were stimulated with LPS (100 ng/ml), and total protein was extracted after 0, 2, 6
and 12 hours. Western blot analysis using an anti-TNFα antibody shows membrane-bound
(m)TNFα and soluble (s)TNFα. The first 8 lanes of this plot are the same as in Figure
2.9F. (F) Roquin expression was examined in protein lysates from cells shown in panel E
by Western blot analysis. The Data in C was obtained by Fabian Pötz. Reproduced with
permission from Cell, Elsevier.
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Figure 5.6: Reproducibility of Roquin-IPs for RNA-Seq. Following IP of Roquin
from LPS-stimulated RAW264.7 macrophages, mRNAs in the Roquin-IP, control-IP and
input material were identified by RNA-Seq in three biological repeat experiments. To
assess reproducibility, log2 of (read counts per gene / total read counts) in the Roquin-IP
and input samples was plotted as a pairwise comparison between the three experiments.
Analysis performed by Johanna Schott. Reproduced with permission from Cell, Elsevier.
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Figure 5.7: Induction of mRNAs Containing Putative CDEs and Roquin Tar-
get mRNA Validation. (A) Induction of endogenous TNFα, Nfkbid, Nfkbiz, Ier3,
Roquin, Roquin2, Bmpr1a, and Pdia6 CDE-containing mRNAs in comparison to control
mRNAs lacking a CDE (Ncl, NupL1, Gapdh, and Rck) in RAW264.7 macrophages stim-
ulated for 2 hours with LPS (100 ng/ml). mRNA levels were measured by RT-qPCR and
are shown relative to the mRNA levels in unstimulated cells as average values ± SE, n
≥ 3. (B) Binding of control mRNAs and CDE-harboring mRNAs to Roquin by RNA-IP.
RAW264.7 macrophages were stimulated with LPS (100 ng/ml) for 2 hours, and Roquin
was IP-ed using anti-Roquin antibodies (Roq). HA-antibody was used for control IP.
mRNA amounts were quantified by RT-qPCR in the Roquin IP, divided by the amount
of mRNA in the control IP, and expressed as average fold enrichment ± SE, n ≥ 3.
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5.2 Supplemental Tables
The following supplemental tables include data that support and complete the
data shown in the Results.
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Table 5.1: CDE Sequences and Globin Reporter mRNA Half-lives in NIH3T3
Cells. CDE sequences that were cloned into the β-globin reporter genes are listed together
with corresponding mRNA half-lives. Reporter mRNA decay was measured in transiently
transfected NIH3T3 cells or, where indicated by an asterisk, in stably transfected NIH3T3
cells. Reproduced with permission from Cell, Elsevier.
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Table 5.2: mRNAs Significantly Enriched by Roquin-IP. RNA was extracted af-
ter IP of endogenous Roquin from RAW264.7 macrophages and subjected to RNA-Seq in
three biological replicates. Beads alone served as control-IP. The table shows all mRNAs
significantly enriched by Roquin-IP (p ≤ 0.005, Roquin-IP vs control-IP) and fold enrich-
ment (Roquin-IP / control-IP) > 8.0. Reproduced with permission from Cell, Elsevier.
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5.3 Roquin Protein Sequence Alignment
In the following alignment, the protein sequence of Roquin of 16 different
species, as annotated in NCBI, were aligned using ClustalW. The specific do-
mains are color-coded and deletion mutants used in this study are indicated.
The alignment was done by Fabian Pötz.
180
5.3 Roquin Protein Sequence Alignment
181
Chapter 5 Supplemental Data
182
5.3 Roquin Protein Sequence Alignment
183
Chapter 5 Supplemental Data
184
6 Appendix
6.1 Materials Used in this Study
6.1.1 Disposable Material and Kits
The following disposable material was used in this study.
Table 6.1: Disposable Material and Kits Used in this Study.
Disposables / Kits Company
1.5 ml, 2 ml Reaction Tubes Eppendorf
15 ml, 50 ml Falcon Tubes Falcon, Greiner, Nunc
1.5 mL DNA LoBind Tubes Eppendorf
2 ml Cryotubes Nunc
Cellscraper CoStar Corning Inc.
CellStar Tissue culture flasks (T75, T25) Greiner Bio-One
CellStar Tissue culture dishes (6, 10, 15cm) Greiner Bio-One
CellStar Cell culture plates (6-well, 12-well, 24-well) Greiner Bio-One
DIG labelling Kit Ambion
Filter paper Whatman 3MM Whatman
Filter tips StarLab
Gloves Meditrade
MegaClear RNA purification Kit Amersham
MegaScript SP6 RNA Polymerase Kit Ambion
Mini quick spin RNA column Roche
Nitrocellulose membrane Peqlab
Pipette tips Steinbrenner Starlab
PureLink HiPure Plasmid Maxiprep Kit Life Technologies
PureLink HiPure Plasmid Midiprep Kit Life Technologies
QIAquick Gel Extraction Kit QIAgen
QIAquick Nucelotide Removal Kit QIAgen
QIAprep Spin Miniprep Kit QIAgen
QIAquick PCR Purification Kit QIAgen
Rapid DNA Ligation Kit Fermentas
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Disposables / Kits Company
RNA Isolation Kit (tissue culture) EURx, Roboklon
Transcriptor First Strand cDNA Synthesis Kit Roche
Xray films FujiFilm
6.1.2 Chemicals and Enzymes
The following chemicals and enzymes were used in this study.
Table 6.2: Chemicals and Enzymes Used in this Study.
Chemicals Company
10x Taq Polymerase Buffer QIAgen
10x Northern Blot Blocking Solution Roche
10x RNaseH Buffer New England Biolabs
2-Mercaptoethanol (2-ME) Sigma
5x Rapid Ligation Buffer Fermentas
5x Transcription Buffer Promega
Acetic Acid Fluka
Acetone Sigma
Actinomycin D AppliChem
Adenosine triphosphate (ATP) Fermentas
Agar Roth
Agarose Biozym Scientific GmbH
Ammoniumpersulfate AppliChem
Ampicillin Applichem
Avidin-agarose beads Pierce, Thermo
Biotin, approx.99%, TLC Sigma-Aldrich
Biotin, 50 mM stock Life Technologies
Bovine serum albumine (BSA) New England Biolabs
Bovine serum albumine (BSA) PAA Laboratories
Bradford Sigma-Aldrich
Bromphenol blue Applichem
Calf Intestine Phosphatase (CIP) New England Biolabs
CDP-Star Reagent New England Biolabs
Chloroform VWR
Chloroquine diphosphate salt Sigma
Complete Protease Inhibitor Cocktail Tablets, EDTA-free Roche
Coomassie Brillant Blue R250 Roth
Coomassie Brillant Blue R250 AppliChem
Cytidine triphosphate (CTP) Fermentas
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Chemicals Company
Desoxyadenosine triphosphate (dATP) Fermentas
Desoxycytidine triphosphate (dCTP) Fermentas
Desoxyguanosine triphosphate (dGTP) Fermentas
Desoxythymidine triphosphate (dTTP) Fermentas
Dextrane sulphate sodium salt from Leuconostoc spp. Sigma
DH5α competent E. coli cells Life Technologies
DIG easy hyb solution Roche
DIG labelling mix Roche
Dimethylsulfoxid (DMSO) Serva Electrophoresis
Disodiumhydrogenphosphate Roth
Dithiothreitol (DTT) Applichem
Dulbecco’s Modified Eagle Medium Life Technologies
Ethanol Riedel-de-Haen
Ethidium bromide (EtBr) Applichem
Ethylenediaminetetraacetic acid (EDTA) Roth
Fetal calf serum (FCS) superior Biochrom AG
Fetal Bovine Serum (FBS) tetracycline negative PAA Laboratories
Formaldehyde Merck
Formamide AppliChem
Gamma-[32P]-ATP Perkin Elmer
Gene Ruler 1 kb Ladder Plus Fermentas
Glutathione (GSH, reduced) Sigma-Aldrich
Glutathione-sepharose 4G beads GE Healthcare
Glycerol Roth
Glycine Gerbu
Guanosine triphosphate (GTP) Fermentas
Heparin sulfate Sigma
HEPES Roth
Horse serum PAA Laboratories
Isopropanol Sigma-Aldrich
Imidazole Sigma-Aldrich
Isopropyl-β-D-thiogalactopyranosid (IPTG) AppliChem, Roth
Isopropanol Sigma-Aldrich
Kanamycinesulfate Roth
L-glutamine PAN
Lipofectamine 2000 Life Technologies
Lipofectamine RNAimax Life Technologies
Magnesium chloride Merck
Maleic acid Fluka
Methanol Fluka
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Chemicals Company
Milk powder Roth
MOPS Roth
Ni sepharose 6 Fast Flow GE Healthcare
Nonidet P-40 (NP-40) US Biological
O’GeneRuler 100bp Plus DNA Ladder Fermentas
PageRuler Prestained Protein Ladder Fermentas
Penicillin-streptomycin PAN
Pfu DNA Polymerase Stratagene
Polyethyleneimine (PEI) Polysciences Europe
Ponceau S MD
Potassiumacetate Roth
Potassiumchloride Roth
Puromycin AppliChem
Protein A/G Ultra Link Resin Thermo Scientific
Random hexamers Fermentas
Restriction enzymes New England Biolabs
RNase A Genomed
RNase H New England Biolabs
RNase H 10x Reaction Buffer New England Biolabs
RNase inhibitor RNasin Promega
Roti-Phenol/Chloroform/Isoamyl alcohol (25/24/1) Roth
Rotiphorese Acrylamide Solution Roth
RQ1 DNase Promega
RQ1 DNase 5x Reaction Buffer Promega
RQ1 DNase Stop Solution Promega
SP6 RNA polymerase Fermentas
Sodium azide AppliChem
Sodium chloride Sigma-Aldrich
Sodium dodecyl sulphate (SDS) Gerbu
Sodium hydroxide pellets Riedel-de-Haen
Sodiumfluoride Sigma-Aldrich
Sodiumvanadate Sigma-Aldrich
Streptavidin-Sepharose High Performance beads GE Healthcare
Taq DNA polymerase QIAgen
TEMED AppliChem
Thermo RNA polymerase buffer New England Biolabs
Transcriptor Reverse Transcriptase Roche
Transcriptor Reverse transcriptase 5x Reaction Buffer Roche
Trichloroacetic acid AppliChem
T4 DNA Ligase Fermentas
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Chemicals Company
T4 Polynucleotide Kinase New England Biolabs
T7 RNA Polymerase New England Biolabs
TriFast PeqLab
Trisodiumcitrate VWR
Triton-X-100 Applichem
Trizma base Sigma-Aldrich
Tryptone AppliChem
Trypsin/EDTA PAN
Tween-20 Sigma-Aldrich
Uridine triphosphate (TTP) Fermentas
Vanadyl ribonucleoside complex (VRC) RNase inhibitor New England Biolabs
Western Lightning enhanced chemiluminescence substrate Perkin Elmer
Xylenexyanol AppliChem
Yeast Pyrophosphatase Sigma
Yeast tRNA Ambion
6.1.3 Technical Equipment
The following technical equipment was used in this study.
Table 6.3: Technical Equipment Used in this Study.
Technical Equipment Company
CCD-camera Andor
Cell Culture Incubator Hera cell
Centrifuge (5417R) Eppendorf
Centrifuge (J2-MC, rotor JA-17) Beckman
Centrifuge (Labofuge M) Heraeus Sepatech
Centrifuge (Multifuge 1S) Thermo
Centrifuge (Pico17) Thermo
EM-CCD camera Hamamastu
Epson Perfection V700 Photo EPSON
Film Development Apparatus (HyperProcessor) Amersham
Freezer -20°C Liebherr
Freezer -80°C x Liebherr
Fridge 4°C Liebherr
GeneAmp PCR System 9700 Applied Biosystems
Heating Block (neoBlock 1) NeoLab
Intelli-mixer NeoLab
Laminar Flow Cabinet Hera cell
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Magnetic Stirrer (MR3001) NeoLab
Micropipettes Gilson
Microwave Privileg
Mini Protean 3 Cell BIORAD
Mini Trans Blot Cell BIORAD
Nanodrop ND 1000 PeqLab
pH Meter (766 Calimetic) Knick
Phosphoimager (FLA-7000) FujiFilm
Poly-Prep column Biorad
Power Supply (powerpack300) Biorad
Scale (440-47N) Kern
Scintillation counter (LS 6000IC) Beckman
Shaker (DOS-20S) NeoLab
Shaker (PMR-30) Grant-bio
Sorvall Discovery 90SE Thermo Scientific
Speedvac Eppendorf
Stainless Steel Beads, 5 mm (200) QIAgen
TurboBlotter (Northern Blot) Whatman
TissueLyzer II QIAgen
UV Gel Documentation System Raytest IDA
UV Table (TVL-312A) Specktroline
Vortex NeoLab
Waterbath GFL
Waterbath memmert
Waterbath huber
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6.1.4 Antibodies
The following antibodies were used in this study.
Table 6.4: Antibodies Used in this Study.
Antigen Clonality Species
Company
(Ordering
Number)
Dilution
(Method)
α-tubulin monoclonal rat Abcam (ab6160) 1:10,000 (WB)
Caf1a polyclonal rabbit
Ann-Bin Shyu
(UTexas)
1:1,000 (WB)
cNot1 polyclonal rabbit
Proteintech
(14276-1-AP)
1:x (WB)
Flag M2 monoclonal mouse Sigma (F-3165) 1:1,000 (WB)
G3BP1 (TT-Y) monoclonal mouse
Santa Cruz
(sc-81940)
1:1,000 (IF)
GFP polyclonal rabbit Abcam (ab290) 1:1.000 (WB)
GFP monoclonal mouse
Roche
(11814460001)
1:1000 (WB)
GST polyclonal goat
GE Healthcare
(27-4577.1)
1:1,000 (WB)
GST polyclonal rabbit
Ludger Hengst
(Innsbruck)
1:5,000 (WB)
HuR (3A2) monoclonal mouse
Santa Ccruz
(sc-5261)
1:500 (WB)
myc (A-14) polyclonal rabbit
Santa Ccruz
(sc-789)
1:1,000 (WB)
Rbms1 monoclonal rabbit Abcam (ab150353) 1:x (WB)
Rck/p54 polyclonal rabbit
Bethyl
(A300-443A)
1:1,000 (WB)
Roquin polyclonal rabbit
Bethyl
(A300-514A)
1:500 (WB)
Roquin polyclonal rabbit
Bethyl
(A300-515A)
1:500 (WB)
T7-Tag monoclonal mouse Novagen (69522-3) 1:1,000 (WB)
TNFα polyclonal goat
Santa Cruz
(sc-1351)
1:500 (WB)
HRP-coupled
2nd ab
rabbit,
mouse, goat
donkey
Jackson
ImmunoResearch
1:10,000 (WB)
α-DIG-Fab-AP - sheep Roche
(11093274910)
1:4.000 (NB)
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6.1.5 Plasmids
The following plasmids were generated in this study.
Table 6.5: Plasmids Generated in this Study. All plasmids mediate ampicillin re-
sistance; O: origin, person cloning the original plasmid: KL: Kathrin Leppek; JS: Johanna
Schott; SR: Sonja Reitter; FP: Fabian Pötz.
Code Name O Description
p2772 pGEX-4T-3-TEV KL TEV insert (G1875/G1876, ENLYFQG) with
BamHI/EcoRI sites, in BamHI/EcoRI-
digested pGEX-4T-3 (p2763)
p2773 pGEX-4T-3-TEV-PP7cp KL PP7cp insert (G1859/G1860, EcoRI/XhoI)
from p2211 (D. Peabody) and TEV insert
(G1875/G1876, BamHI/EcoRI) into
pGEX-4T-3 (p2763)
p2774 pGEX-4T-3-TEV-oPP7cp KL oPP7cp insert (G1860/1861, XhoI/EcoRI)
from p2770 (K. Collins) and TEV insert
(G1875/G1876, BamHI/EcoRI) into
pGEX-4T-3 (p2763)
p2810 pGEX-2T-TEV-TEV-MS2cp KL two TEV inserts (G1852/G1853,
BamHI/BglII) in BamHI-digested
pGEX-2T-MS2cp (p2809)
p2775 pTet-7B-TNF(ARE)-1xS1 KL 1xS1 aptamer insert (G1779/G1780) with
BamHI/BglII sites into BglII-digested
pTet-7B-TNF-ARE (ARE 53) (p2260)
p2776 pTet-7B-TNF(ARE)-2xS1 KL 2xS1 aptamer insert, see p2775
p2777 pTet-7B-TNF(ARE)-3xS1 KL 3xS1 aptamer insert, see p2775
p2778 pTet-7B-TNF(ARE)-4xS1 KL 4xS1 aptamer insert, see p2775
p2779 pTet-7B-TNF(ARE)-5xS1 KL 5xS1 aptamer insert, see p2775
p2780 pTet-7B-TNF(ARE)-6xS1 KL 6xS1 aptamer insert, see p2775
p2788 pTet-7B-TNF(ARE)-7xS1 KL 7xS1 aptamer insert, see p2775
p2781 pTet-7B-TNF(ARE)-1xS1m KL 1xS1m aptamer insert (G1850/G1851) with
BamHI/BglII sites into BglII-digested
pTet-7B-TNF-ARE (ARE 53) (p2260)
p2782 pTet-7B-TNF(ARE)-2xS1m KL 2xS1m aptamer insert, see p2781
p2783 pTet-7B-TNF(ARE)-3xS1m KL 3xS1m aptamer insert, see p2781
p2784 pTet-7B-TNF(ARE)-4xS1m KL 4xS1m aptamer insert, see p2781
p2785 pTet-7B-TNF(ARE)-5xS1m KL 5xS1m aptamer insert, see p2781
p2786 pTet-7B-TNF(ARE)-6xS1m KL 6xS1m aptamer insert, see p2781
p2787 pTet-7B-TNF(ARE)-7xS1m KL 7xS1m aptamer insert, see p2781
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Code Name O Description
p2811 pTet-7B-CDE KL CDE insert (EcoRI/BglII, from Johanna
Schott) into EcoRI/BglII-digested pTet-7B
(p2254)
p2812 puroMXß-CDE KL CDE insert (EcoRI/BglII, from Johanna
Schott) into EcoRI/BglII-digested puroMXß
(p2220)
p2813 puroMXß-CDE37-V1 KL CDE37-V1 (-CT) (G1911/G1912,
5’BglII/BamHI, 3’BglII site) into
BglII-digested puroMXß (p2220)
p2814 puroMXß-CDE37-V2 KL CDE37-V2 (+CT) (G1913/G1914) into
puroMXß
p2823 puroMXß-CDE37-V3 KL CDE37-V3 (+CT-AG) (G1915/G1916) into
puroMXß
p2825 puroMXß-CDE37-V3-M1 KL CDE37-V3 M1 (5’BglII/BamHI, 3’BglII site)
insert into BglII-digested puroMXß (p2220)
p2826 puroMXß-CDE37-V3-M2 KL CDE37-V3 M2 into puroMXß
p2827 puroMXß-CDE37-V3-M3 KL CDE37-V3 M3 into puroMXß
p2828 puroMXß-CDE37-V3-M4 KL CDE37-V3 M4 into puroMXß
p2829 puroMXß-CDE37-V3-M5 KL CDE37-V3 M5 into puroMXß
p2830 puroMXß-CDE37-V3-M6 KL CDE37-V3 M6 into puroMXß
p2831 puroMXß-CDE37-V3-M7 KL CDE37-V3 M7 into puroMXß
p2832 puroMXß-CDE37-V3-M8 KL CDE37-V3 M8 into puroMXß
p2833 puroMXß-CDE37-V3-M9 KL CDE37-V3 M9 into puroMXß
p2834 puroMXß-CDE37-V3-M10 KL CDE37-V3 M10 into puroMXß
p2835 puroMXß-CDE37-V3-M11 KL CDE37-V3 M11 into puroMXß
p2836 puroMXß-CDE37-V3-hCDE KL CDE37-V3 human CDE into puroMXß
p2859 puroMXß-CDE37-V3-M12 KL CDE37-V3 M12 into puroMXß
p2860 puroMXß-CDE37-V3-M13 KL CDE37-V3 M13 into puroMXß
p2861 puroMXß-CDE37-V3-M14 KL CDE37-V3 M14 into puroMXß
p2862 puroMXß-CDE37-V3-M15 KL CDE37-V3 M15 into puroMXß
p2863 puroMXß-CDE37-V3-M16 KL CDE37-V3 M16 into puroMXß
p2864 puroMXß-CDE37-V3-M17 KL CDE37-V3 M17 into puroMXß
p2944 puroMXß-CDE37-V3-M18 SR CDE37-V3 M18 into puroMXß
p2945 puroMXß-CDE37-V3-M19 SR CDE37-V3 M19 into puroMXß
p2946 puroMXß-CDE37-V3-M21 SR CDE37-V3 M21 into puroMXß
p2947 puroMXß-CDE37-V3-M22 SR CDE37-V3 M22 into puroMXß
p2948 puroMXß-CDE37-V3-M25 SR CDE37-V3 M25 into puroMXß
p2959 puroMXβ-CDE37-V3-M20 SR CDE37-V3 M20 into puroMXß
p2960 puroMXβ-CDE37-V3-M23 SR CDE37-V3 M23 into puroMXß
p2961 puroMXβ-CDE37-V3-M24 SR CDE37-V3 M24 into puroMXß
193
Chapter 6 Appendix
Code Name O Description
p2967 puroMXβ-CDE37-V3-M26 SR CDE37-V3 M26 into puroMXß
p2968 puroMXβ-CDE37-V3-M27 SR CDE37-V3 M27 into puroMXß
p2965 puroMXß-CDE17-ss SR CDE17-ss into puroMXß (minCDE)
p2966 puroMXß-CDE17-ds SR CDE17-ds into puroMXß (minCDE-V3)
p2969 puroMXß-CDE150 SR CDE150in native mouse 3’UTR context,
cloned via BamHI/BglII (G2495/G2496)
from p2914 into puroMXß
p2970 puroMXß-CDE150-M16 SR CDE150-M16 in native mouse 3’UTR
context, cloned via BamHI/BglII from p2915
into puroMXß
p2971 puroMXß-CDE150-M19 SR CDE150-M19 in native mouse 3’UTR
context, cloned via BamHI/BglII from p2916
into puroMXß
p2972 puroMXß-CDE150-M20 SR CDE150-M20 in native mouse 3’UTR
context, cloned via BamHI/BglII from p2917
into puroMXß
p2824 puroMXß-4xS1m KL 4xS1m insert amplified with BglII-mismatch
repair primer (G1919/G1918; BglII-site at
both ends) from p2784 into BglII-digested
puroMXß (p2220)
p2856 puroMXß-CDE37-V3-4xS1m KL 4xS1m insert amplified with BglII-mismatch
repair primer (G1919/G1918; BglII-site at
both ends) from p2784 into BglII-digested
puroMXß-CDE37-V3 (p2823)
p2857 puroMXß-CDE37-V3-M7-
4xS1m
KL 4xS1m insert amplified with BglII-mismatch
repair primer (G1919/G1918; BglII-site at
both ends) from p2784 into BglII-digested
puroMXß-CDE37-V3-M7 (p2831)
p2858 puroMXß-CDE37-V3-M9-
4xS1m
KL 4xS1m insert amplified with BglII-mismatch
repair primer (G1919/G1918; BglII-site at
both ends) from p2784 into BglII-digested
puroMXß-CDE37-V3-M9 (p2833)
p2880 pSP73-4xS1m
(SP6 orientation)
KL 4xS1m insert amplified with BglII-mismatch
repair primer (G1919/G1918; BglII-site at
both ends) from p2784 into BglII-digested
pSP73 (p2008);
pSP-BglII-4xS1m-BglII-EcoRV, IVT:
linearize with EcoRV
194
6.1 Materials Used in this Study
Code Name O Description
p2881 pSP73-TNF(ARE)-4xS1m
(SP6 orientation)
KL ARE-4xS1m insert amplified with
BamHI-mismatch repair primer
(G2247/G2235) from p2891 into
BglII-digested pSP73 (p2008);
pSP-BamHI/BglII fusion
site-TNF(ARE)-BamHI/BglII fusion
site-4xS1m-BglII-EcoRV, IVT: linearize with
BglII or EcoRV
p3278 pSP73-4xS1
(SP6 orientation)
KL 4xS1 insert amplified with BglII-mismatch
repair primer (G1919/G1918; BglII-site at
both ends) from p2778 into BglII-digested
pSP73 (p2008)
p3279 pSP73-TNF(ARE)-4xS1
(SP6 orientation)
KL ARE-4xS1 insert amplified with
BamHI-mismatch repair primer
(G2247/G2235) from p2778 into
BglII-digested pSP73 (p2008);
pSP-BamHI/BglII fusion
site-TNF(ARE)-BamHI/BglII fusion
site-4xS1-BglII-EcoRV, IVT: linearize with
BglII or EcoRV
p2882 TOPO-pCRII-4xS1m
(SP6 orientation)
KL pSP-BamHI-4xS1m-BglII-EcoRV, IVT:
linearize with EcoRV (gives additional 100
bp)
p2883 TOPO-pCRII-CDE37-V3-
4xS1m
(SP6 orientation)
KL pSP-BamHI-CDE37-V3-BglII-4xS1m-BglII-
EcoRV, IVT: linearize with EcoRV (gives
additional 100 bp)
p2884 TOPO-pCRII-CDE37-V3-
M7-4xS1m
(SP6 orientation)
KL pSP-BamHI-CDE37-V3-M7-BglII-4xS1m-
BglII-EcoRV, IVT: linearize with EcoRV
(gives additional 100 bp)
p2885 TOPO-pCRII-CDE37-V3-
M9-4xS1m
(SP6 orientation)
KL pSP-BamHI-CDE37-V3-M9-BglII-4xS1m-
BglII-EcoRV, IVT: linearize with EcoRV
(gives additional 100 bp)
p2886 TOPO-pCRII-TNF(ARE)-
4xS1m
(T7 orientation)
KL pT7-BamHI-ARE-BamHI/BglII-fusion-
4xS1m-BglII-EcoRV
p2891 puroMXß-TNF(ARE)-
4xS1m
KL 4xS1m insert amplified with BglII-mismatch
repair primer (G1919/G1918; BglII-site at
both ends) from p2784 into BglII-digested
puroMXβ-TNFα-ARE (p2225)
p2914 puroMXß-TNFα-3’UTR
(mouse)
JS complete 3’UTR of mouse TNFα into
puroMXß
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p2915 pCRII-Topo-TNFα-3’UTR
(human)
KL complete 3’UTR of human TNFα (from Hela
gDNA)
p2991 puroMXß-ICOS-CDE17-ss KL minimal ICOS-CDE element
(ICOS-minCDE), AgeI/XbaI-site cloned,
EcoRI/BglII-transferred into puroMXß
p2992 puroMXß-ICOS-minCDE-nc KL minimal ICOS-CDE element in native
context (ICOS-minCDE-nc), AgeI/XbaI-site
cloned, EcoRI/BglII-transferred into
puroMXß
p2985 pLNCX2-EGFP-RC3H2 SR full-length Roquin2 cDNA cloned via
SalI/ClaI into pLNCX2 (Clontech), EGFP
was SalI-cloned from p2838 into
pLNCX2-Roquin2 (p2984)
p3090 pLNCX2-EGFPA-RC3H1 FP EGFP was SalI-exsized from p2838 and
replaced with PCR-amplified EGFP with a
unique 3’AgeI site into
pLNCX2-EGFP-Roquin (p2838)
p3101 pLNCX2-EGFPA-RC3H1-
S60r
FP four silent point mutations in the RC3H1
N-terminus were introduced by cloning a
PCR fragment into AgeI/MfeI of p3090;
reistant to siRNA S060
6.1.6 DNA Oligonucleotides
The following oligonucleotides were used in this study.
Table 6.6: DNA Oligonucleotides Used in this Study. All DNA oligonucleotides
used for cloning and RT-qPCR are listed in the table. F, forward primer; R, reverse
primer.
Name Sequence Description
G014 GTGCTGGTTATTGTGCTG sequencing β-globin exon 3, F
G37 AATTGAATTCGGATCCCTAAGTCCAAC
F, forward primer for cloning of
6xMS2bs (Jens Lykke-Andersen)
G38 AATTGAATTCAGATCTCCCACTAGACAGC
R, reverse primer for cloning of
6xMS2bs (Jens Lykke-Andersen)
G95
GATCTCCCAGCAGTAAGGGTTTCCATATAAA
CTCCTTATTTCTACG
PP7bs F, BamHI and BglII
compatible
G96
GATCCGTAGAAATAAGGAGTTTATATGGAAA
CCCTTACTGCTGGGA
PP7bs R, BamHI and BglII
compatible
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G078 GGTGGTCGGAAAGCTATC S7 probe F
G083 TTACAAAGTCACTCAGGATG Ncl probe R
G311 AAGCTATCCCACAAATTG sequencing out of GST, F
G314 TTAAGCTAGCAGGGAATGGG mouse TNFα probe F
G316
GCCGATTTAGGTGACACTATAGAATACTGGCTCT
GTGAGG
mouse TNFα probe R
G1000 GTGCATCTGTCCAGTG globin probe R
G1001
GCCGATTTAGGTGACACTATAGAATACCCTGAAG
TTCTC
globin probe F
G1008
GCCGATTTAGGTGACACTATAGAATACTATAGAC
ACCAG
S7 probe R
G1009
GCCGATTTAGGTGACACTATAGAATACTTAGCGT
CTTCG
Ncl probe F
G1612 CCCAAGCTTGATATCATCCACCATGGTGAGCAAG EGFP F, HindIII-EcoRV
G1613 TTAAGGTACCCTTGTACAGCTCGTCCATGCCGAG EGFP R, KpnI
G1706 AGGGGGCAGAAATTGATGGACGAT mouse Ncl qPCR F
G1707 TGGGTTCTGGGGCACTTTG mouse Ncl qPCR R
G1712 GAGCGGGCCGTGGTGTC mouse Ier3 qPCR F
G1713 CTTGGCAATGTTGGGTTCCTC mouse Ier3 qPCR R
G1779
gatccgtagaaaACCGACCAGAATCATGCAAGTGCGTA
AGATAGTCGCGGGCCGGGctgctggga
S1 aptamer F, BamHI and BglII
compatible
G1780
gatctcccagcagCCCGGCCCGCGACTATCTTACGCACT
TGCATGATTCTGGTCGGTtttctacg
S1 aptamer R, BamHI and BglII
compatible
G1844 TGCCTATGTCTCAGCCTCTTC mouse TNFα qPCR F
G1845 GAGGCCATTTGGGAACTTCT mouse TNFα qPCR R
G1850
gatccgtagaaaATGCGGCCGCCGACCAGAATCATGCA
AGTGCGTAAGATAGTCGCGGGTCGGCGGCCGCAT
ctgctggga
S1m aptamer F (15 bp stem,
mismatch repair), BamHI and BglII
compatible
G1851
gatctcccagcagATGCGGCCGCCGACCCGCGACTATCT
TACGCACTTGCATGATTCTGGTCGGCGGCCGCAT
tttctacg
S1m aptamer R (15 bp stem,
mismatch repair), BamHI and BglII
compatible
G1852 gatccGAAAACCTCTACTTCCAAGGGa
TEV cleavage site F, BamHI and
BglII compatible
G1853 gatctCCCTTGGAAGTAGAGGTTTTCg
TEV cleavage site R, BamHI and
BglII compatible
G1854 TTGAGATGAGGATAAAATACTCTGAGTCC
β-globin exon 3 For (in single intron
region, for colony-PCR)
G1855 ATATGTCCTTCCGAGTGAGAGACAC β-globin 3’UTR R (colony-PCR)
G1859 atgcGAATTCATGTCCAAAACCATCGTTCTTTC F, PP7cp (David Peabody), EcoRI
G1860 atgcCTCGAGTTAACGGCCCAGCGGC R, PP7cp (David Peabody), XhoI
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G1861 atgcGAATTCATGGCCAAAACCATCGTTCTT F, oPP7cp (Kathleen Collins), EcoRI
G1875 gatccGAGAACCTCTACTTCCAGGGCg
TEV cleavage site F, BamHI and
EcoRI compatible
G1876 aattcGCCCTGGAAGTAGAGGTTCTCg
TEV cleavage site R, BamHI and
EcoRI compatible
G1899 atgcGAATTCATGGCTTCTAACTTTACTCAGTTCGTT MS2cp F, EcoRI-site attached
G1900 atgcCTCGAGTTAGTAGATGCCGGAGTTTGCT MS2cp R, XhoI-site attached
G1918 GGGCTTCATGATGTCCCC
R, reverse primer for S1m cloning into
puroMXß, downstream of aptamer
tags
G1919
CTTATTATTTATTATTTATTTATTATTTATTTATTT
GAGATCTGTAG
F, mismatch repair forward primer
reconstituting BglII site
G2053 ACTCCACTCACGGCAAATTCAACG mouse Gapdh qPCR F
G2054 AAGACACCAGTAGACTCCACGACA mouse Gapdh qPCR R
G2181 CAGGTGAACACCACGGATT mouse Nfkbiz qPCR F
G2182 CTCACAGCTCCCTTCTGGAT mouse Nfkbiz qPCR R
G2199 ATATTCGTGAACATAAAGGCAAGA mouse Nfkbid qPCR F
G2200 TCAGTGGCGTTAGGCTCTG mouse Nfkbid qPCR R
G2234
CCAAGTAATACGACTCACTATAGGCCTGGCTCACA
AATACCACTG
pT7-in-line F
G2235 AATTTTTGGCAGAGGGAAAAAG in-line R
G2247 CTCACAAATACCACTGGGATCC F, BamHI repair forward primer
G2332
CCAAGTAATACGACTCACTATAGGTTTGGAAGGCC
GGGGT
pT7-CDE150 mouse in-line F
G2333 ATAAATATTTTGTTTTAAACATAAGCAAAAGAG CDE150 mouse in-line R
G2364 CATGGCTGCAACACTTACACAGCA mouse Nupl1 qPCR F
G2365 ATTGCAAGCCAGTGCCAATACCTG mouse Nupl1 qPCR R
G2392 TTGTACCTGAAGCCACTCAGCAGT mouse Roquin qPCR F
G2393 TCCACTAGCTGGCAATGAACCAGA mouse Roquin qPCR R
G2394 TGCCCATTCTCAGGAAGAGCTTGA mouse Roquin2 qPCR F
G2395 GCTGTGGTTGTGACAGTGCTGTTT mouse Roquin2 qPCR R
G2421
TGGACACAGTATCATACCCAGAAAACACCTGT
CTCTTCAACTCTTCCTGTGGCCA
mouse Roquin2 cDNA F
G2427 GATCATCGATTCAGCTGTTAACCATCTTCCCA mouse Roquin2-ClaI cDNA R
G2495 GATCGGATCCTTTGGAAGGCCGGGGT CDE150-BamHI-outF
G2496
GATCAGATCTATAAATATTTTGTTTTAAACATAA
GCAAAAGAG
CDE150-outR-BglII
G2497 TTCTGTGAAATGGGAGCTGAG CDE150-M16 F
G2498 TTTCACAGAAAACATGTCTGTCTGA CDE150-M16 R
G2501 GACAGACATCATTTCTGTGAAATGGGA CDE150-M20 F
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G2502 ATGTCTGTCTGAAGACAGCTTCC CDE150-M20 R
G2554 AAACTAGTATGCGCCGAGATTTACGA Roquin2 cDNA C413R F
G2555 CATACTAGTTTTATACTTGCTGTTTGGCTG Roquin2 cDNA C413R R
G2556 GATCCAATTGTTTTGCAGCGAACTG Roquin2-MfeI cDNA F
G2576 AACATACATGCGTCGAGATATGAAG Roquin cDNA C419R F
G2577 CATGTATGTTTTGTATTTGCTATGCTGT Roquin cDNA C419R R
G2579 GATCCACATGGTGGTGGAGTATAGTACATACC Roquin-DraIII cDNA R
G2592 TTCCCCCTGTTGAAGTTCC mouse Ppp1r10 qPCR F
G2593 CTTGCGAGTCAGCTGGTTG mouse Ppp1r10 qPCR R
G2622 GATACTGTGTCCACTGATCTGGC BstXI-Roquin2 cDNA R
G2623 TCATTTGCACAGAGTGTTCAGG Roquin-DraIII cDNA F
G2723 TGACCTGGGCCTAGCTGTTA mouse Bmpr1a qPCR F
G2724 TTCAGGCTTTCATCCAGCA mouse Bmpr1a qPCR R
G2729 CTCACATCCTGGACACTGGA mouse Pdia6 qPCR F
G2730 ACTGGGCTCCAGCTTCTGT mouse Pdia6 qPCR R
G2737 TGTTGGCCCTCTATGAATCTG mouse Hmgxb3 qPCR F
G2738 TGGAACCACAGACCACCTG mouse Hmgxb3 qPCR R
G2747 TTCATCGTATTGGAAGATCAGG mouse Rck qPCR F
G2748 TTGGGATGGGTTTGATCTCT mouse Rck qPCR R
G2788 AGGGACCGGTGTCGACC AgeI-SalI-Roquin flanking fr1 F
G2789 AGAGCAATTGTTAGCTCCTGAACA MfeI-Roquin flanking fr2 R
G2790 GTGACCGAACTGATTCTCCAGCACCAG siRNA-resistant Roquin fr2 F
G2791 CAGTTCGGTCACTGTGCGTTCACCTAAAG siRNA-resistant Roquin fr1 R
G2840 ATTAATCGATCTATTCCTGTGAATGTG ClaI-Stop-N-term R
G2842 TTATACCGGTGGAACTGGAAAAG Roquin C-term F
G2843 GTCCCACGTGGAATCAGTTG Roquin C-term R
G2855 TTATACCGGTGCGCCCAATGCAGAGGAA ROQ-AgeI F
G2856 TATAATCGATGAGTAACTCCAAATGGGGTCTTAG ROQ-ClaI R
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